Effective chemotherapy support: a matter of timing and combining? by Timmer-Bonte, J.N.H.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/71293
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
  
 
 
 
Effective chemotherapy support:  
a matter of timing and combining? 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cover: ‘Side effects of a thesis’ by Anja Timmer-Bonte 
 
 
ISBN 978-90-9022468-8 
 
© J.N.H. Timmer-Bonte, Nijmegen 2007 
All published papers have been reproduced with permission from the 
publishers of the journals in which they appeared. No part of this publication 
may be reproduced without prior permission of the holder of the copyrights.  
 
 
Printed by PrintPartners Ipskamp, Enschede 
 
  
 
 
 
Effective chemotherapy support:  
a matter of timing and combining? 
 
 
Een wetenschappelijke proeve  
op het gebied van de Medische Wetenschappen 
 
 
Proefschrift 
 
ter verkrijging van de graad van doctor 
aan de Radboud Universiteit Nijmegen 
op gezag van de rector magnificus prof. mr. S.C.J.J. Kortmann, 
volgens besluit van het College van Decanen 
in het openbaar te verdedigen op  
vrijdag 18 januari 2008 
om 10.30 uur precies 
door 
Johanna Nicolasina Helena Timmer-Bonte 
geboren op 11 augustus 1967 
te ’s-Hertogenbosch 
 
 
  
 
 
 
 
 
 
Promotores  Prof. dr. V.C.G. Tjan-Heijnen, Universiteit Maastricht 
   Prof. dr. P.H.M. de Mulder† 
       
Copromotor  Dr. E.M.M. Adang 
 
 
 
Manuscriptcommissie  
Prof. dr. W.T.A. van der Graaf (voorzitter) 
Prof. dr. E.F. Smit, Vrije Universiteit Amsterdam 
Prof. dr. G.J. van der Wilt 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 7 
Table of  Contents 
 
 
Chapter 1 Introduction and outline              9 
 
Chapter 2 Timely withdrawal of G-CSF reduces the occurrence of 
thrombocytopenia during dose-dense chemotherapy        17 
(Published in Breast Cancer Research and Treatment 93: 117, 2005) 
 
Chapter 3 Prophylactic G-CSF and antibiotics enable a significant dose-
escalation of tripletchemotherapy in nonsmall cell lung cancer  37 
(Lung Cancer, in press) 
 
Chapter 4 Prevention of chemotherapy-induced febrile neutropenia by 
prophylactic antibiotics plus or minus granulocyte colony-
stimulating factor in small-cell lung cancer: a Dutch randomized 
phase III study             57 
(Published in Journal of Clinical Oncology, 23: 7974, 2005) 
 
Chapter 5 Cost-effectiveness of adding granulocyte colony-stimulating 
factor to primary prophylaxis with antibiotics in patients with 
small-cell lung cancer           83 
(Published in Journal of Clinical Oncology, 24: 2991, 2006) 
 
Chapter 6 Modeling the cost-effectiveness of secondary FN-prophylaxis 
during standard-dose chemotherapy        105 
(Journal of Clinical Oncology, in press) 
 
Chapter 7 Febrile neutropenia: highlighting the role of prophylactic 
antibiotic and granulocyte colony-stimulating factor during 
standard dose chemotherapy for solid tumors       129 
(Published in Anticancer Drugs, 17: 881, 2006) 
 
Chapter 8 Summary, conclusions and future challenges      155 
Samenvatting en conclusies        165 
Nawoord           173 
Curriculum Vitae          175 
Publicaties           176 
  
  
 
 
hapter 1 
 
 
  
Introduction and outline 
 
J.N.H. Timmer-Bonte 
C
Chapter 1 
10 
Cancer patients treated with chemotherapy may experience therapy-related 
toxicity. A major and potentially life threatening complication of chemotherapy 
is bone marrow suppression. Neutropenia and its febrile complications cause 
morbidity, lead to hospitalization, may compromise further treatment with 
chemotherapy in individual patients and at times can be fatal.  
 
Beginning with pioneering studies in the early 1960s, it has been recognized 
that normal and leukemic blood progenitor cells can be propagated in 
semisolid culture in the presence of soluble growth factors. These factors were 
originally termed colony-stimulating factors (CSF’s) because of their ability to 
support the formation of colonies of blood cells by bone marrow cells plated 
in semisolid medium. During the 1970s and 1980s, it became clear that there 
were multiple types of CSF’s based upon the different types of colonies that 
grew in the presence of the different factors. 
Following the molecular cloning of the genes for many of these factors and 
their receptors during the 1980s and 1990s, it became possible to study in 
detail the structure, function, and biology of the recombinant CSF’s as well as 
the molecular biology of their respective genes. This analysis led to the 
realization that there is a large family of interacting regulatory molecules now 
generally known as cytokines or lympho-hematopoietic cytokines that control 
the hematopoietic and immune systems and integrate their responses with 
those of other systems. [1;2] 
 
Endogenous granulocyte colony-stimulating factor (G-CSF) is a lineage 
specific glycoprotein which is produced by monocytes, fibroblasts, and 
endothelial cells and that acts on hematopoietic cells by binding to specific cell 
surface receptors. A primary effect of G-CSF is to promote the conversion of 
granulocyte colony-forming units into polymorphonuclear leukocytes.  
 
Introduction and outline 
11 
The efficacy of human G-CSF was initially evaluated in simian preclinical trials. 
Cynomolgus monkeys treated with two daily subcutaneous injections of 
purified G-CSF for 14 to 28 days showed a dose-related increase in 
polymorphonuclear neutrophils and neutrophil function was enhanced. These 
initial studies also evaluated two cyclophosphamide-treated animals. After G-
CSF was given the neutrophil count increased dramatically, whereas the 
81control animal remained pancytopenic for three to four weeks after 
treatment. This type of observation provided the rationale for the 
administration of G-CSF to patients with chemotherapy-induced 
neutropenia.[3] 
 
The studies presented in this thesis all consider recombinant methionyl human 
granulocyte colony-stimulating factor (r-metHuG-CSF) or filgrastim. Filgrastim 
is a human granulocyte colony-stimulating factor (G-CSF), produced by 
recombinant DNA technology. Filgrastim is produced by Escherichia coli (E coli) 
bacteria into which has been inserted the human granulocyte colony-
stimulating factor gene. The protein has an amino acid sequence that is 
identical to the natural sequence predicted from human DNA sequence 
analysis, except for the addition of an N-terminal methionine necessary for 
expression in E coli.  Because filgrastim is produced in E coli, the product is 
non-glycosylated and thus differs from G-CSF isolated from a human cell. 
 
In 1994 the first evidence based clinical practice guidelines for the use of CSF’s 
were published by the American Society of Clinical Oncology (ASCO). These 
guidelines were updated in 1996, 2000 and very recently in 2006, both by 
ASCO and by the EORTC (European Organization for the Research and 
Treatment of Cancer) [4;5], after the milestone publication of Jeffrey Crawford 
in the New England Journal of Medicine (1991).[6] Crawford and co-authors 
had shown that G-CSF (filgrastim) was able to reduce the incidence of febrile 
Chapter 1 
12 
neutropenie (FN) by approximately 50% during standard-dose chemotherapy. 
Thereafter, research also focused on the question whether – due to the support 
of G-CSF - it would be feasible to dose-densify (shortening intervals between 
chemotherapy cycles) or dose-escalate chemotherapy, in order to improve long 
term outcome. As for now, CSF’s have shown to allow for a modest to 
moderate increase in dose-density and/or escalated dose of chemotherapy 
regimens. Available data suggest a small survival benefit from the use of dose-
dense (but not dose-escalated) regimens with CSF support in a few specific 
settings (e.g., node-positive breast cancer). However, additional data in these 
settings are needed as these results cannot be generalized to other disease 
settings and regimens. 
 
At the start of the research presented in this thesis, several issues were still 
unanswered.  
First, we questioned whether the at the time most frequently used daily G-CSF 
schedule (for 10 days) was the most adequate schedule to be used, to support 
chemotherapy densification from a 3-weekly to a 2-weekly chemotherapy 
regimen (days 1-3). Others had demonstrated that the hematopoietic 
progenitor cells are still rapidly proliferating for 2–4 days after cessation of G-
CSF, making them susceptible for the effects of chemotherapy. That explains 
why administration of G-CSF until 48 hours before delivery of chemotherapy 
aggravates myelotoxicity in the next chemotherapy cycle.[7] During dose-dense 
2-weekly chemotherapy it may, therefore, be more attractive to cease G-CSF 
more than 4 days before the next chemotherapy cycle.  
Further, it was unclear to what degree the G-CSF support could enable dose-
escalation beyond the standard chemotherapy dose without G-CSF support; 
for example a 25%, 50% or 100% dose-increase due to support with G-CSF? 
A small difference would explain the lack of positive outcome in prior studies; 
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a large difference would support further studies on this topic, with the optimal 
doses with and without G-CSF support being compared. 
Next, we questioned whether there was still a role for G-CSF support, if one 
would chose to use antibiotic prophylaxis in patients at risk of FN. To 
determine whether the clinical impact would be worthy to implement G-CSF 
routinely, we also took economic issues into account. Prior results were 
derived from economic models, where data were based on USA cost prices, 
whereas it is known that those cost prices may vary from country to country. 
Note, that the administration of G-CSF comes with considerable cost; for 
example in the Netherlands in 2002 a ten day course cost approximately 1500 
Euro.  
Furthermore, the economic consequences of secondary prophylaxis are not well 
studied. A prior episode of FN is considered a risk factor for developing FN in 
further cycles. The administration of prophylaxis in subsequent cycles of 
chemotherapy in such patients is called secondary prophylaxis. A previous 
economic analysis based on a Markov model analysis demonstrated that 
secondary prophylaxis with G-CSF in small cell lung cancer (SCLC) patients 
treated with standard dose chemotherapy did not result in cost savings. The 
rationale for secondary prophylaxis with G-CSF is twofold. It may direct the 
use of G-CSF to a subset of patients who are most likely to benefit and in 
addition may prevent the cost and inconvenience in patients who might not 
need G-CSF at all. The G-CSF registration trial by Crawford et al provided an 
indication that secondary prophylaxis might be effective.[6] Placebo treated 
patients with FN in cycle 1 received G-CSF in the subsequent cycle (cross-
over). The incidence of FN was reduced to 23%, whereas in placebo treated 
patients not experiencing FN in cycle 1, the risk of FN remained constant over 
subsequent cycles.  
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Therefore, we initiated a number of studies in SCLC, non-small cell lung 
cancer (NSCLC) and breast cancer, to address 1. the role of G-CSF schedule 
on chemotherapy dose-densification, 2. the impact of G-CSF support on the 
degree of chemotherapy dose-escalation, and 3. the additional clinical value of 
G-CSF as FN prophylaxis besides the use of antibiotic prophylaxis, with 4. the 
economic impact of primary FN prophylaxis and 5. the economic impact of 
secondary FN prophylaxis.  
 
Chapter 2 describes the results of a study comparing two different G-CSF 
administration schedules in advanced breast cancer patients receiving dose 
dense 2-weekly chemotherapy. Patients received an 8-day course of G-CSF 
(until 5 days before the next cycle of chemotherapy) or a 10-day course of G-
CSF (until 2 days before the next cycle) and served as their own control.  
 
Chapter 3 focuses on G-CSF use as support of chemotherapy dose-escalation. 
In advanced NSCLC the standard chemotherapy treatment consists of a 3-
weekly platinum based doublet. A recent review demonstrated better response 
rates of chemotherapy triplets compared to doublets, but with attenuated 
dosages because of increased risk of myelotoxicity and FN.[8] We performed a 
dose escalating study in advanced NSCLC patients studying a triplet 
chemotherapy and hypothesized that the addition of antibiotics and G-CSF 
might facilitate dose escalation. 
 
Apart from the use of G-CSF for dose-densification or - escalation studies, G-
CSF is used as an adjunct to standard-dose chemotherapy to reduce the risk of 
FN. The same is true for the use of antibiotics, and based on the different 
effects of both G-CSF and antibiotics, it seemed worthwhile to investigate 
combined prophylaxis. Chapter 4 describes the clinical results of a randomized 
phase III study that compares primary prophylaxis with G-CSF plus antibiotics 
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to antibiotics alone in SCLC patients with a high risk of FN. This study was 
supported by a research grant from the Dutch Healthcare Insurance Board 
(“Ontwikkelingsgeneeskundeproject OG99053”). 
  
In chapter 5 the results of the companying prospectively conducted economic 
analysis are discussed. Our study was the first and only to collect prospective 
data on cost prices alongside a randomized phase III trial on the impact of G-
CSF prophylaxis. This resulted in a patient based cost data set resulting in a 
better understanding of the cost variance in production processes of primary 
prophylaxis. It was hypothesized that by selecting patients at risk of FN the use 
of prophylaxis may be cost-effective, taking into account the cost savings 
associated with less neutropenia-related morbidity.  
 
Chapter 6 reports a cost analysis of secondary prophylactic use of antibiotics 
plus/minus G-CSF in a population at risk of FN based on the clinical outcome 
described in chapter 4 and using the cost data gathered in the study presented 
in chapter 5. This analysis modeled the investment, consumed medical 
resources and consequences with regard to less morbidity due to secondary 
prophylaxis in monetary terms using a Markov model that took the probability 
of premature chemotherapy cessation and the stage-variant probability of FN 
into account. 
 
Chapter 7 presents the results of a review of the literature anno 2006 on the 
efficacy and cost-effectiveness of prophylactic antibiotics, G-CSF and its 
combination in patients receiving standard dose chemotherapy. 
Recommendations in current guidelines are discussed in light of recent 
evidence, including evidence from studies presented in this thesis. 
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Finally, chapter 8, provides a summary together with the overall conclusions 
of the research presented in this thesis and briefly indicates future challenges 
on the use of G-CSF. 
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Abstract 
Background: Post chemotherapy granulocyte colony stimulating factor (G-
CSF) reduces leucopenia, while G-CSF priming shortly before chemotherapy 
increases myelotoxicity. We performed a trial with a two-schedule crossover 
design to determine the optimal G-CSF schedule for densified 2-weekly 
chemotherapy.  
Methods: During 2-weekly chemotherapy days 1 and 2, G-CSF was given on 
days 3–10, with a G-CSF-free interval before the next chemotherapy cycle of 5 
days, or on days 3–13, with a G-CSF-free interval of 2 days. In schedule A, 
cycle II was preceded by a 5 days, cycle III and IV by a 2 days and cycle V by a 
5 days G-CSF free interval. In schedule B, this was 2, 5, 5, and 2 days, 
respectively.  
Results: Intra-patient comparison for cycles II versus III and cycles IV versus 
V showed that platelet (PLT) nadir count was significantly lower for cycles 
preceded by a 2-days compared to a 5-days G-CSF free interval: mean 
difference 45.7 x 109/l (95% CI 33.2–58.2, p = 0.0001). Neutrophil count did 
not differ significantly (p = 0.85). 
Conclusion: Timely withdrawal of G-CSF in dose-dense chemotherapy 
reduces chemotherapy-related thrombocytopenia. Leucopenia was not 
aggravated, reflecting a protective effect of post-chemotherapy G-CSF. 
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Introduction 
Granulocyte colony stimulating factor (G-CSF) and granulocyte macrophage 
colony stimulating factor (GM-CSF) have shown to be effective in reducing 
both the severity and duration of chemotherapy-induced neutropenia [1]. The 
availability of these growth factors has facilitated the study on dose-escalation 
and dose densification of chemotherapy [2, 3]. In general, it is advised to give 
G(M)-CSF for an average of 10 days, starting 24 h after the end of 
chemotherapy [4].Upfront administration of hematopoietic growth factors has 
also been studied. This is based on the idea of expanding the bone marrow 
progenitor pool before the administration of cytotoxic medication [5]. 
However, GM-CSF and G-CSF have different ‘priming’-effects. While both 
growth factors result in an increase in numbers of bone marrow progenitor 
cells, there is an abrupt decline in number of progenitor cells in S-phase after 
discontinuing GM-CSF administration, while the progenitor cells are still 
rapidly proliferating for 2–4 days after cessation of G-CSF [6–8]. This explains 
the clinical observation, that upfront priming with GM-CSF – before the 
administration of the first chemotherapy cycle – is myeloprotective [9, 10], 
while upfront administration of G-CSF – till 48 h before the delivery of 
chemotherapy – only aggravates the myelosuppression [5, 11, 12]. 
These observations have not fully been appreciated in the design of dose-
densification studies or guidelines on the use of hematopoietic growth factors. 
In the reported 2-weekly chemotherapy regimens G-CSF was continued until 
shortly before the next chemotherapy cycle, since post chemotherapy G-CSF 
was administered for the usual 10 days. And, in some of these studies 
myelotoxicity was increased in these densified treatment arms [13–16]. We 
hypothesized that the negative ‘priming’ effect of post chemotherapy G-CSF in 
the prior cycle may have caused the excess myelotoxicity on the subsequent 
cycle. In case we would be able to proof this hypothesis, the clinical benefit of 
post chemotherapy G-CSF can be enhanced by increasing the window of time 
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between interruption of the G-CSF and re-initiation of the next chemotherapy 
cycle to 5 days, which is beyond the aforementioned 2–4 days of G-CSF-
induced bone marrow proliferation. Therefore, the present study was 
undertaken to determine whether a shortened regimen of daily G-CSF 
administration in relation to 2-weekly chemotherapy was beneficial.  
 
Patients and methods 
Study design 
The here reported study on the optimal G-CSF schedule during 2-weekly 
chemotherapy was part of a larger phase II study in which the efficacy of a 2-
weekly chemotherapy regimen, delivered on days 1 and 2 of each cycle, will be 
determined. To evaluate the effect of two different G-CSF schedules on 
hematological recovery, post chemotherapy G-CSF was started at day 3 and 
administered for a total of 8 days (days 3–10) or for a total of 11 days (days 3–
13). Patients acted as their own control, and were treated either according to 
schedule A or according to schedule B (Figure 1). So, there were no 
comparisons between different patients. In schedule A, the duration of G-CSF 
administration for cycle I through V was: 8,11, 11, 8 and 8 days, respectively, 
with a G-CSF free interval preceding cycle II through V of 5, 2, 2 and 5 days, 
respectively. In schedule B, the duration of G-CSF administration for cycle I 
through V was: 11, 8, 8, 11 and 11 days, respectively, with a G-CSF free 
interval preceding cycle II through V of 2, 5, 5 and 2 days, respectively. Intra-
patient comparisons on peripheral blood cell counts were done for cycle II 
versus cycle III and for cycle IV versus cycle V. Of note, for these coupled 
cycles the duration of G-CSF treatment was the same, while the G-CSF free 
interval before the chemotherapy administration was the only difference: 5 
versus 2 days or 2 versus 5 days.  
Twenty-six patients were registered to participate in the G-CSF-scheduling-
part of the study. To be assessable, patients had to receive at least 3 
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chemotherapy cycles with at least 2 comparator cycles (cycles II and III and 
ideally also IV and V), provided that the time frame was precisely followed (2-
weekly chemotherapy and G-CSF according schedule A or B) and provided 
that the comparator cycles were delivered at the same dosage. As a result, 11 
patients were not assessable: 1 patient went off study after only 2 cycles, 1 
patient died after 1 cycle, 4 patients did not receive G-CSF according to 
schedule (doctor’s mistake) and in the remaining 5 patients none of the cycles 
were comparable due to dose reduction and/or delay for several reasons.  
 
Patient selection  
Patients with locally advanced or metastatic breast cancer aged between 18 and 
70 years with a life expectancy of over 3 months and an ECOG performance 
status 0–2 were considered eligible. Prior hormonal treatment was allowed as 
well as radiotherapy, if recovered from acute toxicity and no more than 20% of 
the total bone marrow compartment was involved. Prior adjuvant 
chemotherapy was allowed (in case of adjuvant classical CMF at least 6 months 
ago), but prior chemotherapy for advanced disease was not allowed. Inclusion 
required a white blood cell (WBC) count > 3.0 x 109/l, platelet (PLT) count > 
100 x 109/l, creatinine-clearance > 60 ml/ min (Cockroft), and bilirubin < 25 
micromol/l. During the study no other anti-tumor treatment or concomitant 
therapy with non-steroidal anti-inflammatory drugs, tetracyclines, phenytoin, 
sulphonamides or high dose vitamin C were permitted. Written informed 
consent was obtained from all patients. The hospital ethical review board 
approved the protocol.  
 
Treatment plan  
Chemotherapy 
Chemotherapy consisted of cyclophosphamide 700 mg/m2, methotrexate 40 
mg/m2 and 5-fluorouracil 600 mg/m2 on days 1 and 2 intravenously every 
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two weeks. Folinic acid started 24 h after the last administration of 
methotrexate in a total dose of 120 mg (8 times 15 mg orally every 6 h). A total 
of six cycles was planned for each patient, unless serious complications or 
progressive disease prohibited continuation of treatment. 
 
G-CSF 
To facilitate the delivery of 2-weekly CMF chemotherapy, G-CSF (filgastrim, 
Amgen B.V. Breda. Netherlands) was administered subcutaneously once a day, 
starting 24 h after each CMF cycle (on day 3) in a dose of 300 microgram 
(weight < 75 kg) or 480 microgram (weight >75 kg), according to schedule A 
or B (Figure 1). 
 
 
Figure 1. Schematic representation of G-CSF schedules 
 
 
 
Myelotoxicity 
To evaluate bone marrow suppression, peripheral blood cell counts and 
differentiation were measured on days 1, 8, 10, 12 and 15 of each 2-weekly 
cycle. Also clinical events related to myelotoxicity as infection with or without 
neutropenia, need of red blood cell or PLT transfusion and hemorrhage were 
documented.  
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Dose-modifications  
Chemotherapy was delayed for 1 week or longer as necessary, if WBC counts 
were < 3.0 x 109/l and/or PLT counts <100 x 109/l. When the delay was more 
than 2 weeks, the patient went off study. Dose adjustments were 
recommended in case of absolute neutrophil count (ANC) < 0.5 x 109/l for 
more than 7 days, ANC <0.5 x 109/l complicated by fever >38.5 oC lasting >2 
days, sepsis or PLT count < 25 x 109/l. Dose adjustments were also 
recommended in case of non-hematological toxicity. Note that dose 
modifications could lead to exclusion of the involved cycles or of the patient 
from analysis of myelotoxicity. 
 
Statistical analysis 
The G-CSF part of the trial was designed as a four period, two-schedule 
crossover design (figure 1). Patients acted as their own control. Due to the 
four-period design the only variable was the G-CSF free interval in the 
preceding cycle, since compared cycles were identical in chemotherapy dose, 
interval between cycles and post chemotherapy G-CSF duration. A cross-over 
design was used to ensure that both a long followed by a short G-CSF free 
interval (schedule A cycle II and III) opposed to a short followed by a long G-
CSF free interval (schedule B cycle II and III) could be assessed in order to 
exclude a bias from a period effect (cumulative chemotherapy-dose). In case 
patients would only be treated according to schedule A and myelotoxicity was 
shown to be more severe in cycle III than in II, it is not possible to determine 
whether this increased toxicity in cycle III would be due to the preceding short 
G-CSF free interval or to the higher cumulative total chemotherapy dose. 
Using a crossover design, it is actually possible to calculate both the size of the 
impact of G-CSF schedule and the period effect of two successive 
chemotherapy cycles. Based on the previous study, it was calculated that 44 
cycles were needed to demonstrate a significant difference (power of 90%, 
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one-sided significance level of 5%) at a G-CSF free-interval effect on nadir 
ANC count of the next cycle of 0.5 x 109/l assuming a residual standard 
deviation of 0.8 x 109/l. This last assumption was based on within- patient 
estimates. 
The nadir blood cell counts were analyzed using a linear mixed model. In this 
model the within-patient comparison was accomplished by assuming a subject 
specific random effect. Furthermore, as independent fixed effects, a period 
effect and the effect of G-CSF-free interval (5 or 2 days) on nadir blood cell 
counts of the next cycle were added to the model. 95% Confidence intervals 
(CI) were calculated for the effect of G-CSF free interval on nadir blood 
counts of the next cycle. All analyses were done within the framework of linear 
mixed models for repeated measurements using procedure Mixed of the SAS 
package. 
 
Figure 2. Patient inclusion and assessed cycles 
 N=number of patients 
Not Assessable
N= 11
cycle II, III and IV, V
N=3
cycle II, III
N=3
cycle IV, V
N=2
schedule A
N= 8
cycle II, III and IV, V
N=2
cycle II, III
N=4
cycle IV, V
N=1
schedule B
N= 7
Assessable
N= 15
Entered
N= 26
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Results 
Patient characteristics 
In total, 40 chemotherapy cycles were evaluated (Figure 2). Five patients 
received 4 comparator cycles and ten patients 2 comparator cycles. Eight 
patients were treated according to schedule A and 7 according to schedule B.  
The patient characteristics are summarized in Table 1. Ten patients had 
metastatic disease of which 5 received prior adjuvant chemotherapy (CMF or 
FEC). Interval to prior chemotherapy ranged from 6 months to 15 years. 
 
 
 
Table 1 Patient characteristics at baseline of all 15 assessable patients 
Median Age (range, years) 48 (37-67) 
ECOG Performance status  (N) 0                    
1 
5 
10  
 
Locally advanced  (N) 
Metastatic (N) 
 
5  
10  
Prior adjuvant chemotherapy (N) 5  
Median WBC (range, x 109/l) 6.8 (4- 11.4) 
Median PLT count (range, x 109/l) 318 (178- 504) 
Median Hb count (range, mmol/l) 7.9 (6.4-  9.1) 
Median creatinine clearance (range, ml/min) 86 (59-143) 
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PLT nadir count 
In schedule A, mean PLT nadir counts in cycles II and V were higher than in 
their respective counterparts, cycles III and IV, and the opposite occurred in 
schedule B. Results are summarized in Table 2 and Figure 3.  
PLT nadir count in cycles preceded by a 5-days G-CSF-free interval was 
significantly higher compared to cycles preceded by a 2-days G-CSF-free 
interval (mean difference of 45.7 x109/l; 95% CI 33.2–58.2, Table 3) 
 
 
 
Table 2  Mean nadir PLT count x109/l per cycle 
Mean PLT nadir count x 109/l  
 
Schedule 
G-CSF 
free 
period 
(days)
Cycle 
II 
(N) 
G-CSF 
free 
period 
(days) 
Cycle 
III 
(N) 
G-CSF 
free 
period 
(days) 
Cycle 
IV 
(N) 
G-CSF 
free 
period 
(days) 
Cycle 
V 
(N) 
A 5 
133.0 
(5) 
2 
38.6 
(5) 
2 
63.2 
(6) 
5 
96.4 
(6) 
B 2 
68.7 
(6) 
5 
81.0 
(6) 
5 
91.3 
(3) 
2 
54.7 
(3) 
N= number of assessed cycles 
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Figure 3. Mean PLT nadir count per cycle 
5 days G-CSF free interval 
PLT nadir count schedule A 
2 days G-CSF free interval 
PLT nadir count schedule B  
 
For patients treated by schedule A, cycle II was preceded by a 5-days G-CSF free interval, 
cycle III and IV by a 2-days G-CSF free interval, and cycle V again by a 5-days G-CSF free 
interval. For patients treated by schedule B, cycle II was preceded by a 2-days G-CSF free 
interval, cycle III and IV by a 5-days G-CSF free interval, and cycle V again by a 2-days G-
CSF free interval. Intra-patient comparison of blood cell counts for cycles II versus III and 
cycles IV versus V shows that PLT nadir count is significantly lower for cycles preceded by 
a short 2-days G-CSF free interval (table 2). 
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Table 3 Differences in mean nadir counts in cycles after 5 versus  
2 days G-CSF-free interval 
 
 Difference  
5 days versus 2 days  
 (95% CI) 
P-value 
PLT x 109/l 45.7 (33.2-58.2) 0.0001 
WBC x 109/l 0.29 (-0.21-0.80) 0.24 
ANC x 109/l 0.06 (-0.60-0.73) 0.85 
Hb mmol/l 0.16 (-0.05-0.38) 0.12 
 
 
 
A PLT nadir count less than 100 x 109/l was seen in 20 cycles after a 2-days G-
CSF – free interval compared to only 11 cycles after a 5-days G-CSF – free 
interval. A PLT nadir count less than 25 x 109/l was observed in 4 cycles, all of 
them preceded by a 2-days G-CSF-free interval. Median PLT nadir count 
occurred on day 10 (range day 8–15) regardless of the preceding G-CSF-free 
interval. Over the entire treatment period the mean nadir values of PLT count 
dropped. The mean PLT nadir was 33.8 x 109/l higher in cycle II compared to 
cycle V (when schedule A and B are combined, p = 0.0003). There was no 
significant difference in mean PLT count on day 15 of the next cycle (data not 
shown). 
 
WBC and ANC nadir counts 
WBC and ANC count were not significantly different for cycles preceded by a 
2-days versus a 5-days G-CSF free interval (1.3 versus 1.6 x 109/l, p = 0.24, 
and 0.81 versus 0.87 x 109/l, p = 0.85, respectively, see also Table 3), nor was 
the moment on which the nadir count occurred (median on day 10). Over the 
entire treatment period, there was no significant effect seen on WBC and ANC 
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nadir values when respectively cycle II, III or IV were compared to cycle V  
(p = 0.33). 
 
 
Table 4 Effect of cumulative chemotherapy dose per period 
Mean difference in nadir count  
compared to cycle V# 
  
PLT  
x109/l 
WBC  
x109/l 
ANC  
x109/l 
Hb 
mmol/l 
 
Cycle  II vs V# 
 
33.81 
 
0.28 
 
0.21 
 
1.24 
Cycle III vs V# -6.97 0.62 0.66 0.53 
Cycle IV vs V# 4.07 -0.01 -0.24 0.41 
P-value 0.0003 0.33 0.35 0.0001 
# Cycles of schedule A and B collectively 
 
 
 
Hemoglobin nadir counts 
Hemoglobin (Hb) nadir counts (5.9 and 5.8 mmol/l respectively, p = 0.12, see 
also Table 3) and moment of nadir (median on day 10) were not significantly 
different for cycles preceded by a 2-days versus a 5-days G-CSF free interval. 
Over the entire treatment period, the mean nadir values of Hb level in cycle V 
significantly dropped respectively by 1.24 mmol/l compared to cycle II, 0.53 
mmol/l compared to cycle III and 0.41 mmol/l compared to cycle IV (p = 
0.0001). 
 
Clinical events 
In none of the assessed cycles clinical overt hemorrhage requiring transfusion 
or episodes of febrile neutropenia were reported. 
Dose reduction or delay in all 26 patients 
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Considering all 26 initially registered patients, 51 of 133 cycles were dose-
reduced or delayed. In 30 cycles (59%) this was PLT-related, that is in 5 cycles 
a PLT nadir count of less than 25 x 109/l necessitated dose reduction and in 25 
cycles a PLT count of less than 100 x 109/l on the planned day of start 
necessitated postponement of the next chemotherapy cycle. In 63% of these 
30 cycles the preceding G-CSF-free interval was 2-days, and in 37% of cycles 
the G-CSF-free interval was 5 days.  
 
Discussion 
This is the first study ever reported, in which the effect of two different G-CSF 
schedules was evaluated in order to determine a preferential G-CSF schedule 
during 2-weekly chemotherapy. Based on prior reports, the clinical benefit of 
post chemotherapy G-CSF during dose-densified chemotherapy may 
theoretically be enhanced by increasing the time between interruption of G-
CSF and re-initiation of chemotherapy beyond 2–4 days. For this purpose, G-
CSF was given during 2-weekly chemotherapy either on days 3–10, with a G-
CSF-free interval before the next chemotherapy cycle of 5 days, or on days 3–
13 with a G-CSF-free interval before the next chemotherapy cycle of 2 days.  
The G-CSF schedule appeared to have a large impact on the degree of 
thrombocytopenia of the next chemotherapy cycle. The mean PLT nadir count 
was 46 x 109/l lower following a preceding ‘short’ 2-days G-CSF-free interval 
compared to a ‘long’ 5-days G-CSF-free interval. Previously, we reported on 
the results of a study in twelve patients with relapsed small cell lung 
carcinoma.[11] Patients were treated with two 4-weekly chemotherapy cycles 
and 6 days G-CSF priming was given till 48 h before the first chemotherapy 
cycle only or till 48 h before the second cycle only with patients acting as their 
own control. G-CSF priming was shown to increase both the chemotherapy-
associated leucopenia and thrombocytopenia. In that study no post-
chemotherapy G-CSF was given. The results of the current study suggest that a 
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possible negative effect on WBC nadir count of the short G-CSF free interval 
before the next chemotherapy cycle can indeed be compensated for by the use 
of post-chemotherapy G-CSF. But, postchemotherapy G-CSF during the next 
cycle cannot protect against the negative priming effect on PLT nadir counts. 
Thrombocytopenia is often reported as an important side effect of dose dense 
chemotherapy schedules and hypothesized to be a consequence of cumulative 
chemotherapy dose.[14,13] Our results do confirm a significant effect of 
cumulative dose on Hb and PLT nadir counts: the mean Hb nadir was 1.24 
mmol/l higher in cycle II versus cycle V (p = 0.0001) and the mean PLT  nadir 
count was 33.8 x 109/l higher in cycle II versus cycle V (p = 0.0003). However, 
mean PLT nadir count did not decline gradually during the course of 
treatment: it was higher in cycle V than in cycle III and IV for schedule A for 
example (Table 2). The double cross over design permitted to demonstrate that 
the scheduling of G-CSF affects thrombocytopenia for an even larger degree 
(difference in mean PLT nadir count 46 x 109/l; 95% CI 33.2–58.2, p = 
0.0001). Although the number of patients and cycles assessed in this study is 
only modest, the 95% CI permits to conclude that the duration of G-CSF-free 
interval is of importance.  
We observed that the majority of PLT-related dose reductions or delays 
occurred in cycles following a short G-CSF-free interval (19 out of 30 cycles), 
so one may hypothesize that earlier discontinuation of G-CSF before the (re-) 
start of chemotherapy can contribute to maintain the delivery of planned 
chemotherapy dose and dose-intensity. As mentioned before, in our study dose 
and dose-intensity in the assessed cycles are by definition the same. But, de Wit 
et al randomized 36 breast cancer patients both to receive pre- and post 
chemotherapy G-CSF or only post chemotherapy G-CSF [12]. They found 
that in patients receiving G-CSF until 48 h before chemotherapy more 
frequent dose reductions because of thrombocytopenia were applied than in 
those patients who did not receive pre-chemotherapy G-CSF. Also in children 
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with neuroblastoma treated with multiple cycles of strongly myelosuppressive 
alkylator-based combination chemotherapy, prophylactic use of G-CSF 
hastened ANC recovery but did not result in augmented dose intensity and was 
associated with prolonged thrombocytopenia (compared to a historical control 
group) [17]. 
The results reported here show, that there is an impact of the duration of the 
G-CSF-free interval before the next chemotherapy cycle on peripheral blood 
counts, but the underlying mechanism(s) for the effect of G-CSF schedule on 
PLT count is (are) not entirely clear. After 2–4 days cessation of G-CSF 
treatment the bone marrow progenitor cells are still rapidly proliferating with 
progenitor cells in S-phase ranging from 38 ± 5 to 63 ± 8% compared with 26 
± 9 to 39 ± 8% before G-CSF treatment [6, 7]. This means that after a 2 days 
G-CSF-free interval compared to a 5 days interval more progenitor cells are 
still proliferating and this might explain in part the observed impact of G-CSF 
schedule on myelotoxicity. A functional G-CSF receptor on PLT’s has been 
identified [18] and there is some in vivo evidence that G-CSF has a suppressive 
effect on the maturation of mouse bone marrow megakaryocytes when 
monitored by the DNA polyploidy [19]. When G-CSF is given to healthy 
donors a drop in PLT count is seen by day 8 and an even lower than pre-
treatment PLT level by day 10 [20, 21]. Some authors hypothesize that splenic 
enlargement due to G-CSF induced extra-medullar hematopoiesis contributes 
to thrombocytopenia [21], but this is contradicted by the observation in 
splenectomized mice that circulating platelets decreased after 5FU-treatment 
followed by G-CSF (whereas granulopoietic recovery was accelerated and all 
stages of bone marrow megakaryocytopoiesis were decreased) [22]. Also 
redirection of hematopoiesis towards neutrophil recovery and subsequent 
suppression of other cell lines is often held responsible. Again in 
splenectomized mice the delayed start of G-CSF treatment for more than 5 
days after chemotherapy (5FU) showed no longer an impact on granulopoiesis 
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but PLT count was still significantly reduced. This indicates that neither 
recruitment nor competition between different hematopoietic cell lines are 
critical events in the cause of decreased PLT counts [22]. The importance of 
G-CSF schedule on myelotoxicity might be of special concern since a long 
acting pegylated G-CSF recently has been introduced. For patients a major 
practical advantage of pegylated G-CSF is that administration is needed only 
once a week. But the variable and sometimes long half life indicates that the 
effect in an individual patient cannot be predicted and may interfere with a safe 
interval to the next cycle, especially during dose dense chemotherapy. Recently, 
the results of a randomized phase III trial showed that a single fixed dose  
(6 mg) of pegylated G-CSF could be administered effectively and safely in a 3-
weekly chemotherapy schedule [23]. But, no published data are available in 
dose dense chemotherapy yet. In another trial with pegylated G-CSF, 
thrombocytopenia was more frequent after chemotherapy in the highest 
dosage group of 100 microg/kg compared to 20 microg/kg and 60 microg/kg 
pegfilgrastim or daily filgrastim [24]. These findings and our results stress the 
importance of carefully determining the optimal dose and timing of 
(peg)filgrastim in relation to the planned chemotherapy regimen. 
In conclusion, during 2-weekly densified chemotherapy daily post 
chemotherapy G-CSF until 2 days before the next cycle compared to post 
chemotherapy G-CSF until 5 days before the next chemotherapy cycle 
significantly worsened the degree of thrombocytopenia. There was no impact 
of G-SCF schedule on the degree of leukopenia, reflecting a counterbalancing 
protective effect of post chemotherapy G-CSF in both the 8 day and 10 day 
schedule. Timely withdrawal of G-CSF during 2-weekly chemotherapy reduces 
chemotherapy related thrombocytopenia without jeopardizing ANC recovery 
and therefore, may realize planned dose intensity increase. 
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Abstract 
Introduction: In advanced non-small cell lung cancer (NSCLC) the clinical 
benefit of a platinum-based doublet is only modest, therefore attenuated dosed 
three-drug combinations are investigated. We hypothesized that with adequate 
support a full dosed chemotherapy triplet is feasible. 
Methods: The study was designed as a dose finding study of paclitaxel in 
chemotherapy-naïve patients. Paclitaxel was given as a 3-hour infusion on day 
1, followed by fixed doses of teniposide (or etoposide) 100 mg/m2 days 1, 3, 5 
and cisplatin 80 mg/m2 day 1 every 3 weeks. As myelotoxicity was expected to 
be the dose limiting toxicity, prophylactic G-CSF and antibiotic support was 
evaluated. 
Results: Indeed, paclitaxel 120 mg/m2 resulted in dose-limiting neutropenia, 
despite G-CSF support. Teniposide/etoposide day 1, 3, 5 was less myelotoxic 
compared to day 1, 2, 3. G-CSF support allowed paclitaxel dose escalation to 
250 mg/m2. The addition of prophylactic antibiotics enabled dose escalation 
to 275 mg/m2 without reaching MTD.  
In conclusion, G-CSF and antibiotics prophylaxis enables the delivery of a full 
dosed chemotherapy triplet in previously untreated NSCLC patients 
.
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Introduction 
The majority of non-small cell lung cancer (NSCLC) patients present with 
locally advanced or disseminated disease which is only amenable to palliative 
treatment. At present, a platinum-based doublet is considered standard of care 
in NSCLC. However, results are only modest with a response rate of 20-30%, 
median survival of 8-11 months and a 1-year survival rate of 35-40% in case of 
advanced disease.[1]  
Several trials have investigated the possibility of adding a third agent to a 
platinum-based regimen, but this necessitated attenuated drug doses due to 
dose-limiting toxicities (DLT), which consisted usually of complicated 
neutropenia.[2] However, maintaining dose intensity is considered relevant for 
optimal anti-tumor efficacy in NSCLC.[3;4]  
The prophylactic use of both G-CSF and antibiotics can successfully reduce 
chemotherapy-induced neutropenic complications, as shown by a 50% 
reduction in the incidence of febrile neutropenia (FN).[5] Accordingly, the 
addition of G-CSF and/or antibiotics provide an opportunity to increase the 
dose intensity of a three-drug regimen. 
The doublets cisplatin-paclitaxel and cisplatin-teniposide were evaluated in a 
randomized EORTC trial. With both regimens demonstrating efficacy, the 
combination of cisplatin and paclitaxel was favored because of better control 
of symptoms.[6] A logical next step could be to evaluate the combined use of 
these three drugs which have non-overlapping mechanisms of action. 
Neutropenia was anticipated to be the major DLT of this combination. With 
single agent paclitaxel administered as a 3-hour infusion the dose limiting 
myelosuppresion is seen at a dose of 250 mg/m2, but when G-CSF is added 
higher doses are feasible with peripheral neuropathy being the DLT at a dose 
of 300 mg/m2 .[7]  
We hypothesized that the addition of G-CSF allows an increased dose of 
paclitaxel as part of combination therapy with standard dosed cisplatin and 
Chapter 3 
40 
teniposide. In addition, the protocol aimed to evaluate whether the addition of 
prophylactic antibiotics to G-CSF allowed a further dose escalation of 
paclitaxel in this setting.[8] 
 
Patients and methods 
Study design 
The study was designed as a dose finding study of paclitaxel (Taxol®) when 
used in combination with fixed doses of cisplatin and teniposide in patients 
with advanced NSCLC. The primary objective was to establish the maximum 
tolerated dose (MTD) of paclitaxel and to investigate whether the prophylactic 
administration of G-CSF and antibiotics would allow further dose escalation of 
paclitaxel.  
DLT was defined as granulocytes <0.5 x 109/l lasting for ≥ 7 days, 
granulocytes <0.5 x 109/l and fever >38.5 0C, platelet count <25 x 109/l and 
any grade > 2 toxicity (with the exception of nausea/vomiting responsive to 
treatment) occurring during the first cycle. Three patients per dose level were 
entered. In case a DLT occurred in one or more patients another 3 patients 
were treated at the same dose level. If ≤ 2 of these 6 patients experienced a 
DLT, escalation to the next dose level was performed. The MTD was defined 
as one dose level below the dose at which a maximum of 2 out of 6 patients 
experienced a DLT. Patients completing at least one cycle were considered 
eligible for evaluation of toxicity according to CTC criteria; patients completing 
2 or more cycles were also considered evaluable for response using WHO 
criteria. 
Initially the dose of paclitaxel was escalated without the prophylactic use of G-
CSF(part A). In case neutropenia was the DLT, G-CSF was added at this dose 
level in order to explore further dose escalation (part B).  
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The protocol was amended to replace teniposide by etoposide, since we 
hypothesized that the observed and unexpected severe myelotoxicity could be 
due to the vehicle of teniposide (cremophor). Cremophor, which is also part of 
paclitaxel formulations, is known to change the pharmacokinetics of 
paclitaxel.[9]  
At reaching MTD with the use of etoposide and G-CSF, further dose 
escalation with the addition of prophylactic antibiotics was evaluated (part 
C).[8] A schematic overview of the study is shown in fig. 1  
 
Patients 
Eligibility criteria included previously untreated patients with a cytologically or 
histologically confirmed diagnosis of locally advanced or metastatic NSCLC, 
age between 18 and 75 years, normal bone marrow, liver and renal functions, 
and a WHO performance status of 0-2. Patients with symptomatic cerebral 
metastases or symptomatic peripheral neuropathy were excluded. The 
institutional ethical committee approved the investigational protocol, and 
written informed consent was obtained from each participating patient. 
 
Treatment 
Paclitaxel was given as a 3-hour intravenous (i.v.) infusion on day 1, followed 
by teniposide or etoposide 100 mg/m2 as a one-hour i.v. infusion on days 
1,3,5, and cisplatin 80 mg/m2 as a 3-hour i.v. infusion on day 1, every 3 weeks. 
The starting dose of paclitaxel was 120 mg/m2, the second and third dose 
levels were 135 mg/m2 and 150 mg/m2 respectively. Further dose escalations 
were planned at steps of +25 mg/m2 each. Both paclitaxel and tenoposide or 
etoposide were administered in 500 ml isotonic saline (0.9%), cisplatin was 
administered in 500 ml hypertonic saline (3%) and standard pre- and post-
hydration schedules for cisplatin were applied. Prophylactic medication 
included dexamethason 20 mg orally 12 and 6 hours before paclitaxel 
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administration, clemastine 2 mg i.v. and famotidine 40 mg i.v., and 
ondansetron 8 mg i.v. on days 1,3 and 5. In case of delayed emesis prolonged 
administration of dexamethason was allowed. 
G-CSF was administered at 300 mcg subcutaneously in patients with a body 
weight of < 75 kg or 480 mcg of > 75 kg, starting 24 hours after the last 
chemotherapy administration. In patients receiving G-CSF, teniposide was 
administered at day 1-3 instead of day 1,3 and 5, in order to allow earlier 
administration of G-CSF. Antibiotic prophylaxis consisted of ciprofloxacin 500 
mg b.i.d. and roxithromycine 150 mg b.i.d. on day 6-15.[9] 
Subsequent cycles were allowed provided that hematological toxicity had 
recovered to CTC < 3, with a maximum delay of 2 weeks. The study protocol 
provided in criteria for dose reduction in case of  persistent CTC grade 2 
hematological toxicity after a delay of 2 weeks and also in case of nefrotoxicity 
or neurotoxicity > grade 2. The duration of treatment depended on the stage 
of disease, toxicity and response with a maximum of 6 cycles. 
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Part A dose level 1
C 80 mg/m2 
T 100 mg/m2 1,3,5 
P 120 mg/m2 
DLT
Part B dose level 1
C 80 mg/m2 
T 100 mg/m2 1,2,3 
P 120 mg/m2 
+ G-CSF  
DLT
DLT
Part B dose level 1 
etoposide 
C 80 mg/m2 
E 100 mg/m2 1,3,5 
P 120 mg/m2 
+ G-CSF 
Part B level 7 etoposide
C 80 mg/m2 
E 100 mg/m2 1,3,5 
P 275 mg/m2 
+ G-CSF 
Part A dose level 1 
etoposide 
C 80 mg/m2 
E 100 mg/m2 1,3,5 
P 120 mg/m2 
Part c level 7 etoposide
C 80 mg/m2 
E 100 mg/m2 1,3,5 
P 120 mg/m2 
+ G-CSF 
+ ciprofloxacin and roxithromycin 
Figure 1. 
 Study flow chart 
Abbreviations 
C=cisplatin; T=teniposide;  
P=paclitaxel;E=etiposide; 
DLT= Dose limiting toxicity 
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Pharmacokinetic evaluation 
Paclitaxel (Taxol®) is formulated in a mixture of cremophor EL and ethanol. 
Cremophor contributes substantially to the non-linear pharmacokinetic 
behavior of paclitaxel plasma levels due to reduced clearance.[8] Teniposide is 
also formulated in cremophor, which increases the amount of administered 
cremophor with nearly 40% and this may influence toxicity. Because of this 
possible interaction, a pharmacokinetic analysis of paclitaxel was planned. In 
selected patients plasma levels pre-dose, 1.5 hours after start of paclitaxel 
infusion, at the end of infusion and at 6, 18, 30 and 60 minutes, 2, 4, 10 and 24 
hours after paclitaxel infusion ended were evaluated. Blood samples were 
centrifugated immediately and plasma was frozen (-20OC). Paclitaxel 
concentrations in plasma were determined by a validated high performance 
liquid chromatographic assay with a solid-phase extraction sample 
pretreatment.[10] 
 
Results 
Patients  
In total 47 eligible patients were included. Patient characteristics are 
summarized in table 1.  
The number of patients treated at the different dose levels (escalating doses of 
paclitaxel with teniposide or etoposide, and with or without G-CSF and 
antibiotics) and the incidence of DLT are summarized in table 2.  
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Table 1 Baseline patient characteristics N=47 
 
 
 N (%) 
Male 
Female 
32 (68) 
15 (32) 
 
Age 
median 
Range 
 
 
58 years
32-74 
WHO Performance Status
0
1
2
Unknown
 
 
13 (28) 
29 (62) 
3 (6) 
2 (4) 
Histology 
squamous
adeno
Other
 
 
20 (43)
18 (38)
9 (18) 
Stage 
IIIA
IIIB
IV
 
13 (28)
9 (19) 
25 (53)
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Table 2 Dose-limiting toxicity (first cycle) 
 DLT specified 
Part/level 
Paclitaxel
mg/m2 
Teni /Eto 
100mg/m2 
day 1,3,5 
Cisplatin
80mg/m2
GCSF AB N DLT 
FN WBC Other 
A-1 teni 120 T   + - - 5 3 3   
B-1 teni 120 T day1,2,3 + + - 3 2 2   
A-1 eto 120 E  + - - 3 2  1 diarrhea 
grade 3 
B-1 eto 120 E  + + - 3 0    
B-2 150 E  + + - 3 0    
B-3 175 E  + + - 6 2 2   
B-4 200 E  + + - 5 
(1NE*)
2   Grade 3 
infection; 
myocardial 
infarction 
B-5 225 E  + + - 3 0    
B-6 250 E  + + - 5 1 1   
B-7 275 E  + + - 3 3 3   
C-7 275 E  + + + 8 1   PNP 
Abbreviations:  
Teni=teniposide; Eto=etoposide; G-CSF=prophylactic growth factor stimulating factor; 
AB=prophylactic antibiotics 
N=number; DLT=dose limiting toxicity; FN=febrile neutropenia; WBC=white blood cell 
count; PNP=polyneuropathy 
*at final analysis one patient was judged ineligible due to impaired renal function at 
inclusion, however this patient did not experience DLT 
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Toxicity 
Myelosuppression was found to be the primary toxicity. Myelotoxicity during 
cycle 1 is shown in table 3. 
In part A dose level 1 MTD was reached as febrile neutropenia (FN) occurred 
in 3/5 pts, with median platelet (PLT, x109/l) nadir 113 (range 64- 168) and 
median absolute neutrophil count (ANC, x109/l) nadir 0.1 (0.1- 0.8). Median 
occurrence of nadir was at day 12 (10-18) and the median duration of grade 4 
neutropenia was 6 days (3-7).The addition of G-CSF with administration of 
teniposide on day 1-3 (part B dose level 1) resulted in increased toxicity 
compared to administration on day 1,3 and 5 without G-CSF, with a median 
PLT nadir of 15 (14- 87), median ANC nadir of 0.0 (0.0- 0.1), median day of 
nadir 10 (8- 10), and median duration of grade 4 neutropenia 3 days (2-5) as 
well as DLT (FN) in 2 out of 3 patients.  
Then teniposide was replaced by etoposide, at first without G-CSF (part A 
etoposide). However, toxicity with etoposide was comparable to teniposide at 
the corresponding level (120 mg/m2 paclitaxel): DLT in 2/3pts (ANC, 
diarrhea), median PLT nadir 146 (94-146), median ANC nadir 0.2 (0.1-0.5) at 
median day 15 (12-18).  
After the addition of G-CSF (days 6-15) with etoposide administration 
maintained on days 1,3 and 5 (part B etoposide) dose escalation was possible 
up to level 6 (250 mg/m2). At dose level 7 (275 mg/m2), DLT occurred in all 3 
patients (FN). After the addition of antibiotics (part C dose level 7) the first 3 
patients remained without DLT. Although formally the MTD was not reached 
we decided not to perform further dose escalation of paclitaxel since others 
have demonstrated that polyneuropathy (PNP) was the DLT at a paclitaxel 
dose of 300 mg/m2 [11]. Another 5 patients were included at dose level 7, 
resulting in one further DLT (PNP).  
Grade 3 and 4 non-hematological toxicity was infrequent, except for electrolyte 
disorders (mainly hypomagnesaemia, most likely cisplatin-related). Table 4 
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summarizes the observed toxicity and also demonstrates that, except for PNP, 
the majority of grade 3 or 4 toxicities occurred early during treatment. 
Seven patients experienced an early death, of which 5 were related to disease 
progression. One patient (paclitaxel dose level 275 mg/m2) died from fatal 
pulmonary bleeding at day 5 of cycle 1, PLT count at time of death was 
unknown, but at start of cycle 1 PLT count was 370 x 109/l. One patient 
known with a cardiac history died from myocardial infarction ten days after the 
start of treatment.  
 
Delivered chemotherapy  
Four patients (9%) stopped early because of progressive disease, two (4%) 
refused further treatment. Five patients (11%) stopped because of toxicity; 
three patients after 1 cycle and 1 patient after 2 and 5 cycles, respectively. 
Reasons were FN due to Staphylococcus Aureus infection of the lung, PNP, 
renal dysfunction and unstable angina pectoris. 
A total of 189 cycles were given to 47 patients (median 4 cycles, range 1-6). 
Thirty-four patients (72%) completed treatment according to the protocol. 
Sixteen cycles (9%) were delayed with a median of  7 days (range 1-17) due to 
drug-related toxicities, with (febrile) neutropenia (occurring in 10 of 16 cycles) 
being the most frequent event. Dose reductions were performed in 22 cycles 
(12%), the majority again for fever (4 patients) or FN (6 patients). Other 
important causes for dose reductions were renal impairment (8 patients) and 
PNP (4 patients). In 7 patients a combination of toxicities required dose 
reduction.  
In the last 8 patients at paclitaxel 275 mg/m2 with antibiotics and G-CSF (dose 
level 7)  four patients completed chemotherapy (3 patients with stage III 
disease received 3 timely and fully dosed cycles and 1 stage IV patient received 
6 cycles on time and fully dosed with the exception of the last cisplatin dose 
which was 25% reduced). Three patients received only one (but fully dosed) 
Prophylaxis enables dose escalation 
49 
cycle due to toxicity, one patient refused further treatment after having 
received 3 (of intended 6) fully dosed cycles. Thus, the actually delivered 
cumulative dose was 70% (range 25-100%) for paclitaxel and etoposide, and 
69% (range 25-100%) for cisplatin; the actually delivered dose intensity 
(calculated in mg/m2/day) was 89% of all agents in the first three cycles and 
60% of all agents in the entire treatment period respectively. 
 
Table 3 Myelotoxicity per dose level in cycle 1 
Median nadir 
Part- 
level N 
Pacl 
mg/m2 
Teni /Eto 
100mg/m2 
day 1,3,5 
Cis 80 
mg/m2 
GCSF AB WBC
x109/l
ANC
x109/l
ANC 
Day 
grade 4 
ANC  
duration  
(days) 
PLT 
x109/l
A-1 
teni 
5 120 T   + - - 1.9 0.1 12 6 118 
B-1 
teni 
3 120 T day1,2,3 + + - 0.5 0 10 3 15 
A-1 
eto 
3 120 E  + - - 1.6 0.2 15 6 146 
B-1 
eto 
3 120 E  + + - 3.6 1.2 11 0 158 
B-2 3 150 E  + + - 7 4.9 10 0 126 
B-3 6 175 E  + + - 3.3 2.1 10 0 130 
B-4 5 200 E  + + - 1.7 3.7 10 0 178 
B-5 3 225 E  + + - 1.5 0.2 10 2 176 
B-6 5 250 E  + + - 3.5 1 10 0 114 
B-7 3 275 E  + + - 0.4 0.1 8 2 107 
C-7 8 275 E  + + + 2 0.6 10 2 148 
Abbreviations:  
Pacl= paclitaxel; Cis= cisplatin;Teni=teniposide; Eto=etoposide; G-CSF=prophylactic 
growth factor stimulating factor; AB=prophylactic antibiotics  N=number; 
DLT=dose limiting toxicity; WBC=white blood cell count; ANC=absolute neutrophil 
count; PLT= platelet 
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Tabel 4 Toxicity grade (gr) 3-4 per patient per cycle and per patient in entire treatment 
 
 
Cycle 1 
N=44*(%) 
Cycle 2 
N=41(%)
Cycle 3 
N=36(%)
Cycle 4 
N=27(%)
Cycle 5 
N=16 
(%) 
Cycle 6 
N=15 
(%) 
Cycle 1-6 
N=44 (%)
Fever 11 (25) - - 1 (4) - - 11 (25) 
PNP - - - - 2 (13) 1 (7) 3 (7) 
Anorexia 1 (2) - - - - - 1 (2) 
Nausea 1 (2) - - - - - 1 (2) 
Vomiting 1 (2) - - - - - 1 (2) 
Diarrhea - - - - - - 2 (4) 
Cardiac 2 (4) 1 (2) - - - - 3 (7) 
Asthenia 1 (2) 1 (2) 2 (6) - 1 (7) - 1 (2) 
Hemorrhage 1 (2) - - - - - 1 (2) 
Electrolyte 
disorder 
3 (7) 1 (2) 1 (3) 4 (15) 2 (13) 1 (7) 5 (11) 
Hematological 
Toxicity 
(grade) 
3  4  3 4  3  4  3 4 3  4 3  4  3  4 
WBC 
10 
(23)
14 
(32) 
6 
(15) 
3 
(7) 
3 
(9) 
3 
(9) 
1 
(4) 
1 
(4) 
3 
(19) - 
4 
(27) - 
11 
(25)
15 
(34)
ANC 
5 
(11)
22 
(50) 
1 
(2) 
10 
(24)
6 
(17)
4 
(12)
2 
(8) 
4 
(15)
2 
(13)
2 
(13) 
4 
(27) 
2 
(14) 
6 
(14)
22 
(50)
PLT 
2 
(4) 
2  
(4) 
2 
(4) - - - - 
1 
(4) - 
1 
(7) - 
1 
(7) 
2 
(4) 
2 
(4) 
Hb 
1 
(2) - 
3 
(7) - 
3 
(9) - 
4 
(15) - 
4 
(25) - 
3 
(20) - 
14 
(32) - 
N= number;PNP= polyneuropathy; WBC= white blood cell count; ANC= absolute 
neutrophil count; PLT= platelet count; Hb= hemoglobuline 
*3 patients were not evaluable for non-hematological toxicity because of incomplete 
records 
 
 
Pharmacokinetics of paclitaxel 
In 5 patients pharmacokinetics of paclitaxel were assessed, 3 patients with 
teniposide and 2 with etoposide. No differences were observed between these 
two groups. (table 5).  
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Table 5 Pharmacokinetics of paclitaxel in teniposide versus etoposide treated patients  
(dose level 1) 
 
Patient Terminal 
half-life (hr) 
Cmax 
(umol/L) 
AUCinf 
(hr*umol/L)
Time Above 
0.1 umol/L 
(hr) 
Time Above 
0.05 umol/L 
(hr) 
1 17.8 2.86 11.7 12.4 26.1 
2 10.6 1.86 7.92 12.9 20.7 
 
teniposid 
4 13.9 1.20 4.22 7.38 12.0 
12 11.2 2.78 8.40 12.0 23.5 
etoposide 
13 11.6 4.29 9.89 10.3 17.6 
 
Patient outcome 
Six patients (13%) were not evaluable for response, including 2 early deaths. Of 
the remaining 41 patients, 19 (40%) achieved an objective response, with one 
complete response and 18 partial responses. Nineteen patients (40%) showed 
stable disease and 3 (6%) progressed during treatment. 
Exploratory analysis in 29 patients with adequate follow up demonstrated a 
mean time to progression of 5.9 months (95% CI 4.3- 7.4). Three patients (all 
with stage III disease at diagnosis and treated with locoregional radiotherapy 
sequential to chemotherapy) did not have signs of progression at final analysis 
(after 58, 72 and 72 months respectively). Of 43 patients survival data are 
available. Median survival was 14 months (95% CI 10-18); 12,5 months (range 
0.5-58), 26 months (range 5-72) and 12 months (range 1-44) for stage IIIA, 
stage IIIB and stage IV, respectively. Overall one, two and five year survival 
was 47%, 26% and 9%, respectively. 
 
 
Discussion 
In this study we performed a dose-finding finding study of paclitaxel given in 
combination with standard dose cisplatin (80 mg/m2) and etoposide (100 
mg/m2 day 1,3,5). We showed that with support of primary G-CSF prophylaxis 
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the dose of paclitaxel could be doubled before reaching DLT (FN). Then, one 
further step of dose-escalation to 275 mg/m2 was feasible due to the use of 
prophylactic antibiotics. Although MTD was not reached, we decided not to 
escalate the dose of paclitaxel beyond 300 mg/m2 because previous data 
showed a high risk for PNP at this dose (ref). [7] 
Further, our data suggest that the schedule of teniposide and etoposide has an 
impact on the occurrence of hematologic toxicity. With administration on days 
1,2,3 no further dose-escalation above dose level 1 was feasible because of 
myelotoxicity, not even with support of G-CSF. 
After observing severe toxicity at part B dose level 1 we initially hypothesized 
that the cremophor-containing solution of teniposide might influence the 
kinetics and therefore toxicity of paclitaxel. However, this was not supported 
by our data on pharmacokinetics of paclitaxel in a small number of patients 
nor when compared to historic controls.[13] Further, main patient 
characteristics (age, PS, stage of disease and organ function) in etoposide- and 
tenopiside-treated patients were comparable. Moreover, myelotoxicity and 
pharmacokinetics of paclitaxel - cisplatin - teniposide dosed day 1,3,5 were 
comparable to myelotoxicity and pharmacokinetics of paclitaxel - cisplatin and 
etoposide day 1,3,5. Therefore, the dosing schedule of teniposide at days 1, 2 
and 3 seems to be the most likely explanation for the observed toxicity in part 
2 dose level I. No direct comparisons between teniposide administration at 
days 1,2 and 3 and days 1,3 and 5 have been reported, but for etoposide a 
pharmacokinetic association between drug concentrations, response and 
toxicity has been demonstrated.[14;15] Antitumor activity was associated with 
prolonged exposure to low concentrations of etoposide whereas toxicity 
appeared to be associated with higher plasma concentrations. Although not 
conclusive, our results suggest that hematologic toxicity is not only dose-
dependent, but also schedule-dependent. As the schedule seemed to be the 
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most likely explanation, we didn’t change the schedule of etoposide (d1,3,5) 
when adding G-CSF, with indeed no DLT at the first level with G-CSF.  
 
Others have also shown that the addition of G-CSF and/or antibiotics 
facilitates the delivery of conventionally dosed chemotherapeutic agents while 
being used in a triplet regimen. [8]. These and our findings suggest a 
supplemental effect of antibiotics to G-CSF, probably due to the different 
mechanisms of action of G-CSF (reducing the depth and/or duration of 
neutropenia) and antibiotics (reducing the number of pathogens) in the 
prevention of complicated neutropenia.  
 
In phase I trial designs, the decisions on dose escalation often depend on the 
occurrence of DLT in the first treatment cycle. If complicated neutropenia is 
the major expected DLT, this may be a reasonable approach as evidence is 
accumulating that complicated neutropenia mainly occurs during the first cycle. 
In our trial, all episodes of FN occurred during the first cycle. We also found 
that uncomplicated grade 3 or 4 neutropenia mostly occurred during the first 
cycle, with only a few of these events occurring during later cycles (table 4). 
This ‘first cycle’ pattern is seen in cycles with and without G-CSF and/or 
prophylactic antibiotics, and is not restricted to NSCLC patients.[10;16-20]  
This should be considered in the design of future (phase I) trials. 
 
Trials comparing a triplet to a doublet regimen show inconsistent 
results.[21;22] A recent meta-analysis showed a modest but significant increase 
in response rate when a third agent was added to a doublet regimen, however 
without a survival benefit. [2] A drawback is that trials included in this meta-
analysis have used decreased doses of chemotherapy in the triplet 
combinations compared to the doublet regimes to reduce anticipated toxicity. 
This implies that adding a third agent compromises the dose–intensity of the 
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other two agents. Therefore, an unambiguous conclusion regarding triplet 
chemotherapy in NSCLC cannot be drawn. In fact, Delbaldo et al. 
demonstrated that trials with a planned drug dose attenuation resulted in lower 
response rates and survival.[2] Our results show that with adequate support 
nearly a standard dosing of a triple drug combination is feasible for an 
adequate number of cycles.  
Exploratory analyses on patient outcome suggest that the combination of 
paclitaxel-cisplatin-etoposide is quite an active regimen in advanced NSCLC. 
This is reflected in the observed response rate of 40%, with another 40% 
showing stable disease, and a median overall survival of 12 months for stage 
IV NSCLC. Due to the small number of patients a dose-response correlation 
for paclitaxel cannot be investigated. 
In essence a similar regimen of cisplatin/etoposide and paclitaxel with G-CSF 
support has been tested in a prospective phase III trial compared to 
cisplatin/etoposide alone, albeit in extensive stage small cell lung cancer.[23] 
While the doses and schedule are somewhat different from what we used, they 
were unable to document a difference in survival, whereas they observed an 
increase in toxic deaths and more significant neurotoxicity. Based on our study 
with essentially good performance status patients, we feel that this regimen 
might be explored in a pre-operative setting where a more limited number of 
dose intensive treatment might be better tolerated (reflected by the achieved 
dose intensity in the first three cycles of 89%) 
In conclusion, G-CSF and antibiotics support allow triplet chemotherapy at 
full dose in NSCLC patients. The clinical outcome of NSCLC patients treated 
with paclitaxel-cisplatin-etoposide is promising and deserves further testing in 
phase II studies. 
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Abstract 
Purpose: Febrile neutropenia (FN) is a major complication of chemotherapy. 
Antibiotics as well as G-CSF are effective in preventing FN. This multi centre 
randomized phase III trial determines whether the addition of G-CSF to 
antibiotic prophylaxis can further reduce the incidence of FN in patients with 
small cell lung cancer (SCLC) at risk of FN.  
Patients and Methods: Patients (N=175) were stratified for stage of disease, 
performance status, age and prior treatment with chemotherapy, and 
randomized for treatment with cyclophosphamide, doxorubicin and etoposide 
(CDE) followed by prophylactic antibiotics alone (ciprofloxacin and 
roxithromycin) or by antibiotics in combination with G-CSF on days 4-13. 
Results: In cycle 1, 20 (24%) patients in the antibiotics-group developed FN 
compared to 9 (10%) in the antibiotics plus G-CSF group (P=0.01). In cycle 2-
5 the incidences of FN were practically the same in both groups (17% versus 
11%). Only the treatment parameter (Odds ratio 0.33, 95%CI 0.14-0.78) and 
age (1.067 per year, 95%CI 1.013-1.0124) were related to the probability of FN 
in cycle 1.  
Conclusion: Primary G-CSF prophylaxis added to primary antibiotic 
prophylaxis is effective in reducing FN and infections in SCLC patients at risk 
of FN with the first cycle of chemotherapy CDE chemotherapy. For patients 
with similar risk of FN, the combined use of prophylactic antibiotics plus G-
CSF can be considered, specifically in the first cycle of chemotherapy. 
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Introduction 
Febrile neutropenia (FN) is still a major threat to patients treated with 
chemotherapy, resulting in loss of quality of life and even death. Several risk 
factors have been identified to assess the risk of FN in an individual patient. 
These risk factors are related to the patient (age, performance status) and 
underlying disease (extent, co-morbidity), but also to the chemotherapy 
regimen used.[1,2,3,4] To prevent chemotherapy related FN, prophylactic 
antibiotics as well as G-CSF have been applied successfully.  
During the last decade, fluoroquinolones have been used increasingly and a 
meta-analysis in 1408 neutropenic patients showed a significant reduction in 
the incidence of gram-negative bacterial infections (relative risk 0.21), total 
infections (0.54) and episodes with fever (0.85).[5] Clinically documented 
infections and infection-related deaths were not reduced by quinolone 
prophylaxis. A combination of a quinolone with prophylaxis directed against 
gram-positive bacilli (penicillin, vancomycin, or macrolides) compared to 
quinolones alone, significantly reduced bacteraemia (relative risk [RR] 0.65), 
streptococcal infections (RR 0.45) and to a smaller extent the incidence of FN 
(RR 0.98), but without affecting the incidence of fever-related morbidity or 
mortality.[6] Prophylactic ciprofloxacin plus roxithromycin versus two 
placebos reduced the incidence of FN, the number of infections, the use of 
therapeutic antibiotics and hospitalizations due to FN by approximately 50%, 
with a reduced number of infectious deaths in patients with small cell lung 
cancer (SCLC) treated with CDE- chemotherapy (cyclophosphamide, 
doxorubicin and etoposide).[2] The prophylactic use of ciprofloxacin and 
roxithromycin versus placebo also proved to be cost-effective and for some 
occasions even cost-sparing.[7] On the other hand, there is concern regarding 
the emergence of resistant micro-organisms when prophylactic antibiotics are 
administered.[8]  
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G-CSF prophylaxis shortens the duration of chemotherapy-induced 
neutropenia, resulting in a decreased incidence of FN, hospitalization and use 
of intravenous therapeutic antibiotics by approximately 50%.[1,9] The 2000 
American Society of Clinical Oncology (ASCO) recommends G-CSF use for 
primary prophylaxis to be reserved for patients considered at high risk for FN 
or for prolonged hospitalization. This advise is based on data failing to 
demonstrate an improvement in clinical outcomes (complications of FN), 
tumor response or survival on the one hand and economic savings if the 
expected incidence of FN is more than 40% (depending on local cost factors) 
on the other hand.[10,11 ] 
Direct comparisons on the efficacy of either prophylactic strategy are not 
available. In the United States there was considerable opposition to direct 
evaluation of the clinical and economic impacts of these both treatments, 
which necessitated the Cancer and Leukemia Group B to withdraw its 
proposed CALGB 9111 clinical trial of G-CSF versus ciprofloxacin as 
alternative strategies against FN among cancer patients with lung cancer, 
despite support from the NCI for this study.[12] The Adams paper provides a 
nice summary of the relevant issues related to G-CSF for SCLC.[13] The paper 
raises concern over the overall costs and benefits of G-CSF during standard 
dose chemotherapy. In fact, they conclude that the findings of a decade of 
health services studies have shifted towards not being supportive of CSF use 
for primary or secondary prophylaxis for SCLC patients. However, they also 
stress that some patients with a substantial increased risk of FN might still 
benefit from prophylaxis and that research should focus on identifying these 
patients.  
To this date, no data of randomized trials were available indicating whether the 
addition of G-CSF to antibiotics prophylaxis can further reduce the incidence 
of FN in patients at risk. We report here the results of a randomized trial in 
which the prophylactic role of G-CSF added to antibiotics (ciprofloxacin plus 
Primary prophylaxis with antibiotics plus G-CSF 
61 
roxithromycin) for the prevention of FN was evaluated in SCLC patients, 
treated with CDE chemotherapy and at risk of FN. CDE is, especially in 
Europe, one of the standard chemotherapy regimens in the treatment of 
extensive disease (ED) SCLC [14,15] with an incidence of FN from 29% to 
53%.[1,2,9] Our goal was to conduct a pragmatic trial with broad entry criteria 
that did not require specialized staging procedures or follow up, thus providing 
results widely applicable to patients with cancer and their care-providers. This 
report focuses on the clinical results; an economic evaluation was also part of 
the study but will be reported separately.  
 
Patients and methods 
Patient selection 
Patients had to meet the following inclusion criteria: age > 18 years, 
histological or cytological proven SCLC, either ED with a Karnofsky 
Performance Score (KS) > 40 % or limited disease (LD) in combination with 
at least one of the following characteristics: KS 40-70%, age over 60 years, or 
judged to be not suitable for combined chemo-radiation therapy. Previous 
treatment with chemotherapy or radiotherapy if recovered from acute toxicity, 
cerebral metastasis, pancytopenia caused by bone marrow involvement and 
previous malignancy if in complete remission, were all allowed. Patients were 
excluded in case of active uncontrolled infection, inadequate renal or hepatic 
function, any evidence or history of hypersensitivity or other contraindications 
to the drugs investigated in this trial. The ethical committee of each institution 
approved the investigational protocol. Written informed consent was obtained 
from each participating patient. 
 
Treatment 
Patients were stratified for stage of disease, performance status, age and prior 
treatment with chemotherapy since ED, KS < 80%, age > 60 years and 2nd 
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line therapy were all considered risk factors of FN. Subsequently, patients were 
randomized for treatment with CDE chemotherapy followed by prophylactic 
antibiotics alone or antibiotics in combination with G-CSF.  
CDE chemotherapy consisted of cyclophosphamide 1000 mg/m2 on day 1, 
doxorubicin 45 mg/m2 on day 1 intravenously and etoposide 100 mg/m2 
intravenously on days 1-3, every 3 weeks for five cycles. Antibiotic prophylaxis 
consisted of ciprofloxacin 500 mg b.i.d. and roxithromycin 150 mg b.i.d orally, 
days 4-13. If randomized for the experiment arm, G-CSF was given 
subcutaneously on days 4-13 at a dose of 300 microg/day in case of body 
weight < 75 kg or 480 µg/kg/day in case of body weight > 75 kg. 
When FN occurred no dose reduction was applied in further cycles of 
chemotherapy, unless FN was complicated by septic shock or ANC remained 
<0.5 x 109/l for 7 days or more. In case of platelet nadir count < 25 x 109/l 
the protocol required a 25 % dose reduction in the next cycles of 
chemotherapy. FN was defined as an ANC <0.5 x 109/l with a temperature > 
38.5OC (or twice > 38OC within twelve hours). According to current standard 
practice in the Netherlands all patients with FN had to be admitted to the 
hospital and treated with parenteral broad-spectrum antibiotics (preferably a 
third generation cephalosporin). In addition standardized criteria had to be met 
before a patient could be discharged from the hospital, i.e. temperature < 37.5 
OC on two consecutive days, no longer clinical signs of infection and ANC > 
0.5 x 109/l. Treating physicians were free to act according to local hospital 
policy in case of fever without neutropenia (i.e., ANC > 0.5 x 109/l), however 
cultures were mandatory. Prophylactic antibiotics were discontinued if 
therapeutic antibiotics had to be given, but G-CSF administration had to be 
continued. 
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Statistical analysis and outcome measures 
Primary outcome was defined as the difference between both treatment groups 
in the proportion of patients with FN in the first cycle of chemotherapy. 
Secondary outcome measures were defined as the difference between both 
prophylactic strategies in incidence of FN in cycle 2-5 and over the whole 
treatment period; incidence of fever in cycle 1, cycle 2-5 and all cycles; number 
of clinically and microbiologically documented infections; cumulative dose and 
dose-intensity. Further explorative analyses were done comparing nadirs and 
duration of neutropenia between cycles. 
The primary parameter, the proportion of patients with FN during the first 
cycle of chemotherapy, was analyzed using the Cochran-Mantel-Haenszel test, 
combining results over non-empty strata. Categorical parameters were analyzed 
using the uncorrected chi-squared test. Continuous parameters were analyzed 
with Wilcoxon’s two-sample test or the generalized Wilcoxon test when data 
were right censored. In the graphical presentation of nadir counts, medians and 
corresponding nonparametric 95% confidence intervals (95%CI) are given. 
To investigate the influence of several possible predictors (or risk factors) on 
the occurrence of FN in the first cycle logistic regression was used, both fixed 
and stepwise. The treatment parameter (G-CSF yes/no) was always forced in 
the models concerned. Candidate predictors were the four parameters that 
determined the 16 strata, all their first-order interactions and the four first-
order interactions with the treatment parameter. The result of the stepwise 
procedure is presented graphically. 
All analyses were performed on the intention-to-treat population (defined as all 
randomized patients who started chemotherapy and signed informed consent). 
Only the hypothesis regarding the primary parameter was statistically tested 
with a two-sided level of significance of 5%. Before analysis, data of all centers 
were pooled. Likewise, data of all strata were pooled, except for analysis of the 
primary parameter.  
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It should be noted that this study was powered (level of power 80%) to detect 
anticipated differences (15% reduction in incidence of FN in the first cycle, 
from 25% to 10%) in the primary parameter. Hence, both statistically 
significant (small p-values) and non-significant (large p-values) test results of 
secondary parameters and of further exploratory analyses should be interpreted 
with caution. Apart from the primary parameter, no p-values will be presented 
or referred to in the results section. However, for ease of reference and to 
enable comparing our results with those published in relevant papers, p-values 
are given in the tables concerned. 
 
Results 
From December 2000 until June 2003, 186 patients were recruited in 15 
participating hospitals (1 university medical centre and 14 general hospitals) in 
the Netherlands. One hundred and seventy five patients were eligible (planned 
accrual 172 patients including 10% ineligibility). See figure 1.  
 
Figure 1. Flow chart 
 
Registration, stratification and randomization 
N= 186 
Arm A (Antibiotics) 
N= 92 
Written informed consent  
N= 86 
Chemotherapy started 
N=85 
 
Arm B (Antibiotics + G-CSF) 
N=94 
Written informed consent  
N= 91 
Chemotherapy started 
N=90 
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Patient characteristics in both treatment arms were well balanced and are 
summarized in table 1. The majority of patients were over 60 years of age with 
ED, a KS > 80% and received no prior chemotherapy. 
 
 
Table 1 Patient characteristics at baseline 
 Arm A  
(AB) 
N= 85 (%)
Arm B  
(AB + G-CSF) 
N=90 (%) 
Median age (yrs) 
Range 
  < 60 
  > 60 
64 
37-81 
23 (27) 
62 (73) 
64 
36-80 
21(23) 
 69 (77) 
Karnofsky score 
   80-100% 
   40-70% 
 
53 (62) 
32 (38) 
 
57 (63) 
33 (37) 
Stage 
   Limited 
   Extensive 
 
26 (31) 
59 (69) 
 
28 (31) 
 62  (69) 
Prior treatment 
   No  
   Yes  
 
73 (86) 
12 (14) 
 
78 (87) 
12 (13) 
Sex 
  Male  
  Female 
 
55 (65) 
30 (35) 
 
58 (64) 
32 (36) 
Number of risk factors* of FN
  0 
  1 
  2 
  3 
  4 
 
1 (1) 
27 (32) 
35 (41) 
20 (24) 
2 (2) 
 
3  (3) 
23 (26) 
39 (43) 
25 (28) 
0 (0) 
*Risk factors are age > 60 yrs, Karnofsky score 40-70%, 
 ED  and/or prior chemotherapy 
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Febrile neutropenia 
The addition of G-CSF to antibiotics prophylaxis significantly reduced the 
overall incidence of FN by nearly 50% in cycle 1: 20 (24%) patients in the 
antibiotics group developed FN compared to 9 (10%) in the antibiotics plus G-
CSF group (P=0.01, see table 2A). The 20 patients with FN in the antibiotics 
group were similar to the 9 patients in the antibiotics plus G-CSF group, with 
respect to stage, age, KS and line of therapy. 
 
The incidence of FN was highest during cycle 1 and decreased thereafter, in 
both arms. The incidence of FN was practically the same (17% versus 11%) in 
both arms for cycles 2-5. But over the whole treatment period (cycle 1-5) the 
incidence of FN was significantly higher in the antibiotics-arm (32% versus 
18%,); but this distinction was largely due to the difference found in cycle 1.  
 
In total, 39 episodes of FN occurred in 27 out of 85 patients in the antibiotics 
arm versus 21 episodes in 16 out of 90 patients in the antibiotics plus G-CSF 
arm. In cycles 2-5, FN occurred in 7% of 268 cycles in the antibiotics arm 
compared to 4% of 278 cycles in the antibiotics plus G-CSF arm. Although 
most patients experienced FN only once, FN itself (in any cycle) appeared to 
be a risk factor for developing FN in subsequent cycles, independent of the 
prophylactic strategy used. About 50% of patients continuing chemotherapy in 
both arms developed at least one other episode of FN after a first episode of 
FN (table 2B). 
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Table 2A Febrile neutropenia. Incidence and duration of FN 
 Arm A  
(AB) 
 N= 85 (%)
Arm B  
(AB + G-CSF) 
N=90 (%) 
P-value 
RR  
(95% CI) 
Patients with FN in (number, %)     
first cycle 
 
20 (24) 9 (10) 0.01 0.47  
(0.24-0.94) 
subsequent cycles 
 
 13 a  (17)  9 b  (11) 0.19 0.74  
(0.33-1.65) 
overall incidence 
 
27 (32) 16 (18) 0.01 0.57 
(0.34-0.97) 
Number of episodes per patient 
    
                     0 
                     1 
                     2 
                     3 
58 (68) 
19 (22) 
4 (5) 
4 (5) 
74 (82) 
11 (12) 
5 (6) 
0 (0) 
  
Number of episodes per cycle 
(% of pts receiving cycle) 
    
cycle  1 
               cycle 2 
               cycle 3 
               cycle 4 
               cycle 5  
20 (24) 
4a (5) 
8c (11) 
2e (3) 
5g (9) 
9 (10) 
3b (4) 
4d (6) 
3f (5) 
2h (3) 
  
Duration FN in patients with FN,  
median (IR), in days 
    
Cycle 1     (N = 20/9 in arm A/B) 4 (2,8) 3 (2,8) 0.48  
Cycle 2-5   (N=13/9 in arm A/B) 5 (2,9) 3 (2,4) 0.10  
All cycles (N=27/16 in arm A/B) 5 (2,10) 3 (2,6) 0.12  
Duration admission in case of FN,  
median (IR), in days 
    
Cycle 1      (N = 20/9 in arm A/B) 10 (8,11) 6 (5,15) 0.45  
Cycle 2-5   (N=13/9 in arm A/B) 8 (6,13) 12 (9,15) 0.27  
All cycles (N=27/16 in arm A/B) 10 (6,20) 11 (7,20) 0.82  
Duration therapeutic AB i.v.,  
median (IR), in days 
    
Cycle 1 (N = 15/6 in arm A/B) 7 (6,11) 8 (7,9) 0.56  
Cycle 2-5 (N=8/8 in arm A/B) 10 (7,18) 11 (8,13) 0.88  
All cycles (N=19/13 in arm A/B) 10 (6,16) 10 (7,14) 0.95 
 
 
Duration admission in entire 
treatment group in cycle 1, mean (IR)#, 
in days 
    
All causes 5.7(0,10) 2.7 (0,0) 0.01  
All causes but FN  3.7 (0,0) 1.8 (0,0) 0.35  
IR = interquartile range *of 27 en 16 patients in arm A and B respectively. 
a: of 76 pts, who received subsequent cycles; b: of 80 pts, who received subsequent cycles; c: of 73 pts, 
who received subsequent cycles; d: of 72 pts, who received subsequent cycles; e: of 66 pts, who 
received subsequent cycles; f: of 66 pts, who received subsequent cycles, g: of 53 pts, who received 
subsequent cycles; h: of 60 pts, who received subsequent cycles. 
# means are presented here rather than medians because the majority of patients is not admitted (see 
also text) 
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Table 2 B  Risk of subsequent episodes of FN 
 Arm A (AB)
N=85 (%) 
Arm B (AB + G-CSF)
N=90 (%) 
1st FN in cycle 1 
Patients continuing chemotherapy
2nd FN* 
2nd and 3rd FN* 
20 (24%) 
13 
2 (15%) 
4 (31%) 
9 (10%) 
5 
2 (40%) 
0 (0%) 
 
1st FN in cycle 2-5 
Patients continuing chemotherapy
2nd FN * 
 
7# (8%) 
4 
2 (50%) 
 
7# (8%) 
5 
3 (60%) 
 
1st FN in cycle 1-5 
Patients continuing chemotherapy
2nd FN* 
2nd and 3rd FN* 
 
27 (32%) 
17 
4 (24%) 
4 (24%) 
 
16 (11%) 
10 
5 (50%) 
0 (0%) 
 
Total number of patients  
with repeated episodes of FN  
(N=17/10 in arm A/B) 
 
 
8 (48%) 
 
 
5 (50%) 
* (%) = of number of patients continuing chemotherapy  
# 2 respectively 1 in cycle 5 
 
 
In patients with FN during cycle 1, the duration of an episode of FN (median 4 
versus 3 days), duration of hospital admission for FN (median 10 versus 6 
days) and the duration of therapeutic antibiotics because of FN (median 7 
versus 8 days) differed marginally between both treatment groups. FN 
occurring over cycles 2-5 and over the whole treatment period was similar 
between both treatment groups with regard to duration of FN, hospital 
admission and therapeutic antibiotics (table 2A). In both study groups 14 
patients (17% and 16% respectively) were admitted in cycle 1 for other reasons 
than FN (including fever/infection without neutropenia). The median duration 
among those hospitalized was longer in the antibiotics group (15 and 7 days 
respectively). Regarding the entire treatment group, hospitalization due to all 
causes but FN was comparable between both study groups in cycle 1, (mean 
3.7 days versus 1.8 days means are presented here rather than medians because 
the majority of patients is not admitted and the median therefore is non-
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informative (zero in both groups)). Duration of hospital admission (all causes) 
in cycle 1 was shorter in the antibiotics plus G-CSF group compared to the 
antibiotics group due to the difference in incidence in FN (mean 5.7 versus 2.7 
days). 
Eight patients died due to the sequels of FN; 5 in the antibiotics arm and 3 in 
the antibiotics plus G-CSF arm, i.e., 19% of patients with FN in both arms or 
6% (arm A) and 3% (arm B) of the total study population. The majority of FN- 
related deaths occurred in the first cycle of treatment (4 in arm A and 2 in arm 
B) and all patients were >60 years of age (median 69 years, range 62-77).    
 
Delivered chemotherapy and tumor response 
Respectively 62% and 67% of patients completed the planned number of 
cycles in arm A and B. Reasons for discontinuation of chemotherapy were 
equally distributed in both treatment groups, the main reason being progressive 
disease (10% and 13%). The median delivered dose intensity of 
cyclophosphamide and doxorubicin for cycles actually delivered was 
statistically significant higher in the antibiotics plus G-CSF arm, but the 
absolute difference was only 7.0 and 0.2 mg/m2/week, respectively. The 
objective (complete and partial) response rate to chemotherapy was similar in 
both treatment arms (64% antibiotics-group and 70% antibiotics plus G-CSF 
group). 
 
Delivered prophylaxis  
Antibiotics were started in 95% and G-CSF in 93% of delivered cycles. 
Prophylactic treatment with antibiotics and G-CSF was well tolerated, side-
effects being the reason for discontinuation of antibiotics in only 5% (arm A) 
and 8% (arm B) and of G-CSF in 2% of patients (Table 3).  
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Table 3  Reasons for discontinuation of antibiotic or G-CSF prophylaxis 
 
Discontinuation of Antibiotic prophylaxis G-CSF prophylaxis
 Arm A  
(AB) 
N= 85 (%)
Arm B  
(AB + G-CSF)
N=89* (%) 
Arm B  
(AB + G-CSF) 
N=89* (%) 
 
Completion of protocol  
Patient non-compliance 
Protocol violation  
Side effects      
Death  
 
76 (89) 
0 (0) 
2 (2) 
4 (5) 
3 (3) 
 
78 (86) 
1 (1) 
0 (0) 
7 (8) 
3 (3) 
 
80 (90) 
3 (3) 
0 (0) 
2 (2) 
3 (3) 
* in one patient G-CSF was not started despite being randomized to  
receive   antibiotics and G-CSF 
 
 
Toxicity  
The worst overall toxicity during all cycles is demonstrated in Table 4. The 
addition of G-CSF not only lessened WBC and ANC nadir, but also shortened 
the median duration of WBC and ANC nadir in all cycles (table 4). Of note, in 
both groups the median ANC nadir is lower and the duration of grade IV 
neutropenia is longer in cycle 1 compared to further cycles, however in the 
antibiotics plus G-CSF group this phenomenon is more pronounced (figure 2, 
table 4). PLT nadir counts declined gradually during the whole treatment 
period, especially manifesting in the G-CSF arm (figure 2). Treatment was 
delayed because of prolonged leuco-/neutropenia or complicated FN in 20 
(26%) of 76 patients and 3 (4%) of 80 patients continuing chemotherapy after 
the first cycle in the antibiotics group and in the antibiotics plus G-CSF group, 
respectively. But dose reduction for that reason was similar in both groups, 
that is 14 (18%) and 9 (11%) patients respectively). (Complicated) FN was the 
main reason for discontinuation of chemotherapy in 3 (1 in antibiotics group), 
2 (1 in each group), 0 and 2 (1 in each group) patients after cycle 1, 2, 3 and 4 
respectively. Non-hematological toxicities were mild and comparable between 
both study groups. 
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Table 4 Toxicity  
Hematological toxicity: Nadir (median) and duration of nadir (median days) 
 
 Arm A  
(AB) 
 
Arm B  
(AB + G-CSF)
 
Arm A  
(AB) 
 
Arm B  
(AB + G-CSF) 
 
 White blood cell count 
 Nadir (x109/l) Days (IR)  < 1.0 x109/l 
 
   Cycle 1 
   Cycle 2 
   Cycle 3 
   Cycle 4 
   Cycle 5 
 
 
0.7 
0.9 
0.8 
0.95 
0.85 
 
1.0* 
1.7* 
2.1* 
1.8* 
2.0* 
 
3  (0, 7) 
0  (0, 7) 
3  (0, 7) 
1  (0, 7) 
3  (0, 7) 
 
0  (0, 4)1 
0  (0, 3)* 
0  (0, 3)* 
0  (0, 2)* 
0  (0, 0)* 
 Neutrophil count 
 Nadir (x109/l) Days (IR) < 0.5 x109/l 
 
   Cycle 1 
   Cycle 2 
   Cycle 3 
   Cycle 4 
   Cycle 5 
 
 
0.12 
0.34 
0.21 
0.28 
0.26 
 
0.43* 
1.30* 
1.73* 
1.23* 
1.21* 
 
7  (0, 7) 
4  (0, 7) 
5  (0, 8) 
6  (0, 7) 
4  (0, 9) 
 
4  (0, 4)* 
0  (0, 3)* 
0  (0, 1)* 
0  (0, 4)* 
0  (0, 0)* 
 Platelet count 
 Nadir (x109/l) Days < 25 x109/l 
 
   Cycle 1 
   Cycle 2 
   Cycle 3 
   Cycle 4 
   Cycle 5 
 
 
93 
119 
111 
109 
84 
 
104 
96 
77 
59* 
61 
 
0 
0 
0 
0 
0 
 
0 
0 
0 
0 
0 
*P<0.01 1P=0.04 
 IR= interquartile range 
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Figure 2. Median nadir count  (95%CI) per cycle and per treatment group 
solid line = antibiotics treatment group (95%CI) 
dashed line = antibiotics plus G-CSF treatment group (95%CI) 
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Fever and infections 
The incidence of fever in cycle 1 was higher in the antibiotics arm with an 
incidence of 27% in antibiotics-arm versus 12% in the antibiotics plus G-CSF 
arm (table 5). Over the whole treatment period the difference in incidence of 
fever was of the same magnitude (40% versus 28% of patients).  
The total number of infections appeared to be higher in the antibiotics arm (73 
in 353 cycles or 0.21 infections per patient-cycle versus 50 in 368 cycles or 0.14 
infections per patient-cycle). But, when excluding infections occurring during 
an episode of FN, there was barely any difference (0.096 versus 0.079 
infections per patient-cycle). There was no relevant difference in clinically 
documented infections between both treatment groups, over the whole 
treatment period 44 (60% of all infections) in the antibiotics arm and 31 (62% 
of all infections) in the antibiotics plus G-CSF group. Culture positive 
infections were more frequent in the antibiotics arm, especially in cycle 1 with 
14 (45% of all infections in cycle 1) in the antibiotics arm versus 3 (17% of all 
infections in cycle 1) in the antibiotics plus G-CSF arm. In patients with fever, 
the median duration of admission to the hospital in patients with fever was 
similar in both arms (11 versus 14 days).  
 
Prognostic factors of FN in the first cycle 
The prophylactic strategy and the four parameters that defined the sixteen 
strata (elderly age, extensive stage of disease, poor KS and second line of 
therapy) were considered risk factors for FN in the first cycle. First a fixed 
logistic regression analysis was done with these five parameters as independent 
variables. Only the treatment parameter (Odds ratio 0.33 in case of G-CSF is 
added) and age (dichotomized, Odds ratio 6.0 if > 60 years) were 
independently related to the probability of FN in the first cycle (table 6). To 
investigate whether some interactions are also related to this probability a 
stepwise logistic regression was done. As possible predictors beside the 5 main 
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Table 5 Fever, clinically and microbiological documented infections 
 Arm A  
(AB) 
 N= 85 (%) 
Arm B 
(AB plus G-CSF) 
N=90 (%) 
 
 
P-value
Patients with fever (number, %) 
Cycle 1 
Cycles 1-5 
 
 
23 (27) 
34 (40) 
 
11 (12) 
25 (28) 
 
0.01 
0.09 
Death due to infection (number,%)
Cycle 1 
Cycles 1-5 
 
 
4 (5) 
5 (6) 
 
2 (2) 
3 (3) 
 
0.37 
0.42 
Episodes of fever  
Cycles 1-5 (% of all cycles) 
 
 
47 (13) 
 
33 (9) 
 
ND 1) 
Site of infection (N of episodes) 
 
First cycle: all infections 
     Respiratory 
     Non - respiratory 
     No clinical site identified 
 
All cycles: all infections 
     Respiratory 
     Non - respiratory 
     No clinical site identified 
 
 
 
31 
2 
17 
9 
 
73 
8 
36 
16 
 
 
18 
1 
9 
6 
 
50 
11 
20 
16 
 
 
0.02 
 
0.94 2) 
 
 
ND1) 
 
ND 1) 
 
Gram positive infections over all 
cycles 
No of pts 
No of infections 
 
 
 
6 
8 
 
 
 
3 
3 
 
 
 
0.26 
Gram negative infections over all 
cycles 
No of pts 
No of infections 
 
 
 
4 
4 
 
 
3 
3 
 
 
0.64 
No= number ND=not done 1) No statistical test performed. 2) Compared are the 
distributions of site of infection: respiratory, non-respiratory or not identified.  
Note that due to muco- cutaneous (Candida-) infections without fever the total 
number of clinically documented infections is higher than the total number of 
patients with fever. 
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parameters above, all their first-order interactions were chosen. In order to use 
as much information as possible, the continuous versions of age and KS were 
used instead of the dichotomous ones. Again, only the treatment parameter 
(Odds ratio 0.36, 95%CI 0.15-0.84) and age (1.067 per year, 95%CI 1.013-
1.0124) were significantly related to the probability of FN in the first cycle 
(figure 3). 
While planning the study we assumed that the number of risk factors would 
influence the risk of FN but this appeared not to be the case. The Odds ratio 
for getting FN when having 2 or 3-4 risk factors instead were 1.55 (95%CI 0.57-
4.24) and 1.36 (95%CI 0.44-4.19) respectively. 
 
 
Table 6 Baseline predictive factors for the occurrence of FN in cycle 1 
Prognostic factor FN (%) Odds Ratio 95% CI P-value 
Prophylactic strategy 
AB   
AB + G-CSF 
 
20 of 85 (24) 
9 of 90 (10) 
 
1.00 
0.33 
 
 
0.14 – 0.78 
 
 
0.01 
Age 
  < 60 yr 
  ≥ 60 yr 
 
2 of 44 (5) 
27 of 131 (21)
 
1.00 
6.00 
 
 
1.34 – 26.90
 
 
0.02 
Karnofsky score   
 ≥ 80% 
< 80% 
 
19 of 110 (17)
10 of 65 (15) 
 
1.00 
0.82 
 
 
0.34-1.99 
 
 
0.66 
Stage of disease 
  LD 
  ED 
 
10 of 54  (19) 
19 of 121 (16)
 
1.00 
0.96 
 
 
0.40 – 2.35 
 
 
0.94 
Chemotherapy 
  1st line 
  2nd line 
 
26 of 151 (17)
3 of 24 (13) 
 
1.00 
0.62 
 
 
0.16 – 2.41 
 
 
0.49 
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Figure 3. Predicted risk of FN in the first cycle in relation to age 
 
Discussion 
This randomized phase III study investigated the role of the addition of 
primary G-CSF prophylaxis to primary antibiotic prophylaxis in SCLC patients, 
who were at risk of FN by elderly age, poor performance status, ED and/or 
prior chemotherapeutic treatment. We showed that with the addition of 
primary G-CSF prophylaxis, the incidence of FN was further reduced in this 
high-risk population by more than 50% in the first chemotherapy cycle (24% 
versus 10%).  
The incidence of FN in the first cycle in the antibiotics group is considerably 
greater than in the antibiotics arm of the previously published EORTC-study 
by Tjan-Heijnen et al and essentially the same as in the placebo group of that 
study, reflecting the (intended) selection of patients with a higher risk of FN in 
the present study.[2] In the EORTC study we selected patients with a good 
performance status to undergo intensified chemotherapy. In the present study 
Predicted risk of FN in relation to age, based on logistic 
regression. Open dots: patients without FN, closed dots: 
patients with FN in the first cycle. 
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we selected patients known to be at risk of FN, that is, among others patients 
with a poor performance status and/or higher age. Based on the current study, 
only age of 60 years or older can be considered a risk factor. But considering 
the evidence from other studies, stage of disease and poor performance status 
cannot be rejected as risk factors.[2,3,9] A systematic review of publications on 
risk models for FN has recently been published.[16] 
The incidence of FN in the second and subsequent cycles abruptly declined to 
5% to 10% per cycle, with no clear differences between the two prophylactic 
treatment arms. The sample size used does not allow the detection of relatively 
small differences in secondary and further exploratory parameters. 
Furthermore we are aware of the risk of an increasing number of false positive 
(type I errors) and false negative (type II errors) results when the number of 
statistical tests involved increases. However, we feel confident that from all 
such results combined emerges a general picture of the processes involved. 
Although counterintuitive, others also observed that the risk of (complicated) 
neutropenia is greatest in the earliest cycles.[2] In advanced breast cancer, 75% 
of observed episodes of FN occurred in the 1st cycle and in non-Hodgkin 
lymphoma 63% of all toxic deaths occurred in cycle 1 (82% were infection 
related).[17,18] The declining incidence of FN after the first cycle may reflect 
patient selection during treatment, as patients are more likely to continue 
treatment if suffering little chemotherapy-induced toxicity or having a tumor 
response. But, in our study, 89% of patients received the second chemotherapy 
cycle in both prophylaxis arm and only 3 patients discontinued chemotherapy 
because of complicated FN. Neither did we observe a difference in median 
chemotherapy dose between cycle 1 and further cycles, which could have been 
another explanation (data not shown).  
Another explanation for the declining incidence of FN might be the lessened 
ANC nadir or the declining median duration of grade IV neutropenia in cycles 
2-5 compared to cycle 1. Only, this mainly occurred in the antibiotics plus G-
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CSF treatment group and cannot explain declining incidence in the antibiotics 
group. The lessened ANC nadir in subsequent cycles in the antibiotics plus G-
CSF group suggests that there might be a carry over or priming effect of G-
CSF administered in the first cycle to subsequent cycles and administration of 
G-CSF early in the course of treatment might be important. Priming is based 
on the idea of expanding the progenitor pool before the administration of 
cytotoxic medication, on the condition that G-CSF is timely 
withdrawn.[19,20,21,22,23] The duration of neutropenia is also related to the 
occurrence of FN as is demonstrated in patients with AML, breast cancer, 
urogenital cancer and SCLC.18,24,25,26 Although in our patients in cycle 1 a 
longer duration of neutropenia was not associated with a higher probability of 
FN (logistic regression model, data not shown), others demonstrated in SCLC 
patients that each 1-day increase in duration of grade IV neutropenia led to a 
1.7-fold increase in the odds of developing FN.[27] However, the observed 
declining duration of grade IV neutropenia after the first cycle is more explicit 
in the antibiotics plus G-CSF group (see table 4) and therefore is unlikely to be 
responsible for the declining incidence of FN in subsequent cycles in both 
study groups. FN itself appeared to be a risk factor, as approximately 50% of 
patients receiving subsequent cycles of chemotherapy developed at least one 
other episode of FN. Thus, patients developing FN despite prophylaxis stay at 
risk in further cycles despite continuing prophylactic measures. Whether an 
additional prophylactic measure can reduce the risk remains to be seen. The 
value of secondary prophylaxis is not well established. The current ASCO 
guideline on the use of secondary G-CSF prophylaxis is primarily based on 
data derived from the G-CSF registration trial in SCLC.[1,10] That placebo 
controlled trial allowed patients in the control arm who developed FN, to 
receive open-label G-CSF in subsequent cycles of chemotherapy. The patients 
who were subsequently treated with open-label CSF had a reduction in the rate 
of FN from 100% in cycle 1 to 23% in cycle 2, despite receiving the same 
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doses of chemotherapy. Since, as discussed before, the incidence of FN is 
highest in early cycles it’s questionable whether the addition of G-CSF is solely 
responsible for this decline.  
The addition of G-CSF to antibiotic prophylaxis did not influence FN related 
mortality. Despite applying a combined prophylaxis, the FN-related mortality is 
still considerable (6% and 3% respectively). One explanation might be that the 
patient population studied is not only at risk of developing FN but is also 
prone to develop complications of FN due to age, burden of disease and co-
morbidity.[16] Other investigators report similar mortality rates in similar 
patient populations.[28,29]  SCLC patients treated with CDE chemotherapy 
offer an opportunity to study the risk of FN as the risk of FN is increased both 
by the underlying disease as by the use of the myelosuppressive chemotherapy 
regimen. An alternative strategy to prevent FN is choosing a less 
myelosuppressive chemotherapy regimen, as is the frequently used cisplatin–
etoposide regimen. However, the use of cisplatin is limited by nephro- and 
neurotoxicity and use of hyperhydration, especially in the elderly. Surveys in 
the United Kingdom (1999) and in the Netherlands (2003) demonstrated, that 
the CDE chemotherapy regimen is one of the most commonly used regimens 
for SCLC patients who are not candidates for combined 
chemoradiotherapy.[14,30] A majority (75%) of Dutch respondents, all 
pulmonologists with a special interest in lung cancer, prescribed CDE 
chemotherapy as first-line treatment in patients with SCLC. In the United 
Kingdom, CDE is the commonest regimen administered in 28% of any stage 
SCLC patients with a WHO performance status 0-2 compared to the second 
most prescribed regimen (Ifosfamide, Carboplatin, Etoposide) in 13%. 
Currently, in cancer treatment and support numerous costly treatment options 
are available and resources are only limited. Therefore, one cannot recommend 
an expensive measure without considering the costs. An economic evaluation 
was part of our study and provides stochastic cost data derived by the case 
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report forms. Ensuing economic analyses will be described elsewhere in detail 
for reason of comprehensibility. However, the clinical data provide sufficient 
information for a rough calculation. The main cost driver in FN related costs is 
hospitalization.[31] In cycle 1, the total duration of FN related hospitalization 
is 213 days in 85 patients and 87 days in 90 patients. In the Netherlands, the 
guideline price for a day of hospitalization is 270 euro.[32] This means that for 
the first cycle on average 1.5 days of hospitalization are prevented, that is 405 
euro saved, opposed to the additional costs of G-CSF of 1,500 euro per 
patient. A similar calculation for the entire treatment period results in on 
average 2.1 days of hospitalization or 567 euro per patient saved, while the 
addition of 5 cycles of G-CSF costs an extra 7,500 euro. So, it can be 
anticipated that the addition of G-CSF is not cost saving.   
In conclusion, this study demonstrated that primary G-CSF prophylaxis added 
to primary antibiotic prophylaxis resulted in a statistically significant reduction 
in the incidence of FN in the first chemotherapy cycle. In particular patients 
over 60 years of age can benefit of the protective effect of G-CSF, since they 
have an increasing risk of FN. Although the combination results in a clinical 
benefit, a definite recommendation about whether to use or not to use the 
combination requires integration of clinical, quality of life and economic data.  
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Abstract 
Purpose: Recently, a Dutch, randomized, phase III trial demonstrated that, in 
small-cell lung cancer patients at risk of chemotherapy-induced febrile 
neutropenia (FN), the addition of granulocyte colony-stimulating factor (G-
CSF) to prophylactic antibiotics significantly reduced the incidence of FN in 
cycle 1 (24% v 10%; P = .01). We hypothesized that selecting patients at risk of 
FN might increase the cost-effectiveness of G-CSF prophylaxis.  
Methods: Economic analysis was conducted alongside the clinical trial and 
was focused on the health care perspective. Primary outcome was the 
difference in mean total costs per patient in cycle 1 between both prophylactic 
strategies. Cost-effectiveness was expressed as costs per percent-FN-
prevented.  
Results: For the first cycle, the mean incremental costs of adding G-CSF 
amounted to 681 euro (95% CI, –36 to 1,397 euro) per patient. For the entire 
treatment period, the mean incremental costs were substantial (5,123 euro; 
95% CI, 3,908 to 6,337 euro), despite a significant reduction in the incidence of 
FN and related savings in medical care consumption. The incremental cost-
effectiveness ratio was 50 euro per percent decrease of the probability of FN 
(95% CI, –2 to 433 euro) in cycle 1, and the acceptability for this willingness to 
pay was approximately 50%.  
Conclusion: Despite the selection of patients at risk of FN, the addition of G-
CSF to primary antibiotic prophylaxis did not result in cost savings. If policy 
makers are willing to pay 240 euro for each percent gain in effect (i.e., 3,360 
euro for a 14% reduction in FN), the addition of G-CSF can be considered 
cost effective.  
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Introduction  
Febrile neutropenia (FN) is a major complication in patients treated with 
chemotherapy, leading to morbidity and consequently consuming medical 
resources, primarily because of hospitalization. Both prophylactic antibiotics 
and prophylactic granulocyte colony-stimulating factor (G-CSF) have been 
shown to reduce hospitalization for FN by approximately 50%.[1-3]  
Risk factors of FN (eg, poor performance status, extensive disease, elderly age, 
or prior chemotherapy treatment) have been identified, making it possible to 
target prophylactic strategies.[1,3-5] We recently reported the results of a 
randomized, phase III clinical trial assessing the impact of primary G-CSF 
prophylaxis in small-cell lung cancer (SCLC) patients treated with standard 
dose chemotherapy and with an estimated 25% baseline risk of FN in the first 
cycle, despite the use of primary antibiotic prophylaxis.6 In this high-risk 
population, the addition of G-CSF reduced the incidence of FN from 24% to 
10% in the first chemotherapy cycle (P = .01). In cycles 2 through 5, this 
reduction was less important: 17% of patients treated with antibiotics alone, 
compared with 11% of patients treated with G-CSF, developed at least one 
episode of FN. During the entire treatment period, the incidence of FN was 
32% with antibiotic prophylaxis alone, compared with 18% with the addition 
of G-CSF, largely because of the different rates found in cycle 1 (Table 1). 
Other chemotherapy regimens that cause less FN are available for SCLC. In 
Europe, cyclophosphamide plus doxorubicin plus etoposide is frequently 
applied. [6] We hypothesized in this study that the addition of prophylactic G-
CSF to prophylactic antibiotics in patients with a predicted 25% risk of FN 
would be clinically effective and cost effective. This hypothesis is independent 
of the cause of increased baseline risk of FN.  
Prophylactic antibiotics can be cost saving in some occasions. [7] However, the 
use of prophylactic G-CSF comes with considerable expense, and restraint of 
use is therefore recommended. [8,9] An early decision model including 
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economic parameters favored the use of primary prophylactic G-CSF in the 
United States, given a probability of FN of at least 40%. [10] Based on updated 
costs, more recent publications estimated that G-CSF prophylaxis might be 
cost saving above FN thresholds of 20% to 25%. [11-13]  
We hypothesized that the addition of prophylactic G-CSF to prophylactic 
antibiotics in patients considered at risk of FN might increase the cost-
effective administration of prophylaxis. Further, we argued that a prospective 
economic evaluation alongside a clinical trial might improve the quality of the 
economic data and might provide a better understanding of the cost variance 
in production processes between patients and prices in the Netherlands.  
G-CSF prophylaxis has not shown any impact on survival. Therefore, our 
primary focus was a cost-minimization analysis to determine whether the 
savings associated with the expected decrease in incidence of FN would offset 
the additional costs of prophylactic G-CSF. A secondary end point was the 
cost per percent FN prevented.  
 
 
Methods 
Design 
Economic analysis was performed prospectively from a health care perspective 
alongside the clinical trial.[6,14-16] Case Report Forms were used to collect 
resource utilization data during the trial period, providing a patient-based cost 
data set. Costs were calculated for the time the patient was receiving 
chemotherapy in the clinical trial.  
The incidence of FN in the first cycle was the primary end point of the clinical 
study, as subsequent episodes may be related. For that reason, economic 
analysis primarily focused on cost-minimization analysis of the first cycle. Cost-
minimization analysis for the entire treatment period and cost-effectiveness 
were taken into account as secondary analyses. Outcome measures were the 
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difference in mean total costs per patient between both prophylactic treatment 
arms and cost-effectiveness expressed as costs per percent FN prevented.[17]  
 
Cost-Minimization Analysis 
Specific costs that were evaluated included actual delivered chemotherapy, 
prophylactic antibiotics, prophylactic G-CSF, delivered transfusions, all costs 
(including hospitalization) related to a period of FN, and costs of 
hospitalization for any other reason. The mean cost of an episode of FN was 
related to the incidence of FN (Table 1) and was based on the resource 
utilization of hospitalization, visits to general practitioner, emergency room or 
outpatient-department, therapeutic antibiotics, laboratory investigations, and 
cultures and radiologic procedures during each FN-related treatment period. 
The study protocol provided stringent definitions of FN and its management, 
according to current standards in the Netherlands.[6]  
 
Prices were retrieved from various sources (Table 2). Available guideline prices 
were used, as defined in 2000 by the Dutch Health Care Insurance Board.[18] 
Prices for chemotherapy, prophylactic antibiotics, prophylactic G-CSF, and 
therapeutic antibiotics were based on the Dutch reimbursement system for 
pharmaceuticals. Prices of laboratory investigations, radiologic procedures, 
microbial cultures, and transfusions were all derived from the national health 
tariffs authority. All prices were adjusted to the price level of 2002 using price 
index numbers for health care as reported by the Central Bureau of Statistics in 
the Netherlands. Prices were given in euro. The monthly euro exchange rate in 
2002 fluctuated between 0.9 and 1.1 US dollars, so the euro was almost 
equivalent to the US dollar.  
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Table 1 Main results of the clinical trial6 
  
Antibiotics 
N=85 (%) 
Antibiotics  
plus G-CSF  
N=90 (%) 
 
P-value 
Patient characteristics 
Median age (years)
> 60 years
Karnofsky score 40-70%
Extensive disease
Prior treatment
 
64 
62 (73) 
32 (38) 
59 (69) 
12 (14) 
 
64 
69 (77) 
33 (37) 
62 (69) 
12 (13) 
 
 
 
 
 
Prophylaxis#  
Ciprofloxacin and roxithromycin
G-CSF 
 
76 (89) 
NA 
 
76 (86) 
80 (90) 
 
Actual delivered median dose intensity  
mg/m2/week, (% of intended) 
Cyclophosphamid 1000 mg/m2  day 1
Doxorubicin 45 mg/m2 day1
Etoposide 100 mg/m2 day 1,2,3 
 
 
326 (98) 
14.7 (98) 
100 (100) 
 
 
333 (100) 
14.9 (99) 
100 (100) 
 
 
0.04 
0.03 
0.11 
Median number of cycles per patient*  4 4  
Number of patients with FN Cycle 1 
     Cycle 2-5 
20 (24) 
13 (17) 
9 (10) 
9 (11) 
0.01 
0.19 
Number of episodes of FN per cycle 
1   (N = 85/90 in arm A/B)
2   (N = 76/80 in arm A/B)
3   (N = 73/72 in arm A/B)
4   (N = 66/66 in arm A/B)
5   (N = 53/60 in arm A/B) 
 
20 (24) 
4 (5) 
8 (11) 
2 (3) 
5 (9) 
 
9 (10) 
3 (4) 
4 (6) 
3 (5) 
2 (3) 
 
Hospitalization due to FN (mean days), cycle 1 2.0 0.7 0.01 
FN related mortality 5 (6) 3 (2) 0.37 
Response (complete and partial) 65 (76) 71 (79)  
 arm A and B= antibiotics group and antibiotics plus G-CSF group respectively;  
* maximum number of cycles of chemotherapy in protocol was five with an interval 
of 21 days;  # number of patients in which prophylaxis was started in all 
administered cycles 
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Table 2  Costs per unit and sources 
Cost parameter Unit Cost per unit 
(euro)a 
Source 
General practitioner Visit 17 Guideline price CvZ 
Out-patient department Visit 47 Guideline price CvZ 
Emergency room  Visit 47 Guideline price CvZ 
Hospitalizationb Day 270 Guideline price CvZ 
Radiology  X-ray 
echo 
CT 
41 
67 
116 
 
COTG 
Microbial culture Culture 28 COTG 
Standard blood test Test 1.30 COTG 
Blood transfusion unit plasma 79 COTG 
aIndexed prices (2002); bSince guideline prices in university hospital and a general hospital 
differ, a weighted mean price for a hospitalization day was calculated based upon the 
distribution in the study of patients admitted to a university or general hospital (12% and 
88% respectively) 
CvZ= Dutch Health Care Insurance Board; COTG= national health tariffs authority 
 
 
Cost-Effectiveness Analysis 
The incremental cost-effectiveness ratio (ICER) was expressed as the 
incremental cost per decrease percent (absolute) of the probability of FN in the 
first cycle. This ratio was also determined for the entire treatment period, 
based on the occurrence of FN per patient. Uncertainty in the ICER was 
presented as a 95% CI (Fieller's method).  
Cost-effectiveness is graphically represented by an acceptability curve. This 
curve summarizes the evidence in support of antibiotics plus G-CSF being cost 
effective for all potential values of the decision rule (willingness to pay per 
percent more effect). Furthermore, it also represents uncertainty in the ICER. 
Acceptability can be interpreted as the probability of adding G-CSF being cost 
effective (for the given willingness to pay) in a Bayesian sense, using an 
uninformative prior. For example, if the acceptability is 0.95 for a certain value, 
W, of the willingness to pay, then for values greater than W, the corresponding 
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ICER is significantly smaller than W (adding G-CSF is cost effective). Thus, 
the net monetary benefit also is significantly greater than zero. We calculated 
an acceptability curve for the additional probability that FN did not occur, 
based on the approximate normal distributions of costs and effects in cycle 1.  
 
Threshold and Sensitivity Analysis Based on the First Cycle 
Threshold analysis was performed per variable to determine at what point both 
strategies would break even. Sensitivity analyses enable generalization and 
transferability to other countries, other chemotherapy regimens, and other 
patient groups.  
In most publications dealing with the economic analysis of prophylactic G-
CSF, only the FN-related costs are incorporated in threshold and sensitivity 
analyses.[8] To weigh our results against previous publications, we also 
incorporated only FN-related costs into threshold and sensitivity analyses, 
based on a formula that is well accepted in the clinical field [7,10,19,20]:  
risk of FN x relative risk reduction by G-CSF x mean cost of episode of FN = 
unit cost x days of G-CSF prophylaxis 
Threshold points were calculated by adjusting one variable at a time while 
keeping all other variables constant. The relative risk reduction as seen in the 
first cycle was used (58%; Table 1). Threshold lines were generated by varying 
the risk of FN from 10% to 80% and the FN-related costs from 1,000 euro to 
35,000 euro at given prices of G-CSF administration of 250, 500, 1,000, 1,500 
and 2,500 euro per cycle. Results of the threshold and sensitivity analyses refer 
to the incidence and cost of the first cycle only.  
 
Results  
Clinical Trial 
The key results of the clinical trial are summarized in Table 1.  
Cost-Minimization Analysis 
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In the first cycle, the mean total costs were 2,103 euro (95% CI, 1,512 to 2,694 
euro) per patient in the antibiotics group compared with 2,783 euro (95% CI, 
2,359 to 3,208 euro) in the antibiotics plus G-CSF group (Table 3). The mean 
difference in total cost amounted to 681 euro (95% CI, –36 to 1,397) per 
patient in cycle 1.  
During the entire treatment period, the mean total costs per patient were 4,564 
euro (95% CI, 3,647 to 5,480 euro) compared with 9,687 euro (95% CI, 8,872 
to 10,502 euro) in the antibiotics and the antibiotics plus G-CSF groups, 
respectively (Table 3). This resulted in considerable extra costs per patient 
(mean, 5,123 euro; 95% CI, 3,908 to 6,337 euro) when G-CSF prophylaxis was 
added. Table 3 provides an overview of the different cost results.  
 
Cost-Effectiveness Analysis 
In the first chemotherapy cycle, the difference in the incidence of FN was 24% 
with antibiotics compared with 10% with antibiotics plus G-CSF, and the 
mean incremental cost of adding G-CSF was 681 euro per patient (95% CI, –
36 to 1,397 euro). This implies an ICER of 50 euro (681 euro/14% risk 
reduction) per percent decrease of the probability of FN (95% CI, –2 to 433 
euro).  
During the entire treatment period, an ICER of 366 euro per absolute decrease 
percent of the probability of FN per patient in any cycle (95% CI, 165 to 4,815 
euro) was calculated.  
If effect is defined as the probability to remain FN-free, then an acceptability 
curve can be computed to show the acceptability of adding G-CSF to 
antibiotics, given the willingness to pay per percent extra effect. In our study, 
we found an ICER of 50 euro per percent extra effect. Figure 1 shows that the 
acceptability for this willingness to pay is approximately 0.5 (50%) and that the 
willingness to pay should be at least 240 euro to be cost effective. For these 
values, the net monetary benefit is significantly greater than zero (P < .05), and 
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the corresponding ICER is significantly smaller than the willingness to pay 
concerned.  
Table 3  Mean total costs per patient (euro) 
NOTE. 2002 annual exchange rate: 0.95 US dollar/euro. a composition of tariffs (GVS) of 
the different chemotherapeutic agents (cyclophosphamid, doxorubicin, etoposide); b300 
microg/day if bodyweight < 75 kg or 480 microg/day if > 75 kg during 10 days including 
administration; administration costs are 24 euro per cycle, based on a weighted proportion 
of different ways of administration: 80% was self-administration (no costs), 20% was 
administrated by home health care (12 euro per visit);c based on a 10 day schedule of 
ciprofloxacin 500mg bid and roxithromycin 150 mg bid; d 1 respectively 2 patients received 
G-CSF despite being randomized in antibiotics treatment arm; e including red cell and 
platelet  transfusions. Abbreviations: G-CSF, granulocyte colony-stimulating factor; FN, 
febrile neutropenia.  GVS = Dutch reimbursement system for pharmaceuticals 
 
 
Antibiotics
(N=85) 
Antibiotics 
plus G-CSF 
(N=90) 
Mean Difference 
(95% CI) 
FN related costs 892 339 553 (28 - 1,077) 
Chemotherapya 269 270 -1 (-10 – 8) 
Antibioticsb  79 77 2 (-2 – 7) 
G-CSFc 14d 1,616 -1,602 (-1,683 – -1,521)
Non-FN 
hospitalization 
810 459 351 (-150 – 853) 
Transfusionse 39 23 16 (-14 – 47) 
CYCLE 1 
Total costs overall 2,103 2,783 -681 (-1397 - 36) 
FN related costs 1,709 866 845 (-72 –  1,761) 
Chemotherapya 1,089 1,062 26 (-93 – 146) 
Antibioticsb  319 304 16 (-23 – 54) 
G-CSFc 95d 6,200 -6,105 (-6,718 – -5,492)
Non-FN 
hospitalization 
1,171 1,067 103 (-527 – 786) 
Transfusionse 183 192 -9 (-78 – 60) 
ENTIRE 
TREAT- 
MENT 
Total costs overall 4,564 9,687 5,123 (-6,337– -3,908)
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Fig 1. Acceptability curve  
based on the probability to remain febrile neutropenia (FN)-free in cycle 1. 
 
 
This figure summarizes the evidence supporting the cost-effectiveness of antibiotics plus 
granulocyte colony-stimulating factor (G-CSF) for all potential values of the willingness to 
pay per percent decrease of the probability of FN. The willingness to pay should be at least 
240 euro to be considered cost effective. 
 
 
FN-Related Costs 
Patients experiencing FN did not differ between treatment arms in duration of 
an episode of FN, duration of FN-related hospital admission, or duration of 
therapeutic antibiotics. Accordingly, the mean cost of an episode of FN did 
not differ substantially between prophylactic strategies, costing 3,308 euro 
(95% CI, 2,236 to 4,380) and 3,285 euro (95% CI, 1,674 to 4,895) in the 
antibiotics and the antibiotics plus G-CSF group, respectively. Hospitalization 
dominated the FN-related costs (average 82%; Table 4).  
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Table 4  Mean cost price of FN per patient and per episode (euro) 
   
Antibiotics 
 
(95%CI) 
Antibiotics  
plus G-CSF  
 
(95%CI) 
Per Patient a 
 
 
Cycle 1 
Entire treat-
ment 
 
834 
 
1479 
 
(392- 1,276) 
 
(631- 2,247) 
 
305 
 
766 
 
(7- 603) 
 
(266- 1,266) 
Per 
Episo
deb 
 
Hospitalization 
Therapeutic 
antibiotics 
Totalc 
 
2,819 
 
388 
3,308d 
 
(1,837 -3,310) 
 
(236- 540) 
(2,236- 4,380)
 
2,831 
 
270 
3,285d 
 
(1,381- 4,281) 
 
(120 – 820) 
(1,674- 4,895)
abased on 85 and 90 patients in antibiotics and antibiotics plus G-CSF group respectively;  
bbased on and  39 and 21 episodes;  c including diagnostic tests; d if based on 20 and 9 
episodes of FN in cycle 1 only: 3,544 (2,266 – 4,822) and 3,047 (1,759 – 4,335) euro 
respectively 
 
 
Threshold and Sensitivity Analyses for the First Cycle 
Threshold analysis demonstrated that, for the Netherlands, the addition of G-
CSF is cost saving if the probability of FN is more than 84%, the price of 
prophylactic G-CSF is less than 469 euro per patient, or the cost of an episode 
of FN amounts to greater than 11,552 euro (Table 5).  
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Table 5 Threshold analyses based on first cycle 
Parameter  Thresholdsx Empirical result 
Probability FN with antibiotics prophylaxis 
Relative reduction by G-CSF  
0.84 
2.0 
0.24 
0.58 
FN related costsy  Total (euro) 
Hospitalization cost/day (euro)
Mean duration of FN (days)      
11,552 
947 
35 
3,308 
270 
10 
G-CSF prophylaxis  Per patient per cycle (euro) 
Mean duration (days) 
469 
3 
1,605 
10 
x (risk of FN x relative risk reduction by G-CSF ) x (costs of episode of fn) = (unit cost x days of G-CSF 
prophylaxis) 
analysed parameter is varied, with other parameters at constant values as determined in the 
clinical study y 82% of costs consist of hospitalization 
 
 
Figure 2 shows the results of a three-way sensitivity analysis. For example, 
using G-CSF costs of 500 euro per cycle, adding G-CSF prophylaxis will be 
cost saving in patients with a 20% risk of FN and a mean cost of an episode of 
FN of 4,310 euro. If G-CSF prophylaxis costs 1,500 euro per cycle at the same 
FN-related costs, though, cost savings only occur when the probability of FN 
is at least 60%.  
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Fig 2. Sensitivity analysis based on cycle 1. 
 
Each curve represents a threshold line for a given cost of granulocyte colony-stimulating 
factor (G-CSF) prophylaxis per cycle. The reduction of the probability of febrile 
neutropenia (FN) is 0.58 in all cases. The area above the curve favors the addition of G-CSF 
to antibiotic prophylaxis at given FN-related costs (vertical axis) and probabilities 
(horizontal axis). 
 
 
Discussion   
To our knowledge, this is the first clinical trial to include economic parameters 
collected prospectively at the patient level when evaluating G-CSF in patients 
at risk of FN. This randomized, phase III trial in SCLC patients demonstrated 
that the addition of G-CSF to antibiotic prophylaxis significantly reduced the 
incidence of FN in selected patients who were considered at risk of FN.[6] In 
cycle 1, the addition of G-CSF to primary prophylactic antibiotics resulted in a 
mean extra cost of 681 euro per patient, but the significance of this result 
could not be established, because of the large variety in outcomes.  
How likely is it that the addition of G-CSF to antibiotics is cost-effective? The 
answer depends on the willingness to exchange money and effectiveness. No 
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reference values exist for the outcome of percent more effect. However, if 
health care policy makers are willing to pay at least 240 euro for a percent 
decrease of the probability of FN (or 3,360 euro for the 14% reduction of FN 
seen in our trial), then Figure 1 shows an acceptability of at least 95%; thus, 
prophylactic antibiotics plus G-CSF is cost effective. When making such a 
decision, economic analysis and clinical effect should be the focus.  
In prior studies, prophylactic administration of G-CSF was not routinely 
advised because cost savings were unproven.[21,22] When survival was the 
same in arms with and without G-CSF, the less expensive arm optimally was 
chosen. However, good clinical practice may require examining more than 
survival. Although cost per percent-FN-prevented may seem artificial, it has 
been used by Messori et al and in other fields of medicine: cost-effectiveness is 
expressed as cost per headache-day-prevented in menstrual-associated 
migraine, cost per exacerbation-chronic obstructive pulmonary disease 
[COPD]-prevented, and cost per gastrointestinal-ulcer-prevented when using 
different NSAIDs.[17,23-25] In economic analyses, the preferred approach 
may be to use multiple analyses, because strategies may differ in their clinical 
effects but not in survival.[16] In our opinion, some money may be spent for 
supportive care matters, even without an impact on survival. Policy makers 
should decide on the acceptable amount of money to spend.  
Threshold analysis showed that, for the Netherlands, the addition of G-CSF to 
antibiotics is only cost saving if the probability of FN is greater than 84%, the 
price of prophylactic G-CSF is less than 469 euro per patient, or the cost of an 
episode of FN is greater than 11,552 euro.  
Although the mean non–FN-related costs did not differ significantly in cycle 1 
(mean difference, 351 euro; 95% CI, –150 to 853; Table 3), they actually did 
impact the cost analysis. When including non–FN-related hospitalization costs 
in the threshold formula, the addition of G-CSF in the first cycle was cost 
saving when the probability of FN was greater than 65%, the price of 
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prophylactic G-CSF was less than 806 euro per cycle, or the cost of an episode 
of FN was greater than 9,000 euro. Threshold values differed considerably 
when including non–FN-related costs. Our findings stress the importance of 
prospectively collecting cost and resource-utilization data.  
Although the 2000 guidelines on the use of hematopoietic growth factors 
published by ASCO refer to an FN threshold of 40%, above which primary 
prophylaxis with G-CSF is cost saving in the United States, more recent 
publications estimate a threshold of 20% to 25%.[9,11-13] Sensitivity analysis 
of our data cannot identify thresholds for the United States, as economic 
implications can vary between countries. Smith et al26 demonstrated the 
differences in health care systems and practical management of cancer care by 
comparing treatment of ovarian cancer in Europe and the United States.  
The mean cost of an episode of FN in our trial was 3,300 euro, or 
approximately 3,135 US dollars, based on the 2002 annual exchange rate of 
0.95 US dollar per euro. This cost is less than the cost of an episode of FN in 
the United States ($12,302 in patients with solid tumors in 1995-2000 as 
reported by institutions to the University Health System Consortium).[27] The 
difference in our study may be related to several factors, including the strict 
definition of FN-related costs (eliminating costs of possible comorbid 
conditions), no required admission to the intensive care unit, and a fairly low 
cost of therapeutic antibiotics in the Netherlands.[28] Nevertheless, the 
difference in FN-related cost seems mainly caused by differing hospitalization 
costs in the Netherlands and the United States.  
In the near future, outpatient treatment for FN will gain importance and 
interest, especially in patients with a predicted low risk of complications of FN. 
The Multinational Association of Supportive Care of Cancer (MASCC) risk-
index score is based on seven independent factors present at the onset of FN. 
Although comorbidity data was not collected systematically in our trial, a 
substantial number of patients in our trial may have suffered COPD. In 
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addition, the majority of patients with FN was older than 60 years and had 
extensive disease. This results in a MASCC risk index score of 18, which is 
associated with a high risk of complicated FN.[29,30] Therefore, cost savings 
by outpatient treatment of FN is unlikely to be relevant in the studied 
population.  
The control arm was based on a placebo-controlled trial in SCLC patients 
conducted by the European Organisation for Research and Treatment of 
Cancer, in which prophylactic ciprofloxacin plus roxithromycin reduced both 
the incidence of FN and FN-related hospitalizations by approximately 50% 
and proved cost effective.[3,7] The efficacy of antibiotic prophylaxis has been 
confirmed in patients with hematologic and solid cancers.[31,32] Different 
antibiotic regimens have a similar relative risk reduction for FN, so it is 
unlikely that G-CSF has a different impact on the risk of FN when combined 
with quinolones other than those used in our study.  
At the time of the study design, pegylated filgrastim was not yet available. 
Because of the advantage to the patient (only one injection per cycle) and equal 
or greater efficacy compared with daily filgrastim, pegylated filgrastim will 
increasingly be used.[33,34] In the Netherlands, the price of one injection of 
pegylated filgrastim is comparable to the cost of G-CSF used per cycle in our 
study. Therefore, pegylated filgrastim is economically exchangeable with daily 
G-CSF.  
A high incidence of FN in the first cycle with a lower incidence of FN in later 
cycles has been reported before in SCLC and in other malignancies without 
proper explanation.[3,35-37] Possible explanations are patient selection, 
reduced median chemotherapy dose, and declining occurrence or duration of 
severe neutropenia in later cycles; these did not occur in our study. In our 
study, continuing G-CSF prophylaxis in all cycles led to substantial additional 
costs of 5,123 euro per patient (95% CI, 3,908 to 6,337 euro) and 360 euro per 
decreased percent of the probability of FN per patient in any cycle (95% CI, 
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174 to 2,116 euro). Analysis of the first cycle may thus underestimate the 
additional costs. Our results suggest administering primary G-CSF prophylaxis 
in the first cycle only.  
We performed a prospective economic analysis alongside a multicenter, phase 
III clinical trial of primary G-CSF and antibiotic prophylaxis in SCLC patients 
at risk of chemotherapy-induced FN. Despite the selection of patients with a 
24% baseline risk of FN, and despite the significant reduction of FN, the 
addition of G-CSF did not result in cost savings. Only if one is willing to pay 
3,360 euro to achieve a 14% reduction of FN, or 240 euro for each percent 
gain in effect, can the addition of G-CSF to primary prophylaxis with 
antibiotics be considered cost effective. However, the continued use of G-CSF 
beyond the first chemotherapy cycle does not appear cost effective, even at 
these rates of FN.  
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Abstract 
Introduction: Current guidelines (ASCO, EORTC) do not recommend 
secondary infection prophylaxis, where in contrast care-givers prefer secondary 
prophylaxis to chemotherapy dose reduction after an episode of febrile 
neutropenia (FN). As G-CSF is expensive, this study investigates the economic 
consequences of secondary prophylactic use of different prophylactic strategies 
(antibiotics, antibiotics plus G-CSF and a combined sequential approach) in a 
population at risk of FN, using a Markov model.  
Patients and methods: The input for the model is mainly based on the 
clinical outcome and patient-based cost dataset (adopting the health care 
payer’s perspective for the Netherlands) derived from a randomized study on 
primary prophylaxis in small cell lung cancer (SCLC) patients; establishing 
mean cost of an episode FN of 3290 and prophylaxis of 79 (antibiotics) 
plus/minus 1,616 Euro (G-CSF) per cycle. The economic analysis was 
analyzed probabilistically using first and second order Monte Carlo simulation. 
The incremental cost-effectiveness ratio (ICER) was defined as ‘cost per FN-
free cycle’. 
Results: Secondary prophylaxis with antibiotics was the least expensive 
strategy (mean 4,496 Euro per patient). The strategy antibiotics plus G-CSF 
was most expensive (mean 8,998 Euro). Comparison of these two strategies 
resulted in an unacceptable high ICER (343,110 Euro per FN-free cycle) in the 
Dutch context. In scenario’s using higher FN-related costs (as found in the 
USA), the strategies are less distinct in their monetary effects, but still favor 
antibiotics. 
Conclusion: This model-based economic analysis demonstrates that in the 
Netherlands and most likely also in the USA, if secondary prophylaxis is 
preferred, the strategy with antibiotics is recommended. 
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Introduction 
Febrile neutropenia (FN) is a potentially fatal chemotherapy-related 
complication leading to morbidity and consuming medical resources, primarily 
because of hospitalization and intravenous antibiotics use. Primary prophylaxis 
with antibiotics or with G-CSF can significantly decrease the incidence of 
FN.[1-3] Recently we reported the results of a randomized phase III clinical 
trial assessing the impact of primary G-CSF prophylaxis in small cell lung 
cancer (SCLC) patients treated with standard dose chemotherapy and an 
estimated baseline risk of FN in the first cycle of at least 20% despite the use 
of primary antibiotic prophylaxis. Patients receiving prophylactic antibiotics 
plus G-CSF developed significantly less FN (18% compared to 32%).[4] 
Because of considerable expenses (G-CSF) and antimicrobial resistance 
(antibiotics) current guidelines recommend restraint use of primary prophylaxis 
and only in patients considered at risk of FN.[5-7] A prospective economic 
analysis performed alongside our randomized trial demonstrated that, the 
addition of primary G-CSF prophylaxis to antibiotics was not cost saving.[8] 
The mean incremental cost of adding G-CSF per patient in the first cycle (with 
the highest incidence of FN) amounted to 681 euro (95%CI –36 to 1,397), for 
the entire treatment arm the mean incremental costs were substantial (5,213 
euro; 95%CI 3,908-6,337). The EORTC conducted a study in SCLC patients 
investigating primary FN prophylaxis with antibiotics compared to placebo. 
They found that primary antibiotic prophylaxis was the dominant strategy, 
showing both superior clinical efficacy and cost savings in the Netherlands and 
Germany.[9] 
 
A prior episode of FN is considered a risk factor for developing FN in further 
cycles, recurrences are reported in 50-66% of patients.[10-12] The 
administration of prophylaxis after a prior episode of FN is called secondary 
prophylaxis. The placebo controlled G-CSF registration trial by Crawford et al 
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(1991) provided some evidence on the efficacy of secondary prophylaxis as 
patients in the control arm who developed FN received open-label G-CSF in 
subsequent cycles of chemotherapy. Such patients who were subsequently 
treated with open-label G-CSF had an incidence of (only) 23% in cycle 2, 
despite receiving the same doses of chemotherapy.[13] Because of missing high 
level evidence data, present guidelines do not recommend secondary 
prophylaxis. However, in clinical practice care-givers prefer secondary 
prophylaxis to chemotherapy dose reduction after an episode of FN in 50-90% 
of patients, as several surveys in 1996, 2003 and 2005 have demonstrated.[14-
16]  
 
The previously reported prospective economic evaluation alongside our 
randomized trial on primary FN prophylaxis resulted in a patient based cost 
data set resulting in a better understanding of the cost variance in production 
processes of primary prophylaxis.[17] As an extension to our primary 
prophylaxis trial, using the data from this trial as input, we planned a modeling 
study investigating the economic consequences of secondary prophylaxis 
comparing three secondary prophylaxis strategies. In this prospective 
economic analysis consumed medical resources and consequences with regard 
to less morbidity are modeled in monetary terms and FN-free cycles using a 
Markov model taking into account the probability of premature chemotherapy 
cessation and the stage-variant probability of FN.  
 
  
Methods 
Sources 
This analysis is to a large extent based on input from the clinical outcome and 
cost data set from our randomized phase III study in SCLC patients. [18] That 
study included patients at risk of FN defined as 60 years or older, extensive 
disease, a Karnofsky performance score of 40%-70% and/or received prior 
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chemotherapy. Patients were treated with 5 cycles of at the time standard-dose 
chemotherapy (cyclophosphamide, doxorubicin and etoposide) every 3 weeks 
and received primary prophylaxis with antibiotics (ciprofloxacin and 
roxithromycin) or with antibiotics plus G-CSF. Primary outcome was the 
incidence of FN and treatment related cost. The combination of G-CSF and 
antibiotics in primary prophylaxis more effectively reduced the incidence of 
FN compared to antibiotics, with the effect being largest in the first cycle. 
However, this gain in clinical effect came with substantial incremental costs 
(table 1). 
Not all necessary input for the model could be derived from these study results 
and consequently data from other published sources were used.  
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Table 1 Main clinical and economical outcome of the randomized trial.  
 Antibiotics  
N=85 (%) 
Antibiotics  
plus G-CSF  
N=90 (%) 
Patient characteristics 
Median age (range)
> 60 years
Karnofsky score 40-70%
 Extensive SCLC disease
Prior chemotherapy
 
64 (37-81) 
62 (73) 
32 (38) 
59 (69) 
12 (14) 
 
64 (36-80) 
69 (77) 
33 (37) 
62 (69) 
12 (13) 
Number of episodes of FN  in cycle  
1   (N = 85/90 in arm A/B)
2   (N = 76/80 in arm A/B)
3   (N = 73/72 in arm A/B)
4   (N = 66/66 in arm A/B)
5   (N = 53/60 in arm A/B) 
 
20 (24) 
4 (5)  
8 (11)  
2 (3)  
5 (9)  
 
9 (10) 
3 (4)  
4 (6) 
3 (5) 
2 (3) 
Number of patients with first/ recurrent FN in cycle 
 1
2
3
4
5
 
20/0 
1/3 
5/3 
0/2 
2/3 
 
9/0 
2/1 
2/2 
1/2 
1/1 
FN related mortality 5 (6) 3 (2) 
Mean total cost of episode of FN (Euro)  3,308a 3,285a 
FN related  892 339 
Full dose 269 270 
Chemotherapyb 
Reduced dose 194 194 
Antibioticsc 79 77 
Mean cost (Euro) 
per patient per cycle 
Prophylaxis  
G-CSFd 24e 1,616 
a based on 39 and 21 episodes respectively, hospitalization was main cost driver with 2,819 
and 2,831 euro respectively b cyclophosphamide 1000mg/m2 day 1, doxorubicin 45mg/m2 
day1 , etoposide 100mg/m2 day 1,2,3 c ciprofloxacin 1000 mg and roxithromycine 300mg 
daily d 10 day administration including administration cost by health care provider daily dose 
300 microgr if <75 kg and 480 if >75 kg  e 2 patients received G-CSF despite randomization 
in arm A  
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Markov Model  
The clinical process and the morbidity and mortality that a hypothetical patient 
went through during a maximum of 5 chemotherapy cycles was modeled by 
means of a probabilistically analyzed Markov chain process (figure 1), which is 
a multi-state transitory model that allows patients to make event driven 
transitions among various health states, at different transition probabilities, 
over certain periods. After each chemotherapy cycle, the patient may be in 
different states that are mutually exclusive (figure 2). We assumed that an 
episode of FN without prophylaxis always leads to modification of therapy and 
that in all subsequent cycles prophylaxis was administered (figure 1). Three 
secondary prophylactic strategies are considered: either 1) antibiotics, 2) 
antibiotics plus G-CSF or 3) antibiotics after the 1st episode of FN and 
antibiotics plus G-CSF after another episode of FN (‘sequential’). The passage 
of time is divided into intervals representing a complete chemotherapy cycle 
(up to 5 cycles). During each cycle, each hypothetical patient may remain in the 
same state of health or move to another state (figure 2, ‘FN’ and ‘no FN’), 
except when chemotherapy is discontinued (absorbing state, ‘stop’ fig 2). The 
consequences of FN vary per strategy (in money and effect). The probability of 
making a transition from one state to another during a given cycle is called a 
transition probability. The costs of FN, full dose or reduced dose 
chemotherapy, prophylactic antibiotics and/ or prophylactic G-CSF were 
assigned to health states and driven by events that occured following transition 
probabilities. All this information was analyzed using software from TreeAge 
(Williamstown, MA). 
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Figure 1. Markov Model 
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Input for the model: Costs 
The clinical trial on primary prophylaxis provided in a patient-based cost 
dataset adopting the health care payer’s perspective in the Netherlands, as 
described elsewhere in detail.[19,20]. 
Figure 3. Distribution of FN related cost (Euro);  
results after bootstrapping (1000x repetition) the original cost data 
 
Average 3,290
SD 425
Max 4,573
Min 2,45
 
2000 2500 3000 3500 4000 4500 
FN  NoFN  
   Stop  
Figure 2. Health states used in Markov model on FN related prophylaxis 
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For the Markov model the original sample of ‘cost data related to FN’ was 
bootstrapped and resulted in a normal distribution of costs of FN treatment 
(figure 3).[16] The model was probabilistically analyzed using combined first 
and second order Monte Carlo simulation. This procedure runs a fixed number 
(1000) of individual hypothetical patients randomly through the model and 
simultaneously samples from the distributions assigned to variables in the 
model. Our overall analysis contained two multi-dimensional Monte Carlo 
simulations: one considering ‘costs’ as outcome parameter only and one 
considering ‘cost-effectiveness’. 
 
Input for the model: Transition Probabilities  
The probabilities were derived from the randomized phase III trial, except for 
the probabilities of the first episode of FN. The efficacy of the ‘sequential’ 
prophylactic strategy has never been clinically investigated; therefore, we used a 
combination of probabilities as found in our clinical trial. [21] Table 2 provides 
an overview of critical probabilities in the model and their sources. The 
probability of a first episode of FN was based on the pivotal G-CSF trial by 
Crawford et al [22] and as such on a similar patient population as in our 
primary prophylaxis study. If a patient stopped after an episode of FN, 
transition costs were calculated. The ‘stop probability’ in patients who did not 
experience FN was based on a subgroup of SCLC patients treated in an 
EORTC trial with standard dose CDE without prophylaxis (0.05, 0.09, 0.03, 
0.44 and 0.36 in cycles 1,2,3,4 and 5 respectively). [23;24] The stop 
probabilities in patients having experienced FN -and thus receiving 
prophylaxis- were based on the probabilities found in our trial and varied per 
prophylactic strategy (0.04, 0.09, 0.19 and 0.20 in cycle 1,2,3 and 4 with 
antibiotics; 0.11, 0.1, 0.11 and 0.09 with antibiotics plus G-CSF; 0.09, 0.1, 0.11 
and 0.09 in sequential prophylaxis). 
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Input for the model: Effects 
The underlying study on primary prophylaxis did not find a difference in 
mortality rates between treatment groups. However, the different strategies 
resulted in different FN rates and consequently the extra costs might be traded 
off by an extra effect. Therefore, effect was defined as a FN-free cycle. We 
assigned to each cycle without FN a value of 1 and if FN occured a transition 
reward of –1 was applied.  
The incremental cost-effectiveness ratio (ICER) was expressed as the mean 
incremental cost per FN-free cycle. A cost-effectiveness plane and a derived 
acceptability curve graphically represent cost-effectiveness.  
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Table 2  Probabilities used in the Markov model 
 
 P_1stFN   
For all strategiesa 
Cycle 1 
Cycle 2 
Cycle 3 
Cycle 4 
Cycle 5 
0.57 
0.10 
0.03 
0.02 
0.05 
 P_FN_xb 
 AB AB + G-CSF Sequential 
0.23 0.20 0.23 
0.15 0.33 0.33 
0.13 0.50 0.50 
Cycle 1 
Cycle 2 
Cycle 3 
Cycle 4 0.08 0.50 0.50 
 P_1ststop 
For all strategiesc 
Cycle 1 
Cycle 2 
Cycle 3 
Cycle 4 
Cycle 5 
0.05 
0.09 
0.03 
0.44 
0.36 
 P_stop_xb 
 AB AB + G-CSF Sequential 
0.04 0.11 0.09 
0.09 0.1 0.1 
0.19 0.11 0.11 
Cycle 1 
Cycle 2 
Cycle 3 
Cycle 4 0.20 0.09 0.09 
a Based on Crawford et al 1 b Based on our clinical data4 c  based on Tjan-Heijnen et al 3,16 
P_1stFN =probability of first FN per stage =cycle  
P_FN_x =probability of recurrent FN subsequent to  a cycle in which prophylaxis has been 
administered 
P_1ststop= probability of stop without occurrence of FN per stage =cycle 
P_stop_x = probability of stop after a cycle with prophylaxis 
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Exploration of non-parametric uncertainty: Sensitivity Analyses  
To explore uncertainty the following deterministic parameters in the model, 
were subjected to sensitivity analyses. The 2006 ASCO guideline recommends 
administration of primary prophylaxis in case the expected probability on 
developing FN is at least 0.2 per patient.[6] We analyzed the cost of secondary 
prophylaxis in case the probability of FN in cycle 1 was 0.2.  
In the baseline model we used recurrence rates as found in our primary 
prophylaxis trial.[4] Note, that in this study we observed -based on a small 
number of patients- higher recurrence rates in the antibiotics plus G-CSF arm 
compared to the antibiotics arm. As variations in recurrence rates of FN 
depend on patient characteristics, we subjected the recurrence rates to 
sensitivity analysis. We identified one article where patients who experienced 
FN in cycle 1 continued full dose chemotherapy with secondary G-CSF 
prophylaxis and they reported a FN recurrence rate of 0.16 and 0.10 in cycles 2 
and 3 respectively.[10] 
The cost of an episode of FN found in our trial is relatively low (mean 3300 
Euro) compared to the USA (mean $19,110; median $8,376 (approximately 
13,377 Euro and 5,863 euro) per episode of FN).[18].  The European FN costs 
are 20-30% as great as the US FN costs and the European G-CSF costs are 70-
80% as great as the USA G-CSF costs.[19]  Currently, there is a tendency to 
treat low-risk patients experiencing FN in the out-patient setting, resulting in 
less FN-related costs: a recent pilot study in the USA found FN-related costs 
of 1,329 US dollar (973 euro using euro-dollar conversion rate of 0.7).[20] 
Analyses using USA FN-related cost in the model were therefore also 
considered 
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Results 
Baseline model of secondary prophylaxis 
The first multi-dimensional Monte Carlo simulation focusing on ‘costs’ only 
showed that secondary prophylaxis with antibiotics was the least expensive 
strategy with mean costs of 4,496 Euro (95% CI 3,637-5,436) per patient (table 
3). The most expensive strategy was antibiotics plus G-CSF, mean 8,998 Euro 
(95% CI 6,286- 8,969). The sequential strategy resulted in mean additional 
costs of 5,970 Euro per patient (95% CI 4,867- 7,254). From this we conclude 
that the extra cost associated with the addition of prophylaxis (G-CSF) was not 
compensated for by reduction in FN-related cost.  
 
Table 3  Cost per patient per secondary prophylactic strategy in baseline model (Euro) 
   Bootstrap 
Mean (95%CI) 
Antibiotics  4,496 (3,637-5,436) 
Antibiotics  plus G-CSF 8,998 (7,608-10,467) 
1st Antibiotics 2nd G-CSF 5,970 (4,867-7,254) 
Analysis by first and second order Monte Carlo simulation  
bootstrap= the original cost data sample was parameterized normally by  
bootstrapping the original sample;  
 
 
Cost-effectiveness 
Including effects as well as costs, demonstrated that the mean incremental cost 
compared to antibiotics were 5,824 and 2,156 Euro and the mean incremental 
effect, defined as FN-free cycle, were 0.02 and -0.11 for the antibiotics plus G-
CSF strategy and sequential strategy respectively (table 4). The results are 
graphically presented in figure 4 and this implies an ICER of respectively 
343,110 Euro per FN-free cycle for the antibiotics plus G-CSF strategy. Figure 
5 shows the acceptability for a given willingness to pay (WTP) for a FN-free 
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cycle. Figure 5 demonstrates clearly that, in the Dutch context, this will not be 
reached for any reasonable WTP (the WTP 300,000 Euro for a FN-free period 
is approximately 0.45). 
 
Table 4  Cost-effectiveness 
 Cost  
(Incr Cost) 
Effect  
(Incr Effect)
C/E ICER 
Antibiotics  4.745 3,81 1,244  
Antibiotics + G-CSF  10,567 
(5,824) 
3,83 (0,02) 1,865 343,110 
1st Antibiotics 2nd G-CSF  6.901 (2,156) 3,70 (-0,11)  2,759 dominated 
Abbreviations Incr = Incremental; Eff= effects; C/E=cost/effectiveness ratio; ICER= 
incremental cost effectiveness ratio. All cost in Euro 
 
 
 
Figure 4. Baseline cost effectiveness 
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Figure 5. ICER 
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Acceptability curve based on the probability to remain febrile neutropenia (FN)-free. 
This figure summarizes the evidence supporting the incremental cost-effectiveness 
ratio of antibiotics plus granulocyte colony-stimulating factor strategy for all 
potential values of the willingness to pay per FN-free cycle. As the sequential 
strategy was dominated by the antibiotics strategy an acceptability curve was not 
calculated 
 
 
Sensitivity Analyses 
Sensitivity analyses demonstrated that for the clinically important threshold of 
the probability of FN in cycle 1 of 0.2, prophylaxis with antibiotics remained 
the most favorable alternative with respect to costs (table 5). Compared to the 
baseline model (FN-probability cycle 1 0.57), a lower FN probability in cycle 1 
results in lower incremental costs of antibiotics plus G-CSF. But still, both 
strategies are dominated by the antibiotics strategy, as the effects between 
strategies are rather similar (figure 6).  
Haim et al. reported less frequent FN-recurrences than we found in our 
primary prophylaxis study, this affected both the incremental effect as the 
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incremental costs (figure 6) resulting in an ICER of antibiotics plus G-CSF and 
sequential strategy of 17,766 and 70,833 Euro respectively (table 5). 
 
 
Table 5  Sensitivity analyses (mean cost per patient in Euro, SD) 
 Cost (Incr 
Cost) 
Eff (Incr 
Eff) 
C/E ICER 
2.962 4,11 719  
5.729 (2.767) 4,09 (-0.02) 949 dominated 
 
FN1st 
0.2 
Antibiotics
Antibiotics + G-CSF
1st Antibiotics 2nd G-CSF 3.855 (892) 4,06 (-0,05) 1.399 dominated 
4.566 3,86 1.182  
8.861 (3.307) 4.06 (0,19) 2.181 17.766 
 
Haim 
[10] 
Antibiotics 
Antibiotics + G-CSF 1st 
Antibiotics 2nd G-CSF 5.553 (4.062) 3.88 (0,02) 1.433 70.833 
Analysis by first and second order Monte Carlo simulation ; the original cost data sample 
was parameterized normally by bootstrapping the original sample;  
F1st 0.2= probability of FN in 1st cycle is  0.2, other probabilities and cost as in baseline 
model; Haim = recurrence rate in all 3 strategies according to publication (0.16, 0.10, 0.10 
and 0.10), other probabilities and cost as in baseline model 
 
 
When using the lower out-patient FN-related cost as determined by Bennett et 
al or the higher FN-related cost in the US as determined by Kuderer et al as 
input for the model, the mean cost were 2,421, 4,001 and 7,260 Euro following 
Bennett or 15,275, 17,202 and 16,201 Euro following Kuderer for antibiotics, 
antibiotics plus G-CSF and sequential strategy respectively.[18,19] This 
demonstrates that with higher FN related costs the different strategies are less 
distinct in their monetary effects. 
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Figure 6. Cost effectiveness; different scenario’s 
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Cost-effectiveness plane scenario recurrence according to Haim
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Discussion 
To our knowledge, this is the first study comparing the economic 
consequences of the use of different secondary prophylactic strategies in 
preventing FN by means of a Markov model based on a prospectively derived 
patient-based cost data set in SCLC patients at risk of FN. Secondary 
prophylaxis is not advocated by international guidelines, but preferred and 
commonly used by many caregivers. The cost analysis adopted the health care 
payer’s perspective for the Netherlands and investigated three different 
strategies (antibiotics only, antibiotics plus G-CSF and a combined sequential 
approach). Secondary prophylaxis with the combination of antibiotics plus G-
CSF was more costly than antibiotics alone. The cost-effectiveness of 
antibiotics plus G-CSF depends on the willingness to exchange money for 
effectiveness.  
Figure 5 shows that a reasonable WTP is not reached for the antibiotics plus 
G-CSF strategy in the baseline model and the sequential strategy is dominated 
by the antibiotics strategy (less effect, additional costs). Combining these 
results with accompanied sensitivity analyses allow to conclude that the cost of 
G-CSF prophylaxis is the crucial factor with regard to the economics of 
secondary prophylactic strategy. Baseline risk of FN, recurrence risk or the cost 
of FN have, given a realistic range of outcomes, no influence on the 
economics of secondary prophylaxis. 
We could not demonstrate differences in survival or response to anti-tumor 
treatment in the primary prophylaxis trial. Still, good clinical practice may 
require examining more since strategies may differ in their clinical effects 
without impact on survival and as a consequence the preferred approach may 
be to use multiple economic analyses. As discussed elsewhere [8,21], cost per 
FN-free period may seem artificial, but can be a useful assessment. Policy 
makers should decide on the acceptable amount of money to spend for 
supportive care, where there is no impact on survival. 
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Today, with expanding treatment options but limited financial resources, 
rational choices have to be made. Phase III clinical trials investigating new 
treatment strategies preferably should incorporate economic analyses as well. 
However, for different reasons cost-effectiveness studies are not always 
feasible along-side clinical trials and then modeling cost-effectiveness might be 
the answer.[22] However, if a detailed presentation of the model is provided, 
for instance as in our model, those interested can assess the transferability of 
the model to their specific situation.[23] 
 
Our model demonstrates that the cost (and effects) of secondary prophylaxis 
with antibiotics plus G-CSF move toward the antibiotics strategy if there is a 
low probability of a first FN (figure 6). When care givers have implemented the 
recently updated guidelines, that is selecting patients with a risk of 20% or 
higher for use of primary G-CSF prophylaxis, merely patients with a low 
baseline risk are eligible for secondary prophylaxis. In such a patient 
population the absolute economic differences between the different secondary 
prophylactic strategies are less distinct but -due to comparable efficacy- 
antibiotics are still the less costly alternative. 
 
We assumed in our model that the relative recurrence reduction of FN by 
secondary prophylaxis is similar to that seen in our study on primary 
prophylaxis. However, a high incidence of FN is consistently reported in the 
first cycle of chemotherapy. In most studies approximately half of all patients 
experiencing FN during their treatment, do so in the first cycle.[3,24-26] In 
cycle 2 to 5 (table 1), both  the incidence of a first episode of FN as well as 
recurrence seemed to be low and rather similar in both the arm with primary 
antibiotics and primary antibiotics plus G-CSF prophylaxis. Put otherwise, this 
suggests that the addition of G-CSF may not impact recurrence rates, at least 
not to the degree seen in first cycle with primary prophylaxis. These clinical 
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findings support the use of primary prophylaxis rather than of secondary 
prophylaxis.  
 
Two other strategies to prevent recurrent FN (no prophylaxis but 
chemotherapy dose reduction and secondary prophylaxis with G-CSF) were 
not included in our model, as they were not investigated in our primary 
prophylaxis trial and literature does not provide sufficient data on these 
strategies to incorporate them in the model. Most likely, secondary prophylaxis 
with G-CSF alone will result in comparable cost to antibiotics plus G-CSF 
strategy as antibiotics are associated with little extra costs. Using the results of 
38 SCLC patients treated in an EORTC trial with standard CDE 
chemotherapy receiving no prophylaxis and ‘our’ costdata, a global calculation 
results in mean cost of approximately 3,900 Euro per patient (using the 
probabilities in our baseline model with the exception of the probability of first 
FN; 0.57, 0.16, 0.03, 0.06 and 0.09 in cycle 1, 2, 3, ,4 and 5 respectively).[3,16] 
Comparing these results to our baseline model (4,496, 8,998 and 5,970 Euro 
respectively), this indicates that independent of the chosen strategy, secondary 
prophylaxis will most likely never result in cost savings within the health care 
sector. A decade ago, Chouaid et al performed a Markov model based analysis, 
based on retrospective USA-based cost, comparing no prophylaxis to 
secondary prophylaxis with G-CSF (but not antibiotics).[11] They 
demonstrated that secondary prophylaxis with G-CSF in SCLC-patients treated 
with standard dose chemotherapy did not result in cost savings overall (taking 
account of the savings associated with less morbidity).  
 
In conclusion, this model-based economic analysis demonstrated that for a 
realistic range of FN baseline risk and FN related costs secondary prophylaxis 
with antibiotics is least expensive compared to antibiotics plus G-CSF or a 
sequential approach. This study demonstrated that the relatively high price of 
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administering G-CSF is the determining factor as effects are less distinct. 
Taking into account that there is no high level of evidence of the clinical 
efficacy of secondary prophylaxis, at this point secondary prophylaxis cannot 
be recommended. Essentially, the clinical efficacy of different secondary 
prophylactic strategies compared to placebo needs to be prospectively assessed 
with accompanying economic analyses. 
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Abstract 
The prevention of chemotherapy-induced febrile neutropenia is important as it 
reduces hospitalization and is likely to improve quality of life. Several 
prophylactic strategies are available, although their use in patients with an 
anticipated short duration of neutropenia is controversial and not 
recommended. This paper presents the results of a review of the literature on 
the efficacy and cost-effectiveness of prophylactic antibiotics and/or 
granulocyte colony-stimulating factor, and also discusses the recommendations 
in current guidelines in view of recent publications. Both primary prophylactic 
granulocyte colony-stimulating factor and prophylactic antibiotics reduce the 
risk of febrile neutropenia considerably, and the addition of prophylactic 
granulocyte colony-stimulating factor to antibiotics is even more effective. As 
antibiotics, however, give rise to antimicrobial resistance and granulocyte 
colony-stimulating factor is expensive; tailoring of prophylaxis is clearly 
needed. This will increase the absolute clinical and economical benefits of 
prophylaxis. Patient-related, treatment-related and disease-related factors 
enhancing the risk of febrile neutropenia are discussed, including the, 
underrated, high risk of febrile neutropenia specifically in the first cycles of 
chemotherapy. Half of the patients developing febrile neutropenia during 
treatment do so in the first cycle of chemotherapy, which favors primary 
prophylaxis. The efficacy of secondary prophylaxis is not well documented. 
Finally, new interesting agents in the treatment and supportive care of solid 
tumors have become available, and these are discussed in relation to the 
incidence and prevention of febrile neutropenia. 
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Introduction 
Cancer patients treated with chemotherapy may experience therapy-related 
toxicity. Prevention of serious treatment-related toxicity is important to 
improve the quality of life. One of the major complications of chemotherapy is 
neutropenia and its febrile complications, in particular. Febrile neutropenia 
(FN) causes morbidity, leads to hospitalization and may compromise further 
treatment with chemotherapy in individual patients. Thirty years ago FN was a 
fatal complication in almost half of the patients affected [1]. Although 
substantial progress has been made due to immediate initiation of empiric 
antibiotic therapy in patients presenting with FN, at present mortality rates are 
still 10% [2]. 
FN can be prevented, but prophylaxis of FN is controversial, especially in 
patients expected to have only a short duration of neutropenia and a low risk 
of FN. In the 1980s, lithium carbonate and human lactoferrin (a natural milk 
protein) were tested in patients receiving chemotherapy, and were believed to 
be promising means of lowering the risk of infection [3,4]. Today, antibiotics 
and colony-stimulating factors are most commonly used in FN prophylaxis. 
The rationale of prophylactic antibiotics is based on the assumption that most 
infections are caused by endogenous pathogens, particularly when cytotoxic 
agents damage the mucosal barrier. Granulocyte colony-stimulating factors (G-
CSF) stimulate myeloid progenitors by increasing cell division, shorten the 
bone marrow transit time, and modulate function and activity of developing 
and mature neutrophils [5]. 
Besides the prevention of neutropenic complications in standard-dose 
chemotherapy, the use of prophylaxis and especially of G-CSF to support 
chemotherapy dose intensification has been extensively investigated. In this 
article, however, we give an overview of the results and continuing debate of 
prophylaxis of neutropenia-associated infectious complications, focusing on 
adult patients with solid tumors receiving standard-dose chemotherapy and 
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emphasizing antibacterial prophylaxis and the most widely used human 
recombinant hematopoietic growth factor, G-CSF. 
A literature search was performed using ‘Randomized Controlled Trial’ 
(Publication Type) AND ‘Anti-Bacterial Agents’ (MeSH) OR ‘Granulocyte 
Colony-Stimulating Factor’ (MeSH) AND ‘Neutropenia’ (MeSH) limits: all 
adults: 19+ years, English. References of identified articles were scanned for 
additional articles. A few meta-analyses on both prophylactic antibiotics and 
G-CSF are available, and their results are summarized, if essential 
supplemented with results of later trials. 
 
 
Primary prophylaxis 
Prophylaxis can be given either as primary or as secondary prophylaxis. 
Primary prophylaxis refers to the situation that prophylaxis is started upfront in 
the first chemotherapy cycle. Administering prophylaxis in subsequent 
chemotherapy cycles after FN occurred in a prior cycle is referred to as 
secondary prophylaxis. 
 
Primary prophylaxis with antibiotics 
Quinolones 
In the late 1990s, a meta-analysis was published on 18 randomized trials 
assessing the impact of prophylactic quinolones during chemotherapy [6]. It 
was demonstrated that quinolones resulted in a significant reduction in the 
incidence of Gram-negative bacterial infections [relative risk (RR) 0.21, 95% 
confidence interval (CI) 0.12–0.37], total infections (RR 0.54, 95% CI 0.31–
0.95) and episodes with fever (RR 0.85, 95% CI 0.73–0.99) when compared 
with no prophylaxis or placebo. In a side analysis quinolones were compared 
with trimethoprim-sulfamethoxazole (TMS). One of the theoretical advantages 
of the quinolones over the older TMS is that the aerobic Gram-negative flora 
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is eradicated (including Pseudomonas species and of newer agents some Gram-
positive bacteria as well), while the anaerobic flora – which protects against 
super infections – stays intact [7]. Opposed to TMS, quinolones are ineffective 
against Pneumocystis carinii. It was shown that quinolones caused a significant 
reduction in Gram-negative (RR 0.3, 95% CI 0.17–0.54) and overall infections 
(RR 0.83, 95% CI 0.7–0.98), suggesting quinolones to be more effective than 
TMS. 
The majority of trials included in this meta-analysis concerned hematological 
malignancies (11 trials with 773 patients) or included both solid and 
hematological cancer patients (six trials with 593 patients), with only one trial 
regarding solid tumors only (42 patients). Other drawbacks of this meta-
analysis are that the definition of neutropenia, starting date of prophylaxis and 
other inclusion criteria varied widely, variations that could not be fully 
appreciated in the different analyses. Most important, the majority received 
high-dose chemotherapy and bone marrow transplant, thus prohibiting 
straightforward implementation of results for patients with solid tumors 
receiving standard-dose chemotherapy. 
A recently published double-blind placebo-controlled randomized trial in 1565 
patients confirms the efficacy of quinolone prophylaxis in patients with solid 
tumors receiving standard-dose chemotherapy [8]. Patients with solid tumors 
or lymphoma (12.8%) were included. Quinolone prophylaxis significantly 
reduced the incidence of fever (defined as a temperature exceeding 38°C, RR 
0.71, 95% CI 0.55–0.92), probable infection (0.82, 95% CI 0.73–0.94) and 
hospitalization (RR 0.73, 95% CI 0.59–0.90). This study used levofloxacin, a 
well-tolerated quinolone that is administered only once a day, optimizing 
compliance of prophylaxis. The efficacy of levofloxacin was confirmed in 
another recently published placebo-controlled study regarding 760 patients 
expected to experience prolonged neutropenia (more than 7 days). Patients 
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were stratified according to underlying disease, acute leukemia versus solid 
tumor or lymphoma and the effectiveness proved similar [9]. 
 
Combined antibiotic prophylaxis 
Two decades ago, the majority (70%) of isolated pathogens in neutropenic 
patients were Gram-negative bacteria, but today up to 70% are Gram-positive 
cocci [10]. It is important to realize that these trends are often associated with 
local treatment practices, and therefore the epidemiological pattern of bacterial 
infection continues to evolve globally and locally at the institutional level. 
During the last decade, fluoroquinolones have been used increasingly and this 
is thought to be one of the reasons for the shift towards Gram-positive 
infections. Whether the addition of prophylaxis directed against Gram-positive 
bacteria can more effectively reduce fever and infections than quinolones alone 
has been subject of a meta-analysis by Cruciani et al. [11] (nine trials including 
1202 patients). Again, most of these nine trials concerned hematological cancer 
patients or patients with solid tumors receiving bone marrow transplant, 
reflected in a mean duration of neutropenia of 8–30 days. A combination of a 
quinolone with a Gram-positive-directed antibacterial agent compared with 
quinolones alone, significantly reduced bacteremia (RR 0.65, 95% CI 0.53–
0.79) and streptococcal infections (RR 0.45, 95% CI 0.3–0.69), but hardly the 
incidence of FN (RR 0.98, 95% CI 0.86–1.0). 
Not included in this meta-analysis was a trial of the European Organization for 
Research and Treatment of Cancer (EORTC) in 163 patients with small-cell 
lung cancer (SCLC) randomized for combined antibiotic prophylaxis – with 
ciprofloxacin and roxithromycin – as compared with two placebos [12]. 
Combined antibiotic prophylaxis significantly reduced the incidence of FN 
over all cycles from 43 to 24% of patients. This was a two-by-two factorial-
designed trial in patients with an excellent performance status also comparing 
standard-dose chemotherapy to intensified-dose chemotherapy. The protective 
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effect was more distinct in the intensified chemotherapy group as prophylactic 
antibiotics reduced the incidence of FN from 56 to 24% of patients treated 
with intensified chemotherapy compared with from 29 to 24% of patients in 
the standard dose group. 
 
Effect of antibiotic prophylaxis on mortality 
Both prior discussed meta-analyses did not establish a positive effect of 
prophylaxis on infection-related mortality. Yet, a recently published meta-
analysis by Gafter-Gvili et al. [13] showed that antibiotic prophylaxis reduces 
mortality. This large meta-analysis included 95 studies between 1973 and 2004. 
All-cause mortality (in 2910 patients in 40 trials, RR 0.67, 95% CI 0.54–0.81) as 
well as infection-related mortality (in 2913 patients in 37 trials, RR 0.58; 95% 
CI 0.45–0.74) were significantly reduced when comparing antibiotic 
prophylaxis to placebo or no intervention. Prophylaxis with quinolones (1244 
patients in 14 trials) reduced both all-cause mortality and infection-related 
mortality more effectively compared with TMS (870 patients in 14 trials) or 
other systemic antibiotics (525 patients in six trials). A subanalysis in 1232 
patients showed that the addition of Gram-positive-directed antibiotics to 
quinolones did not affect mortality when compared with quinolones alone (RR 
infection-related mortality 1.11, 95% CI 0.63–1.95). 
Again, these results, do not apply straightforward to patients with solid tumors 
receiving standard-dose chemotherapy, as only five of the 95 trials included 
primarily patients with solid tumors treated with standard-dose chemotherapy. 
The largest of these five trials is the previously discussed EORTC trial in SCLC 
patients that demonstrated a significantly reduced mortality rate in patients 
receiving prophylaxis compared with patients receiving placebo. In this trial, 
the number of infectious deaths was nil in the antibiotics arm versus five (6%) 
in the placebo arm (P=0.02). This is the only trial in patients with solid tumors 
comparing a combination of Gram- and Gram-negative-directed agents to two 
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placebos, in contrast to the other trials comparing combined antibiotic 
prophylaxis to a single antibiotic agent or a single antibiotic prophylaxis to a 
single placebo. 
 
Primary prophylaxis with granulocyte colony-stimulating factor 
Daily G-CSF 
The first two randomized controlled trials evaluating the effectiveness of 
primary G-CSF prophylaxis on infectious complications of neutropenia were 
performed in SCLC patients receiving standard-dose chemotherapy [14;15]. 
Both trials demonstrated that G-CSF prophylaxis shortened the duration of 
chemotherapy-induced neutropenia, resulting in a decreased incidence of FN, 
hospitalization and use of intravenous therapeutic antibiotics by approximately 
50%. 
A meta-analysis published in 2002 identified eight randomized controlled trials 
comparing primary G-CSF prophylaxis to placebo or to no prophylaxis during 
standard-dose chemotherapy [16]. Included were trials in patients receiving 
chemotherapy for solid tumors (750 patients in five trials concerning SCLC, 
germ cell tumors, soft-tissue sarcoma or breast cancer) or non-Hodgkin's 
lymphoma (391 patients in three trials). The risk of FN in the control arm of 
these eight trials ranged from 7, 29, 34, 44, 52, 58, 71 to 77% per patient, 
respectively. The use of G-CSF was associated with a significant reduction in 
incidence of FN (odds ratio 0.38, 95% CI 0.29–0.49, P=0.001) and overall risk 
of documented infections (odds ratio 0.51, 95% CI 0.36–0.73, P=0.001). 
Moreover, this meta-analysis demonstrated that the reduction in the incidence 
of FN was relatively constant across the wide range of baseline risks. Infection-
related mortality was not significantly affected (odds ratio 0.60, 95% CI 0.30–
1.22, P=0.16). 
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Once-per-cycle pegylated G-CSF 
In 2002 a pegylated G-CSF was introduced. All the randomized controlled 
trials comparing once-per-cycle pegylated G-CSF to daily G-CSF demonstrated 
at least equal efficacy [17;18]. Due to its convenience to the patient one can 
expect increasing use of pegylated G-CSF. Lyman and Kuderer [19] presented 
a forest plot of the RR of FN in the four most important trials (three trials 
with 513 breast cancer patients and one trial with 66 patients suffering 
malignant lymphoma), suggesting a further reduction in risk of FN with 
pegfilgrastim compared with daily G-CSF with a summary RR of 0.66 (95% CI 
0.44–1.0). 
Pegfilgrastim was also evaluated in a placebo-controlled randomized trial in 
928 breast cancer patients receiving chemotherapy associated with a 17% 
baseline risk of FN. The incidence of FN, FN-related hospitalization and use 
of parenteral antibiotics were all significantly reduced (17 versus 1%, 14 versus 
1% and 10 versus 2% of patients, respectively) [20]. This trial demonstrated 
that pegylated filgrastim can also effectively reduce neutropenic complications 
in a population with a relatively low baseline risk of FN. 
 
Effect of G-CSF prophylaxis on mortality 
An updated meta-analysis presented at the American Society of Clinical 
Oncology (ASCO) 2005 Annual Meeting, including 14 randomized controlled 
trials (one in pegylated G-CSF, three in lenograstim and the remaining in 
filgrastim, with total 3091 patients), showed for the first time a significant 
reduction of infection-related mortality favoring G-CSF; subgroup estimates in 
solid tumors revealed an RR of 0.47 (95% CI 0.23–0.93) [21]. 
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Comparing primary prophylactic strategies 
 
Antibiotics versus G-CSF 
Only one very small prospective randomized trial has been published 
comparing antibiotics to G-CSF (lenograstim) in stage IV breast cancer 
patients treated with intermediate-dose chemotherapy: 18 patients received 
prophylactic G-CSF, and 22 patients received prophylactic ciprofloxacin and 
amphotericin B. The vast majority of events occurred in the first cycle with no 
clear difference between both groups (seven patients in each arm developed 
FN), while the costs of G-CSF were almost 7 times higher than those of 
antibiotics [22]. 
In the mid-1990s the Cancer and Leukemia Group B withdrew its proposed 
Cancer and Leukemia Group B 9111 clinical trial of G-CSF versus 
ciprofloxacin as alternative strategies against FN among cancer patients with 
lung cancer because there was considerable opposition to direct evaluation of 
the (economic) impacts of both prophylactic strategies, which made it 
impossible to raise funding for this trial [23]. 
 
Antibiotics in combination with G-CSF 
Both prophylactic antibiotics as well as prophylactic G-CSF have been shown 
to reduce the incidence of FN significantly. Whether antibiotics in 
combination with G-CSF result in a further decline has not been studied 
extensively, but results are consistent and favor the combination. 
We recently reported the results of a randomized controlled trial comparing 
the efficacy of antibiotics (ciprofloxacin and roxithromycin) only to antibiotics 
and daily G-CSF in 175 SCLC patients receiving standard-dose chemotherapy 
(cyclophosphamide, doxorubicin and etoposide), and considered at risk of FN 
because of age, poor performance status, prior chemotherapy or extensive 
disease [24]. Especially in the first cycle, combined prophylaxis significantly 
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reduced the incidence of FN (from 24 to 10%, P=0.01), while the incidence of 
FN declined in further cycles regardless of type of prophylaxis used (17% 
compared with 11% of patients experienced FN in cycles 2–5). 
In the last couple of years, docetaxel–doxorubicin–cyclophosphamide (TAC) 
combination chemotherapy is being increasingly used in breast cancer patients. 
This regimen is associated with a high incidence of FN and accordingly 
primary prophylaxis has been applied frequently. Two abstracts reported the 
results of the addition of G-CSF to primary prophylaxis with ciprofloxacin 
during TAC chemotherapy. In the first, three consecutive cohorts receiving 
neoadjuvant TAC were reported [25]. The first cohort (390 patients) received 
prophylaxis with daily G-CSF, the second cohort (323 patients) with pegylated 
G-CSF, and the third cohort (236 patients) with a combination of pegylated G-
CSF and ciprofloxacin. The incidence of FN was 4.3% in the cohort receiving 
the prophylactic combination compared with 17.1 and 6.4% in the cohorts 
receiving daily G-CSF or pegylated G-CSF (P<0.001). The other abstract 
reported on 530 patients who received adjuvant TAC [26]. The first 114 
patients received prophylactic ciprofloxacin with an incidence of FN of 24.6% 
(95% CI 16.7–32.5%), whereas in the second cohort of 416 patients daily G-
CSF was added to ciprofloxacin and an incidence of FN of 5.8% (95% CI 3.5–
8%) was found. 
The main results of primary prophylaxis on the incidence of febrile episodes or 
FN are summarized in table1. 
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Table 1 Incidence of febrile episodes using different primary prophylactic strategies  
[relative risk (95%CI)] 
N= number of patients Q=quinolones, Q+=quinolones plus gram positive directed agents, 
PCB= placebo, TMS= trimethoprim-sulfamethoxazole 
*Odds ratio 
 
 
Secondary prophylaxis 
A theoretical advantage of applying secondary prophylaxis is that it prevents 
the use of prophylaxis in patients who would not have developed FN anyhow. 
Thus far no prospective randomized controlled trials have been reported 
comparing secondary prophylaxis with antibiotics or G-CSF to placebo or to 
dose reduction. Only indirect evidence is available that secondary prophylaxis 
with G-CSF prevents FN in patients having experienced FN in a prior cycle of 
chemotherapy. 
 
 
Publication [ref] N Prophylaxis compared Febrile episodes 
Meta analysis 
Engels [6] 
1408 Q to nil or PCB 
Q to TMS 
0.85 (0.73-0.99) 
0.89 (0.74-1.07) 
Cullen [8] 1565 Q to PCB 0.71 (0.55-0.92) 
Bucaneve [9] 760 Q to PCB 0.76 (0.69-0.83) 
Meta analysis 
Cruciani [11] 
1202 Q+ to Q 0.98 (0.86-1) 
Meta analysis 
Gafter-Gvili [13] 
9283 All antibacterial agents to PCB  
Q to nil or PCB 
TMS to PCB 
0.79 (0.72-0.87) 
0.67 (0.56-0.81) 
0.79 (0.69-0.90) 
Meta analysis 
Lyman [16] 
1144 Fil-/lenograstim to nil or PCB 0.38 (0.29- 0.49)* 
Vogel [20] 928 Pegfilgrastim to PCB 0.07 (0.03-0.15) * 
Forrest plot 
Lyman [19] 
579 Pegfilgrastim to filgastrim 0.66 (0.44-1.00) 
Schroder [22] 40 Lenograstim to Q 0.84 (NS) 
Timmer-Bonte [24] 175 Q+ plus filgrastim to Q+ 0.57 (0.34-0.97)* 
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Secondary prophylaxis with G-CSF 
The placebo-controlled trial by Crawford et al. [14] allowed patients in the 
placebo arm that developed FN to receive open-label G-CSF in subsequent 
cycles of chemotherapy. This resulted in a reduction in the rate of FN from 
100% in cycle 1 to 23% in cycle 2. As many trials report a decline in the 
incidence of FN in later cycles without administering (additional) prophylaxis, 
however, no definite conclusions on the efficacy of secondary prophylaxis can 
be drawn from these observations. 
 
Secondary prophylaxis with antibiotics and G-CSF 
In the early 1990s Maiche and Muhonen [27] briefly reported the results of the 
comparison of secondary use of G-CSF to secondary G-CSF and a quinolone 
in, respectively, 30 and 29 patients having experienced FN in the previous cycle 
of chemotherapy (without prophylaxis). Infectious complications occurred 
during grade IV neutropenia in seven of 10 G-CSF-supported cycles compared 
with two of seven cycles supported by G-CSF and quinolones (P=0.09) [27]. 
More recently, Lalami et al. [28] conducted a prospective randomized trial in 48 
patients having experienced FN. In subsequent cycles, secondary prophylactic 
G-CSF or G-CSF and amoxicillin/clavulanate and ciprofloxacin was started. 
No recurrence of FN was observed in the G-CSF strategy and one episode of 
FN in the combined strategy. With the small numbers of patients and lack of a 
placebo-controlled trial it remains difficult to draw conclusions with a high 
level of evidence. 
 
Cost-effectiveness of febrile neutropenia prophylaxis 
Economic evaluations of prophylactic antibiotics are scarce. Despite the 
availability of various publications, the cost-effectiveness of G-CSF is not 
settled. This is in part due to the fact that there is no consistency in costs to be 
considered (all or only FN-related), the perspective to be used (healthcare, 
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social, etc.) and the time horizon (duration of chemotherapy or longer). 
Furthermore, clinical results can have different economic effects in different 
countries because of different healthcare systems [29]. 
 
Primary antibiotic prophylaxis 
Prophylaxis with antibiotics is inexpensive and significantly reduces 
hospitalization. As the cost of hospitalization is the main cost driver of FN-
related costs, it can be anticipated that antibiotic prophylaxis can be cost-saving 
in many situations. We identified only one report that prospectively analyzed 
the cost-effectiveness of prophylactic antibiotics [30]. This report is based on 
the earlier mentioned EORTC study in SCLC patients, and showed that 
prophylactic ciprofloxacin and roxithromycin was cost-saving for The 
Netherlands and cost-neutral for Germany. Sensitivity analysis demonstrated 
that antibiotic prophylaxis would be cost-saving for a broad range of baseline 
risks of FN. For example, for the Dutch situation antibiotics may already be 
cost-saving with a baseline risk of FN of 6% or more. 
 
Primary G-CSF prophylaxis 
The high cost price of G-CSF generally prohibits cost-savings at standard-dose 
chemotherapy with intermediate risks of FN. In the US, a threshold above 
which the administration of prophylactic G-CSF was estimated to be cost-
saving was initially established at a baseline risk of FN of 40% [31]. It is 
important to realize that hospitalization costs, the main cost driver in FN, 
differ to a great extent among countries. Therefore, the 2000 ASCO guideline 
observation that primary prophylactic-only G-CSF is expected to be cost-
saving when the risk of FN 40% or higher, should be applied with prudence in 
other countries [32]. Moreover, in the US FN-related cost have risen in the last 
decade and cost-effectiveness analysis based on updated cost estimates 
indicated a new FN threshold of 20–25% [33,34]. When indirect costs were 
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included this threshold was suggested to be even less than 20% [35]. 
Thresholds for most European countries are likely higher than US thresholds 
as FN-related hospitalization costs in Europe in general are considerably lower 
than in the US (e.g. [Euro sign]3300 in The Netherlands compared with $12 
000 in the US) [33,36]. 
Most single studies did not find a survival gain in the patient group using G-
CSF prophylaxis and concluded that prophylactic administration of G-CSF 
cannot be advised as a routine prescription in case there are no cost-savings 
[37,38]. So, the less-expensive arm was favored in settings in which survival 
was the same. In economic analyses, however, the preferred approach may be 
to use more than one form of analysis. For example, when two alternative 
strategies do not result in survival differences but are yet not identical with 
respect to other clinical effects. In that situation, a cost-minimization is unlikely 
to suffice. Some studies therefore express cost-effectiveness as cost per 
episode FN prevented [36,39]. The issue is whether one should only be willing 
to pay in case of life years saved or whether it is worthy to spend some money 
for supportive care without an impact on survival. 
 
Prophylaxis in current guidelines 
Several international guidelines address prophylaxis of infectious complications 
in neutropenic episodes. In general, guidelines concentrate on either antibiotics 
(Infectious Diseases Society of America guideline) or on G-CSF [ASCO and 
National Comprehensive Cancer Network (NCCN) guideline] [32,40–42]. 
 
Antibiotic prophylaxis in current guidelines 
Despite the fact that prophylactic antibiotics are proven effective in reducing 
the incidence of FN, the 2002 Infectious Diseases Society of America guideline 
does not recommended their routine use, but states that antibiotics should only 
be considered in patients at high risk of FN [40]. 
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In the guideline, specifically mentioned conditions associated with a high risk 
of FN (cytarabine use, severe mucositis and profound neutropenia longer than 
one week) are, however, all conditions not frequently associated with the 
treatment of solid tumors. Cytarabine is seldom used in solid tumor treatment. 
Although some degree of mucositis develops in approximately 40% of patients 
receiving cancer therapy, severe mucositis interfering with normal food intake 
and/or needing parenteral support is not common at standard-dose 
chemotherapy. Finally, prolonged grade IV neutropenia (absolute neutrophil 
count less than 0.5 ×109/l) lasting 7 days or more is uncommon in solid 
cancer patients receiving standard dose chemotherapy. Nevertheless, specific 
patient, disease and chemotherapy-related factors may increase the risk as will 
be discussed later. 
The recommended restrictive use results from the hazard of inducing 
antimicrobial resistance. The concern that resistant microorganisms emerge 
when prophylactic antibiotics are routinely administered seems justified. 
Fluoroquinolones give rise to cross-resistance within their own class as well as 
to unrelated antibiotics such as imipenem [43]. The resistance to 
fluoroquinolones is increasing. The European Antimicrobial Resistance 
Surveillance System is an international network of national surveillance 
systems, which performs ongoing surveillance of antimicrobial susceptibility in 
Streptococcus pneumoniae, Staphylococcus aureus, Escherichia coli and 
Enterococcus faecalis/faecium causing invasive infections, and monitors 
variations of antimicrobial resistance over time and place. For example, in E. 
coli resistance against fluoroquinolones increased from 9 to 14% between 2001 
and 2004 [44]. 
Of note, two reports in neutropenic patients with hematological malignancies 
demonstrated that despite emerging resistance, fluoroquinolone prophylaxis 
still effectively reduced the incidence of Gram-negative infections [45,46]. One 
prospective observational study in patients with hematological cancers was 
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terminated ahead of planned time due to a dramatic rise in infection-related 
mortality after (scheduled) discontinuation of prophylaxis with quinolones. 
Mortality declined again after re-initiating prophylaxis (death due to infection 2, 
9, 33 and 1%). E. coli isolated during the discontinuation period was 
susceptible to levofloxacin in vitro, whereas all E. coli isolated during both 
prophylaxis periods were resistant. So, quinolone resistance appears a poor 
indicator of the clinical efficacy of fluoroquinolone prophylaxis, whereas the 
rate of documented Gram-negative bacteremia may be a more reliable tool to 
detect loss of efficacy of fluoroquinolone prophylaxis. 
 
G-CSF in current guidelines 
The 2000 ASCO guideline on CSFs did not recommend routine use of primary 
prophylactic G-CSF during standard-dose chemotherapy regimens unless the 
risk of FN is 40% or more [32]. Mainly on the basis of the trials by Vogel et al. 
and Timmer-Bonte et al., the NCCN Myeloid Growth Factors Clinical Practice 
Guideline published in 2005 recommended the use of primary prophylactic G-
CSF at a risk of FN of 20% or more. The NCCN recommends further to 
consider G-CSF use when the anticipated risk is 10–20%, especially when 
patient factors (Fig. 1) determine the anticipated risk category [42]. 
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Fig. 1. Patient, cancer and treatment-related factors.  
 
 
 
The 2006 update of the ASCO guideline agrees that reduction in FN was an 
important clinical outcome that justified the use of primary CSF when the risk 
of FN was approximately 20% or more, on condition that an equally effective 
but less myelotoxic regimen was not available [41]. 
Further, the ASCO 2000 and 2006 updated guideline acknowledge the lack of 
evidence of randomized controlled trials on secondary prophylaxis, and do not, 
recommend the secondary use of G-CSF, but instead to reduce chemotherapy 
dose in the palliative setting. The NCCN guideline recommends re-evaluation 
of each patient every cycle and to consider G-CSF if FN or another dose-
limiting neutropenic event has occurred in the prior cycle. 
 
Assessing risk of febrile neutropenia 
Although on the basis of different arguments all guidelines advocate restrictive 
use of prophylaxis, in fact only in patients ‘at risk’ of FN. Obviously, both the 
absolute clinical and economical benefits will be more distinct in patients at 
risk of FN. The different guidelines, however, provide different information 
on which factors are to be considered risk factors. In effect, little high-level 
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evidence is currently available on predisposing factors. Until now, in studies 
designed to evaluate neutropenic complications, only elderly age and advanced 
disease are consistently reported to increase the risk of FN [12,24,47,48]. 
Several other, but less well-documented, pretreatment factors reported to be 
associated with the risk of FN are: tumor type, one or more comorbidities, 
previous episode of FN, hemoglobin <12 g/dl, pretreatment absolute 
neutrophil count <1.5×109/l, serum albumin <3.5 g/dl, intended high 
chemotherapy dose intensity, female gender [24,49,50]. The Awareness of 
Neutropenia in Chemotherapy Study Group is currently prospectively 
registering neutropenic outcome in patients starting with chemotherapy in 125 
centers in the US, and the intended result of this study is to develop a risk 
model for selecting patients for appropriate and timely supportive care. 
Preliminary results validate some of the previously cited factors [51]. 
The incidence of FN of several chemotherapy regimens is fairly well known, 
e.g. anthracycline-based regimens are frequently associated with a risk of FN of 
above 20% [14,51–54]. All these (interrelated) factors sum up to determine the 
estimated risk in an individual patient (Fig. 1). Several studies indicate that the 
risk of FN is highest in the first cycles of chemotherapy (see Table 2) 
[12,14,15,17,18,20,22,24,55]. This finding is probably not sufficiently 
appreciated, but at least half of patients with FN during treatment develop FN 
in the first cycle. 
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Table 2  The incidence of FN in cycle 1 compared to the incidence of FN in the entire 
treatment period (incidence per patient)* 
FN per patient 
(%) 
  Author, year [ref] Tumor N  Prophylaxis 
Cycle 
1 
All 
cycles 
Tjan-Heijnen, 2001 
[12] 
SCLC 79
82
placebo 
antibiotics 
20 
9 
34 
20 
Crawford, 1991 [14] SCLC 
 
102
92
placebo 
filgrastim 
57 
28 
77 
40 
Trillet-Lenoir, 1993 
[15] 
SCLC  64
65
placebo 
filgrastim 
41 
20 
53 
26 
Vogel, 2005 [20] Breast 465
463
placebo 
pegfilgrastim 
11 
0.7 
17 
1 
Nabholtz, 2002 [55] Breast 135
139
139
filgrastim 
leridistim 5mg/kg 
leridistim 10 mg/kg 
4 
11 
14 
7 
19 
22 
Green, 2003 [17] Breast  77
75
pegfilgrastim 
filgrastim 
9 
15 
13 
20 
Holmes, 2002 [18] Breast 149
147
pegfilgrastim 
filgrastim 
7 
12 
9 
18 
Schroder, 1999 [22] Breast 18
22
lenograstim 
ciprofloxacin+amphotericinB 
28 
27 
39 
32 
Timmer-Bonte, 
2005 [24] 
SCLC 85
90
Cipro + roxi 
Cipro + roxi+filgrastim 
24 
10 
32 
18 
Only prospective controlled trials with neutropenic complications as primary endpoint are 
considered ; Cipro + roxi = Ciprofloxacin + roxithromycin 
 
 
Conclusions 
In conclusion, both primary prophylactic antibiotics and primary prophylactic 
growth factors effectively reduce the risk of FN, even more when used as a 
combination. The efficacy of secondary prophylaxis is not well documented 
and therefore dose reduction seems a reasonable alternative, especially for 
regimens given with palliative treatment intent. 
The prophylactic antibacterial agent of choice is a quinolone rather than TMS. 
The addition of a Gram-positive-directed antibacterial agent further reduces 
the amount of bacteremia. Prophylactic antibiotics reduce infection-related 
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mortality, but antibiotics may also lead to microbial resistance with changing 
infection profiles. 
G-CSF reduces FN to the same extent as prophylactic antibiotics, an 
approximately 50% relative decrease compared with the baseline risk. 
Filgrastim and pegylated filgrastim are the most widely studied growth factors, 
both being at least equally effective. On the other hand, G-CSF is expensive 
and despite the reduction in hospitalization still too expensive for many 
standard chemotherapy regimens. Due to differences in healthcare 
organization, the economic break-even point of prophylactic G-CSF varies 
among countries. 
Guidelines recommend prophylaxis only in patients at risk. An assessment of 
the risk of FN can only be made at the patient level. At present, the best-
documented risk factors are elderly age and advanced disease during the first 
cycles of chemotherapy 
 
Future directions 
In our view, it is important to develop new strategies to prevent FN to provide 
high-quality cancer care to patients receiving chemotherapy. If not for cost, at 
present G-CSF would likely be the prophylactic agent of choice in comparison 
with the use of prophylactic antibiotics. For now, further knowledge on 
patient, cancer and treatment-related FN-promoting factors is urgently needed, 
and will hopefully be provided for in the next few years. This will result in 
better tailored prophylaxis and may also lead to a more cost-effective use of 
prophylaxis. 
Potential new prophylactic agents are investigated. Very recently a pilot study 
was published successfully exploring the use of competitive inhibition of bowel 
colonization by lactic acid bacteria, using a pro-biotic strain E. faecium M-74 
[56]. A nontoxic fermented wheat germ extract (Avemar), claimed to have 
immunomodulatory effects, was evaluated in 22 children treated with 
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chemotherapy for solid tumors and significantly reduced the incidence of FN 
[57]. 
Preserving the integrity of the mucosal barrier may help to reduce the 
incidence of systemic infections during profound myelosuppression. 
Palifermin, a purified recombinant truncated form of human keratinocyte 
growth factor, has been developed to reduce the severity and duration of oral 
mucositis, and was studied in patients with hematologic malignancies who 
received myeloablative radio- and/or chemotherapy. In the palifermin group 
not only the duration of grade 3 or 4 oral mucositis, but also the incidence of 
FN was significantly reduced compared with the placebo group [58]. 
Finally, new treatment strategies for solid tumors (e.g. vascular endothelial 
growth factor and epidermal growth factor receptor inhibitors) causing less 
myelotoxicity and less mucosal damage have become increasingly available, and 
this will reduce the incidence of FN, and thus the need of prophylaxis during 
antitumor therapies. 
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Summary and Conclusions 
Cytotoxic therapy is one of the cornerstones in cancer treatment. Unavoidably 
cytotoxic therapy comes with side effects. Supportive care can alleviate 
chemotherapy-induced toxicity. With the introduction of filgrastim caregivers 
were provided with a useful tool to prevent chemotherapy-induced 
neutropenia, but also with an economic burden.  
G-CSF is an effective tool as it reduces (complicated) chemotherapy induced 
neutropenia by an approximately 50% relative decrease compared to the 
baseline risk. On the other hand, G-CSF is expensive and despite the reduction 
in hospitalization not cost saving for many standard chemotherapy regimens in 
solid tumors. Due to differences in healthcare organization, the economic 
break-even point of prophylactic G-CSF varies among countries.  
 
The first chapter provides with a brief historical overview of the development 
of G-CSF and outlines the research presented in this thesis. 
The aims of the studies presented in this thesis were to investigate the role of 
G-CSF schedule on chemotherapy dose-densification, the impact of G-CSF 
support on the degree of chemotherapy dose-escalation, the additional clinical 
value and economic consequences of G-CSF as FN prophylaxis when added to 
primary antibiotic prophylaxis and finally the economic impact of secondary 
FN prophylaxis.  
 
The results of a study in advanced breast cancer patients demonstrated that a 
shortened regimen of daily G-CSF administration in relation to 2-weekly 
chemotherapy was the preferred schedule (chapter 2). To evaluate the effect 
of increasing the window of time between interruption of the G-CSF and start 
of the next chemotherapy cycle, post chemotherapy G-CSF was administered 
for a total of 8 days (resulting in a 5 day G-CSF-free window before the 
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subsequent cycle) or for a total of 11 days (resulting in a 2 day G-CSF-free 
window before the subsequent cycle). Patients acted as their own control, and 
were treated either according to two different schedules (8, 11, 11, 8 and 8 days 
or 11, 8, 8, 11 and 11 days respectively). By doing this we assured that a) for 
comparator cycles the duration of post chemotherapy G-CSF treatment was 
the same, while the G-CSF free interval before the chemotherapy 
administration was the only difference: 5 versus 2 days or 2 versus 5 days and 
b) we could account for potential effects of cumulative dose. In total, 40 
chemotherapy cycles were evaluated. The G-CSF schedule appeared to have a 
significant impact on the degree of thrombocytopenia of the next 
chemotherapy cycle. The mean platelet nadir count was 46 x109/l less 
(95%confidence interval (CI) 33-58 x109/l) following a preceding ‘short’ 2-days 
G-CSF-free interval compared to a ‘long’ 5-days G-CSF-free interval. The G-
CSF schedule did not influence neutrophil recovery (mean difference in ANC 
0.06 x109/l, 95%CI -0.6 -0.73). In conclusion, timely withdrawal (until 5 days 
before the next cycle of chemotherapy) of G-CSF in 2-weekly dose-dense 
chemotherapy reduces chemotherapy-related thrombocytopenia. There was no 
impact of G-SCF schedule on the degree of leukopenia, reflecting a 
counterbalancing protective effect of post chemotherapy G-CSF in both the 8 
day and 10 day schedule. Timely withdrawal of G-CSF during 2-weekly 
chemotherapy may realize planned dose intensity increase. 
 
When exploring new chemotherapy triplets in the treatment of NSCLC G-CSF 
support might be crucial to enable ‘full’ dosed triplets. We demonstrated that 
G-CSF and antibiotic prophylaxis enabled the delivery of a full dosed 
chemotherapy triplet in previously untreated NSCLC patients (chapter 3). 
Without G-CSF support dose limiting toxicity occurred at a paclitaxel dose of 
120 mg/m2 when used in combination with standard dosed cisplatin and 
etiposide. G-CSF support made dose escalation of paclitaxel to 250 mg/m2 
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possible. The addition of prophylactic antibiotics to prophylactic G-CSF 
facilitated dose escalation of paclitaxel to 275 mg/m2 without reaching 
maximum tolerated dose. Further dose escalation was not pursued because of 
the recognized high incidence of severe PNP with the administration of 
paclitaxel doses beyond 300mg/m2 (monotherapy). 
The efficacy of the combination of G-CSF and antibiotics was assessed in 
SCLC patients receiving standard dose chemotherapy and considered at risk of 
complicated neutropenia. We demonstrated that the combination of G-CSF 
with antibiotic prophylaxis significantly reduced the incidence of FN when 
compared to antibiotics alone (chapter 4). One hundred seventy five SCLC 
patients considered at risk of FN due to extensive disease, age above 60 years, 
prior chemotherapy and/or poor performance status were randomized to 
receive primary prophylaxis with antibiotics (ciprofloxacin and roxithromycin) 
or antibiotics plus daily filgrastim. In the first cycle of chemotherapy 20 (24%) 
patients with antibiotic prophylaxis developed FN compared to 9 (10%) 
patients with antibiotics plus G-CSF (P=0.01, RR 0.47; 95%CI 0.24-0.94). 
However, in cycles 2-5 the incidences of FN were not only far less compared 
to the first cycle (ranging from 3-11%), but also practically the same in both 
treatment arms with 17% and 11%, respectively (P=0.19, RR 0.74; 95%CI 
0.33-1.65). In cycle 1, apart from G-CSF administration, age was related to the 
probability of FN (odds ratio 1.067 per year; 95% CI 1.013-1.124). In 
conclusion, primary G-CSF prophylaxis added to primary antibiotic 
prophylaxis resulted in a statistically significant reduction in the incidence of 
FN in the first chemotherapy cycle. For patients with similar risk of FN, the 
combined use of prophylactic antibiotics plus G-CSF can be considered, 
specifically in the first cycle of chemotherapy. In particular patients over 60 
years of age can benefit of the protective effect of G-CSF, since they have an 
increasing risk of FN. Although the combination results in a clinical benefit, a 
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definite recommendation about whether to use or not to use the combination 
requires integration of clinical and economic data.  
 
The prospective cost-minimization analysis (chapter 5), performed alongside 
the multi-center phase III clinical trial of primary G-CSF and antibiotic 
prophylaxis in SCLC patients at risk of chemotherapy-induced FN presented in 
chapter 4, demonstrated that the significant decrease in incidence of FN did 
not offset the additional costs of prophylactic G-CSF. For the first cycle, the 
mean incremental costs of adding G-CSF amounted to 681 Euro (95% CI, -36 
to 1,397 Euro) per patient. The incremental cost-effectiveness ratio was 50 
Euro per percent decrease of the probability of FN (95% CI, -2 to 433 Euro) 
in cycle 1, and the acceptability for this willingness to pay was approximately 
50%. The willingness to pay should be at least 240 Euro per percent decrease 
of the probability of FN or 3,360 Euro for a 14% reduction in FN, to consider 
the addition of prophylactic G-CSF cost effective in the first cycle. However, 
the continued use of G-CSF beyond the first chemotherapy cycle is not cost 
effective. For the entire treatment period, the mean incremental costs were 
substantial (5,123 Euro; 95% CI, 3,908 to 6,337 Euro). 
 
Recurrence of FN after a prior episode of FN is reported in 50-66% of 
patients. Chapter 6 presents the results of a prospective cost minimization 
analysis in which the investment, consumed medical resources and 
consequences of secondary FN prophylaxis with regard to less morbidity are 
modeled in monetary terms using a Markov model. The cost analysis adopted 
the health care payer’s perspective for the Netherlands and investigated three 
different secondary prophylactic strategies (antibiotics, antibiotics plus G-CSF 
and a combined sequential approach). The input for the Markov model was to 
a large extent based on the clinical outcome (chapter 4) and patient-based cost 
dataset (chapter 5) derived from a randomized phase III study in SCLC 
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patients at risk of FN. Secondary prophylaxis with antibiotics was the cheapest 
strategy (mean 4,496 Euro per patient (95%CI 3,637- 5,436). The strategy 
antibiotics plus G-CSF was most expensive (mean 8,998 Euro (95%CI 7,608- 
10,467). To explore deterministic uncertainty in the model, probabilistic 
sensitivity analyses were performed demonstrating that for a realistic range of 
FN baseline risk and FN related costs secondary prophylaxis with antibiotics is 
least expensive compared to antibiotics plus G-CSF or a sequential approach. 
The relatively high price of administering G-CSF is the determining factor. 
 
The high cost price of G-CSF generally prohibits cost-savings at standard-dose 
chemotherapy with intermediate risks of FN and the use of prophylactic 
antibiotics is associated with emerging antimicrobial resistance. As a 
consequence prophylaxis of FN is still restricted in use, especially in patients 
expected to have only a short duration of neutropenia and a low risk of FN. 
Chapter 7 gives an overview of the position of prophylaxis of FN anno 2006 
and puts the results of the studies described in this thesis into the perspective 
of relevant literature and the current guidelines. Both primary prophylactic 
antibiotics and primary prophylactic growth factors effectively reduce the risk 
of FN, even more when used as a combination.  
The prophylactic antibacterial agent of choice is a quinolone rather than 
trimethoprim-sulfamethoxazole. The addition of a Gram-positive-directed 
antibacterial agent further reduces the amount of bacteremia. Prophylactic 
antibiotics reduce infection-related mortality, but antibiotics may also lead to 
microbial resistance with changing infection profiles.  
G-CSF reduces FN to the same extent as prophylactic antibiotics, an 
approximately 50% relative decrease compared with the baseline risk. 
Filgrastim and pegylated filgrastim are the most widely studied growth factors, 
both being at least equally effective. On the other hand, G-CSF is expensive 
and despite the reduction in hospitalization still too expensive for many 
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standard chemotherapy regimens. Due to differences in healthcare 
organization, the economic break-even point of prophylactic G-CSF varies 
among countries.  
The efficacy of secondary prophylaxis (with either antibiotics or G-CSF) is not 
well documented and therefore dose reduction seems a reasonable alternative, 
especially for regimens given with palliative treatment intent.  
Guidelines recommend prophylaxis only in patients at risk. An assessment of 
the risk of FN can only be made at the patient level. At present, the best-
documented risk factors are elderly age and advanced disease during the first 
cycles of chemotherapy. 
 
Future Challenges 
In the early years of the development of G-CSF, bearing in mind that other 
than hematopoietic cells express G-CSF-receptors as well, there were some 
concerns about the safety of G-CSF. Based on results in thousands of patients 
treated in randomized trials, G-CSF use was considered safe. Recently 
however, Hershman et al published the results of a retrospective cohort study 
in 5510 women treated with adjuvant chemotherapy for breast cancer. In this 
cohort 906 women received G-CSF or GM-CSF support. Sixty-four of the 
latter women were diagnosed with acute myeloid leukemia (AML) or 
myelodysplastic syndrome (MDS) before breast cancer recurrence compared to 
48 of 4604 women not receiving CSF-support.[1] The hazard ratio was 2.14 
(95% CI 1.12- 4.08). Thus, although the absolute risk remained low, CSF use 
seems to be associated with a doubling in the risk of subsequent AML or 
MDS. Even if this association is confirmed prospectively, the benefits of G-
CSF may still outweigh the risks. Nevertheless, these results are important to 
bear in mind, using G-CSF in situations were its benefit is not convincingly 
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demonstrated by phase III trials. This also implicates that in future research the 
long term outcome of patients treated with G-CSF needs to be assessed. 
 
Based on the research presented in this thesis the optimal schedule of daily G-
CSF in dose-dense chemotherapy regimens is established. Further studies are 
needed to determine whether daily G-CSF can be safely replaced by the 
(patient convenient) once-per-cycle pegylated G-CSF. Based on our results one 
may also hypothesize that earlier studies investigating dose-dense 
chemotherapy with G-CSF support until shortly before the next cycle, could 
not deliver chemotherapy as planned and this may have confounded the results 
of dose-densification. So, the use of dose-dense chemotherapy supported with 
timely withdrawn G-CSF support deserves further studying. 
 
As treatment results of several advanced malignancies are only modest in terms 
of response rate and (disease-related) survival,combined use of several drugs 
with non-overlapping mechanisms of action may be a rational step to try to 
improve outcome. But, in multi-drug regimens doses of the individual drugs 
often are limited due to severe side-effects as myelotoxicity and ensuing FN. 
We demonstrated that with adequate support with G-CSF and antibiotics, a 
full dosed triplet is feasible in NSCLC patient, whereas without support 
complicated neutropenia indeed was the DLT at one third of the final dose of 
the third agent. Maintaining dose-intensity is considered relevant in the 
treatment of some solid tumors, as NSCLC. Based on our results it is 
recommended to investigate the MTD of new drug combinations with and 
without support with G-CSF plus or minus antibiotics, before engaging the 
new regimen in a phase III trial. 
 
The clinical efficacy of primary prophylaxis with G-CSF is beyond doubt and 
this resulted in several international guidelines advocating its use in case the 
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risk of FN is calculated 20% or more. We showed that FN predominantly 
occurs in the first cycle, with a significant reduction of FN by primary 
prophylaxis in particular for cycle 1.  
The issue is that supportive care cannot always be easily translated into cost 
per life year saved (LYS) or cost per quality adjusted life year (QALY) 
saved. Recently for the Netherlands approximately 80.000 Euro per QALY, 
linked to a high burden of disease, is suggested as being acceptable. Yet, in our 
opinion some money may be spent for supportive care matters. It seems 
unethical to withhold a patient supportive care that is able to reduce the risk of 
complications associated with anxiety and discomfort. This requires an 
interactive approach where stakeholders (caregivers, researchers and 
policymakers) come to some kind of consensus about what is acceptable to 
invest in for example a percentage decrease of the probability of FN. Based on 
our research, for the Dutch situation, the addition of G-CSF in cycle 1 comes 
with acceptable additional costs and can be considered cost-effective, but G-
CSF support during the entire chemotherapy treatment period is not cost-
effective. Based on our results randomized studies should explore whether it is 
successful, safe and cost-effective to support the first chemotherapy cycle only 
and to withhold G-CSF support in later cycles. Currently, a study in breast 
cancer patients designed to address this question has been approved for 
funding (Dutch Health Care Insurance Board, ZonMw). 
 
By modeling cost-effectiveness of secondary prophylaxis we demonstrated that 
secondary prophylaxis with antibiotics is most favorable in monetary terms. 
But, both the clinical efficacy and economic consequences of secondary 
prophylaxis with antibiotics and or G-CSF are not well established. Even 
taking into account current guidelines advocating the use of primary 
prophylaxis in patients with a baseline risk of FN of 20% or more, still a 
greater part of patients with solid tumors will not be eligible for primary 
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prophylaxis and may be considered for secondary prophylaxis. Randomized 
phase III studies are therefore necessary to clarify both the clinical and cost 
effectiveness of secondary FN prophylaxis.  
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Samenvatting en Conclusies 
 
Chemotherapie is een van de hoekstenen van de behandeling van kanker. Dit 
gaat onvermijdelijk gepaard met bijwerkingen. Goede ondersteunende 
behandeling, ook wel supportive care genoemd, kan de nadelige gevolgen van 
chemotherapie beperken. Een van de belangrijke bijwerkingen van 
chemotherapie is neutropenie (verlaagd aantal witte bloedcellen welke van 
belang zijn bij de afweer tegen infecties). Patiënten die tijdens neutropenie 
koorts en een infectie ontwikkelen (zogenoemde febriele neutropenie, FN) 
moeten voor behandeling in het ziekenhuis worden opgenomen en overlijden 
soms aan de gevolgen hiervan. Filgrastim is een granulocyt-kolonie 
stimulerende groeifactor (G-CSF) en met de introductie hiervan in de jaren 
negentig van de vorige eeuw, werd tevens een dilemma geïntroduceerd; 
enerzijds is G-CSF een doeltreffend middel om door chemotherapie 
veroorzaakte neutropenie te voorkomen, anderzijds gaat de toediening ervan 
gepaard met hoge kosten.  
 
Bij start van het onderzoek gepresenteerd in dit proefschrift waren er nog een 
aantal vragen rondom het gebruik van G-CSF onbeantwoord. Tevens  was 
inmiddels bekend dat het gebruik van antibioticaprofylaxe een effectief en in 
sommige situaties kostenbesparend alternatief is om de complicaties van 
neutropenie te voorkomen. 
Hoofdstuk 1 presenteert een kort historisch overzicht van de ontwikkeling 
van G-CSF en schetst de vragen die in de latere hoofdstukken worden 
onderzocht zoals, welk toedienschema is het best tijdens 2-wekelijkse 
chemotherapie, maakt ondersteuning met G-CSF in combinatie met antibiotica 
toediening van hogere dosis chemotherapie mogelijk, heeft toevoegen van G-
CSF aan ondersteuning met antibiotica tijdens standaard dosis chemotherapie 
zin en wat zijn de economische gevolgen hiervan? 
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Uit eerder onderzoek is bekend dat G-CSF gegeven tot kort voor de volgende 
kuur chemotherapie van invloed is op de mate van neutropenie in die volgende 
kuur. Er is veel aandacht voor chemotherapie dosis-densificatie (het geven van 
chemotherapie met kortere intervallen tussen de kuren), waarbij ondersteuning 
met G-CSF meestal noodzakelijk is en er  vaak een kort interval tussen G-CSF 
toediening en de volgende kuur is. Hoofdstuk 2 beschrijft een onderzoek in 
patiënten met borstkanker die 2-wekelijks chemotherapie krijgen ondersteund 
door 2 verschillende regimes G-CSF, gedurende 8 of 11 dagen aansluitend aan 
de chemotherapie. Dit resulteert in een ‘lang’ respectievelijk ‘kort G-CSF- vrij 
interval’ tot de volgende kuur. Omdat dezelfde patiënt in opvolgende kuren 
chemotherapie hetzij 8 dagen hetzij 11 dagen G-CSF voorgeschreven kreeg, 
fungeerde een patiënt als haar eigen controle. Bovendien garandeerde het 
gebruik van 2 verschillende G-CSF schemata dat 1) de duur van G-CSF na de 
kuur chemotherapie in te vergelijken kuren gelijk was en  dientengevolge de 
enige variabele het ‘G-CSF vrije interval’ en 2) een eventueel effect van 
cumulatieve chemotherapie doses meegenomen werd. 
Veertig kuren chemotherapie konden geëvalueerd worden en het G-CSF 
schema bleek significant van invloed op de bloedplaatjes (trombocyten). In 
kuren volgend op een ‘kort G-CSF-vrij interval’ bleken de bloedplaatjes 
gemiddeld lager (gemiddeld verschil 46x109/l), terwijl er geen effect was op de 
witte bloedcellen. We concluderen dan ook dat tijdig staken van G-CSF 
ondersteuning (in elk geval 5 dagen voor start van de volgende kuur 
chemotherapie) tijdens 2 wekelijkse chemotherapie herstel van de witte 
bloedcellen niet nadelig beinvloedt , maar wel tot minder trombocytopenie 
(verlaagd aantal trombocyten) leidt en daardoor mogelijk bijdraagt aan het 
realiseren van de geplande dosis-intensificatie. 
 
Patiënten met een gevorderd stadium niet-kleincellig longkanker kunnen niet 
genezen worden, maar behandeling met chemotherapie resulteert in een deel 
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van de patiënten in overlevingswinst. De overlevingswinst van de huidige 
standaard bestaande uit een combinatie van 2 chemotherapeutica is echter 
bescheiden en er wordt dan ook naarstig gezocht naar effectievere 
behandelingen. Een van de onderzochte strategieën is het combineren van 3 
verschillend werkzame chemotherapeutische middelen. Echter door elkaar 
versterkende bijwerkingen (o.a. neutropenie) is het dan vaak niet mogelijk om 
alle drie de middelen in de optimale dosering toe te dienen. In hoofdstuk 3 
wordt aangetoond dat dit wel mogelijk is met ondersteuning van G-CSF en 
antibiotica. Zonder G-CSF kon paclitaxel zelfs niet in een dosering van 
120mg/m2 worden toegevoegd aan cisplatin 80mg/m2 en etoposide 
100mg/m2, met G-CSF kon een dosering paclitaxel van 250 mg/m2 worden 
toegevoegd (dosisescalatie). Als aan G-CSF ondersteuning antibiotica werden 
toegevoegd, kon een dosering van 275 mg/m2 paclitaxel worden toegevoegd 
zonder dat er belangrijke bijwerkingen optraden.  
 
Zoals al gesteld, was bekend dat antibioticaprofylaxe bij patiënten met 
kleincellig longkanker de kans op complicaties van neutropenie significant 
verminderd en in Nederland zelfs kostenbesparend is. Onbekend was echter of 
het toevoegen van G-CSF aan antibioticaprofylaxe zinvol is tijdens de 
standaardbehandeling van patiënten met kleincellig longkanker die een 
verhoogde kans hebben op het ontwikkelen van FN (door hogere leeftijd, 
eerdere behandeling met chemotherapie, door de uitgebreidheid van de ziekte 
of een slechte algemene conditie/ performance status). Hoofdstuk 4 laat zien 
dat de toevoeging van G-CSF aan antibioticaprofylaxe inderdaad leidt tot een 
klinische en statistisch significante daling van FN. Opvallend is dat dit effect 
het grootst is in de eerste kuur (van 24% naar 10%), mede doordat in latere 
kuren maar weinig patiënten FN ontwikkelen (totaal in kuur 2 t/m 5 van 17% 
naar 11%). De helft van de episodes FN treden op in de eerste kuur en de 
toevoeging van G-CSF resulteert hier in een relatieve reductie van ongeveer 
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50%. Vooral de leeftijd bleek gerelateerd aan de kans op het ontwikkelen van 
FN. Op basis van deze studie kan men de toevoeging van G-CSF profylaxe 
aan antibioticaprofylaxe aanbevelen bij patiënten met een vergelijkbare kans op 
FN, in de eerste kuur chemotherapie, zeker indien ouder dan 60 jaar.  
Hoofdstuk 5 staat stil bij de economische gevolgen hiervan. Toevoeging van 
G-CSF blijkt niet kostenbesparend. Met andere woorden, de bespaarde kosten 
gerelateerd aan de behandeling van FN (denk aan ziekenhuisopname, 
onderzoeken naar de bron van de infectie en therapeutische antibiotica) in een 
deel van de patiënten wegen niet op tegen de kosten gemoeid met de 
toediening van G-CSF aan alle patiënten. Als de maatschappij bereid is 
(‘willingness-to-pay’) om 240 euro per procent voorkomen FN te betalen, kan 
de toevoeging van G-CSF kosteneffectief genoemd worden tijdens de eerste 
kuur chemotherapie. Doorgaan na de eerste kuur is niet kosteneffectief, voor 
de gehele behandeling ligt dit bedrag namelijk vele malen hoger (te hoog) en 
bedraagt 5123 euro. 
 
Patiënten die in een eerdere kuur chemotherapie FN hebben ontwikkeld, 
hebben een grote kans dit later nog eens te krijgen (50-66% wordt in de 
literatuur gerapporteerd). Hoofdstuk 6 beschrijft een kosten-minimalisatie 
analyse waarin de kosten en de baten van secundaire FN-profylaxe worden 
onderzocht gebruikmakend van een Markov model. Een Markov model is een 
economisch model dat het mogelijk maakt dat hypothetische patiënten gevolgd 
kunnen worden tijdens verschillende gezondheidstoestanden (wel/niet FN) 
dientengevolge gepaard gaande met verschillende kosten, met verschillende 
kansen hierop op verschillende momenten (kuren). Secundaire profylaxe 
betekent dat alleen patiënten die FN hebben ontwikkeld in volgende kuren 
profylaxe met antibiotica en/of G-CSF krijgen. De benodigde gegevens voor 
het model (‘kansen en kosten’) kwamen uit het onderzoek beschreven in 
hoofdstuk 4 en uit literatuurgegevens. Secundaire profylaxe met antibiotica was 
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de goedkoopste strategie (4496 euro per patiënt, ter vergelijking kost G-CSF 
plus antibiotica 8998 euro per patiënt). Om de robuustheid van het model te 
toetsen werden sensitiviteitanalyses verricht, gebruikmakend van een 
realistische spreiding van zowel de kansen als de kosten. Hieruit bleek dat 
antibiotica in de Nederlandse situatie de goedkoopste strategie blijft. De relatief 
hoge kosten van G-CSF bleken de bepalende factor hiervoor. 
 
In hoofdstuk 7 wordt een overzicht gegeven van de plaats die profylaxe van 
FN heeft, waarbij ook de in dit proefschrift beschreven onderzoeksresultaten 
in perspectief worden geplaatst. Zowel primaire profylaxe met antibiotica als 
G-CSF zijn effectief ter voorkoming van FN, vooral in de eerste kuur, en de 
combinatie is zelfs nog effectiever. Het nadeel van antibiotica is echter de 
ontwikkeling van resistentie van micro-organismen. G-CSF is echter duur en 
leidt daardoor in vele landen, waaronder Nederland, niet tot kostenbesparing. 
Secundaire profylaxe is onvoldoende onderzocht, waardoor de klinische 
relevantie evenmin als de kosten niet goed duidelijk zijn.  
De actuele internationale richtlijnen pleiten voor een terughoudend gebruik 
van profylaxe, zowel van antibiotica als van G-CSF, en adviseren uisluitend 
profylaxe toe te passen bij patiënten met een verhoogd risico. Een risico 
inschatting kan alleen op patient-nivo worden gemaakt. Op dit moment zijn de 
best gedocumenteerde patiënt-gerelateerde risico factoren hogere leeftijd en 
gevorderde ziekte.  
 
Dit proefschrift beantwoordt een aantal vragen. Goede ‘timing’ tijdens 
chemotherapie van G-CSF draagt bij aan de effectiviteit. ‘Combining’ met 
antibiotica draagt bij aan de effectiviteit. De relatief hoge kosten van G-CSF 
leiden er echter toe dat ondersteuning van chemotherapie in de Nederlandse 
situatie niet tot kostenbesparing leidt. 
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Er blijven echter ook vragen onbeantwoord. In de ontwikkelingsfase van G-
CSF was er zorg over de veiligheid van G-CSF. Immers, het betreft een 
groeifactor en andere cellen, waaronder tumorcellen, kunnen ook gevoelig zijn 
voor G-CSF. Gebaseerd op de resultaten in duizenden patiënten concludeerde 
men destijds dat de toediening veilig was. Recent is er echter opnieuw enige 
zorg ontstaan naar aanleiding van een onderzoek in ruim 5000 vrouwen die 
adjuvant behandeld werden met chemotherapie voor borstkanker. 
Retrospectief bleken in de groep van 900 vrouwen die G-CSF hadden gehad 
meer vrouwen leukemie te hebben gekregen (hazard ratio 2.1). Hoewel het 
risico absoluut nog steeds klein is, is het wel verdubbeld. Hiernaar moet zeker 
verder onderzoek gedaan worden om beter de balans tussen de voor- en de 
nadelen van G-CSF profylaxe te kunnen opmaken. 
 
Dit proefschrift heeft profylaxe met dagelijkse toediening van G-CSF 
onderzocht, waarbij gemiddeld 7-10 dagen een injectie moet worden 
toegediend aansluitend aan de chemotherapie. Inmiddels is er ook een 
langwerkend G-CSF preparaat beschikbaar, waarbij slechts 1 injectie per kuur 
chemotherapie nodig is. De voordelen voor de patiënt zijn duidelijk, maar de 
lange werkzaamheid van deze eenmalige injectie tijdens dosis-densificatie moet 
zorgvuldig worden bekeken. Het is dan immers niet meer mogelijk ‘tijdig te 
stoppen’.  
Verder kan men hypothetiseren dat eerdere studies met dose-dense 
chemotherapie waarbij G-CSF vaak tot kort voor de volgende kuur werd 
gegeven, daardoor niet tot optimale resultaten hebben geleid en de waarde van 
dose-dense chemotherapie nader onderzocht moet worden met tijdig gestaakt 
G-CSF. 
Hetzelfde geldt voor combinaties van meerdere chemotherapeutische 
middelen. Gebaseerd op onze resultaten verdient het aanbeveling, zeker bij 
tumoren waar aangetoond is dat behoud van dosisintensiteit van belang is voor 
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de uitkomst, de optimale dosering van nieuwe combinaties te bepalen zowel 
met als zonder G-CSF plus of min antibiotica ondersteuning. 
 
Dat primaire profylaxe met G-CSF de complicaties van chemotherapie relevant 
doet afnemen is wel duidelijk. Dit heeft er dan ook in geresulteerd dat op dit 
moment  internationale richtlijnen het gebruik hiervan aanbevelen bij patiënten 
waarin het risico op chemotherapie-geinduceerde FN wordt geschat als 20% of 
hoger. Deze aanbeveling is  overigens uitsluitend gebaseerd op de klinische 
relevantie, niet op kosteneffectiviteit. 
Supportive care kan niet makkelijk vertaald worden naar kosten per gewonnen 
levensjaar of per ‘QALY’ (quality-adjusted life years). Dit is van belang gezien 
de maatschappelijke discussie over kosten in de gezondheidszorg en de recent 
vastgestelde norm van 80.000 euro per QALY voor aandoeningen met een 
hoge ziektelast. Toch mag er naar onze mening ook wel geld besteed worden 
aan supportive care. Kosten-effectiviteit gaat immers niet om kostenbesparing, 
maar om meer waar voor je geld. Dit vraagt om een consensus tussen 
betrokkenen waaronder zorgverleners en beleidsmakers. In Nederland kan 
men wellicht stellen dat bij patiënten met een risico op FN van 20% of hoger, 
de toevoeging van G-CSF in de eerste kuur de moeite waard is, maar niet in de 
gehele behandeling (zie hoofdstuk 4 en 5). Maar eerst zal moeten worden 
onderzocht of het inderdaad veilig is om G-CSF support na de eerste kuur te 
staken. Een dergelijke studie is recent opgezet (o.l.v. prof. dr. V. Tjan-Heijnen) 
en zal financieel worden ondersteund door ZonMw, College van 
Zorgverzekeraars. 
 
Hoewel in het Markov model secundaire profylaxe met antibiotica het minste 
duur bleek, is onvoldoende bekend of dit wel een goede strategie is. 
Zelfs als zorgverleners de richtlijn implementeren en alle patiënten met een 
risico groter dan 20% G-CSF profylaxe krijgen, dan valt een grote groep 
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patiënten met solide tumoren hierbuiten. Veel gebruikte chemotherapieregimes 
gaan immers met een lager risico gepaard en derhalve komt een groep 
patiënten nog in aanmerking voor secundaire profylaxe. Gerandomiseerde 
studies zijn daardoor noodzakelijk om zowel de klinische als kosten-
effectiviteit van secundaire profylaxe vast te stellen. Gezien de grote groepen 
patiënten die hiervoor nodig zijn, zal het echter moeilijk zijn financiering voor 
dergelijke studies rond te krijgen. 
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Nawoord 
De jaren waarin dit proefschrift tot stand is gekomen, kunnen met recht 
bewogen jaren worden genoemd. Zowel in de persoonlijke als in de collegiale 
kring waren er hoogtepunten, maar ook dieptepunten. 
Een aantal dierbaren is mij in de afgelopen jaren ontvallen. Zij maken de 
afronding van dit proefschrift niet mee. 
 
De gebeurtenissen van de afgelopen jaren hebben mij meer dan eens doen 
beseffen dat je niet moet uitstellen.  
Zeker niet met belangrijke zaken als waardering. Daarom heb ik geprobeerd 
om in de afgelopen jaren mijn waardering te laten blijken aan allen die bij mij 
en mijn werk betrokken zijn geweest. Door gewoon tussendoor dankjewel te 
zeggen en niet te wachten op een moment als dit, een nawoord in een 
proefschrift. Ik hoop dat mensen dit ook zo ervaren hebben en niet 
teleurgesteld zijn hier niet bij name genoemd te worden. 
 
Ik heb veel om dankbaar voor te zijn. Ik heb veel van anderen mogen leren. 
Uiteraard geldt ook voor mij dat ik dat dit proefschrift niet tot stand had 
kunnen brengen zonder de inspanningen van vele anderen. En of dit nu grote 
of kleine, kortdurende of langdurende inspanningen zijn geweest, ik ben een 
ieder daar dankbaar voor. Maar ik hoop vooral dat iedereen dat al eerder heeft 
gemerkt en niet hier en nu moet lezen.  
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zij de studie geneeskunde aan de Rijksuniversiteit Limburg te Maastricht aan, 
alwaar in 1992 het artsexamen werd behaald. Van maart 1992 tot oktober 1993 
werkte zij als arts-assistent niet in opleiding achtereenvolgens op de afdelingen 
interne geneeskunde van het St. Gregorius ziekenhuis te Brunssum, het 
Academisch Ziekenhuis Maastricht en het St. Elisabeth Ziekenhuis te Tilburg. 
Hier startte zij in oktober 1993 met de opleiding tot internist (opleider dr. C 
van der Heul). In april 1997 werd deze vervolgd in het Academisch Ziekenhuis 
Maastricht (opleider prof. dr. H.Hillen) en afgerond op 1-10-1999. Van 1-10-
1999 tot 1-2-2000 werkte zij als waarnemend internist in ziekenhuis Gelderse 
Vallei, locatie Juliana Ziekenhuis, te Ede. Aansluitend hieraan werkte zij tot 1-
1-2001 als chef-de-clinique in het Carolus Ziekenhuis te ’s-Hertogenbosch. In 
januari 2001 werd zij in deeltijd aangesteld als algemeen internist op de afdeling 
medische oncologie van het Universitair Medisch Centrum St. Radboud te 
Nijmegen (hoofd prof. dr. P. de Mulder†) en startte zij onder leiding van V. 
Tjan-Heijnen met het onderzoek dat de basis zou vormen voor dit 
proefschrift. In november 2002 ving zij aan met een deeltijdopleiding (50%) in 
het aandachtsgebied medische oncologie, hetgeen resulteerde tot inschrijving 
per 1-11-2004 als internist met aandachtsgebied medische oncologie. Naast 
haar werkzaamheden voor de afdeling Medische Oncologie is zij sinds 1-1-
2006 ook verbonden aan het Universitair Longcentrum Nijmegen en in het 
bijzonder werkzaam op de locatie Dekkerswald te Groesbeek. Sinds 1-6-2006 
is zij als staflid verbonden aan de afdeling Medische Oncologie.  
Zij is gehuwd met Frans Timmer. Samen hebben zij drie kinderen, Stijn (1998), 
Lara (2000) en Femke (2004). 
Publicaties 
176 
Publicaties (peer reviewed) 
L. de Geus-Oei, H. F. M. van der Heijden, E. P. Visser, R. Hermsen, B. A. van 
Hoorn, J. N. Timmer-Bonte, A. T. Willemsen, J. Pruim, F. H. M. Corstens, P. 
F. M. Krabbe, W. J. G. Oyen. Chemotherapy response evaluation with FDG-PET in 
patients with non-small-cell lung cancer. J Nucl Med. 2007, 48:1592-1598 
 
Tjakiena Henriette Levenga and Johanna N. H. Timmer-Bonte. Review of the 
value of colony stimulating factors for prophylaxis of febrile neutropenic episodes in adult 
patients treated for haematological malignancies. British Journal of Haematology, 
2007, 138:146–152 
 
J.N.H. Timmer-Bonte, V.C.G. Tjan-Heijnen Febrile neutropenia: highlighting the role 
of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose 
chemotherapy for solid tumors. Anticancer Drugs. 2006, 17(8):881-889 
 
J.N.H Timmer-Bonte, E.M.M Adang,, H.J.M Smit, B. Biesma, F.A. Wilschut,  
G.P. Bootsma, Th. De Boo, V.C.G Tjan-Heijnen Cost-effectiveness of adding 
granulocyte-colony stimulating factor to primary prophylaxis with antibiotics in patients with 
small cell lung cancer. J Clin Oncol, 2006, 24(19):2991-2997  
 
J.N. Timmer-Bonte, Th.M. de Boo, H.J. Smit, B. Biesma, F.A. Wilschut,  
S.A. Cheragwandi, A. Termeer, C.A.Hensing, J. Akkermans, G.P. Bootsma,  
V.C. Tjan-Heijnen. Prevention of chemotherapy-induced febrile neutropenia by prophylactic 
antibiotics plus or minus granulocyte-colony stimulating factor in small cell lung cancer: a 
Dutch randomized phase III study J Clin Oncol 2005, 23: 7974-7984  
 
J.N.Timmer-Bonte,  L.V.Beex, P.G. Peer, P.H.M. de Mulder, V.C. Tjan-
Heijnen. Timely withdrawal of G-CSF reduces the occurrence of thrombocytopenia during 
dose dense chemotherapy. Breast Cancer Res Treatment 2005, 93: 117  
 
J.N.H. Timmer-Bonte, V.C.G. Tjan-Heijnen. Eindrapport voor College van 
Zorgverzekeraars, maart 2004 Ontwikkelingsgeneeskunde project 99-053 
 
